<SEC-DOCUMENT>0001213900-26-035450.txt : 20260327
<SEC-HEADER>0001213900-26-035450.hdr.sgml : 20260327
<ACCEPTANCE-DATETIME>20260327151924
ACCESSION NUMBER:		0001213900-26-035450
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		23
FILED AS OF DATE:		20260327
DATE AS OF CHANGE:		20260327

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellyan Biotechnology Co., Ltd
		CENTRAL INDEX KEY:			0002007702
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-294685
		FILM NUMBER:		26806752

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ROOM B1, 5/F. WELL TOWN IND. BUILDING
		STREET 2:		13 KO FAI ROAD, YAU TONG
		CITY:			KOWLOON
		PROVINCE COUNTRY:   	K3
		BUSINESS PHONE:		(852) 26189289

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		ROOM B1, 5/F. WELL TOWN IND. BUILDING
		STREET 2:		13 KO FAI ROAD, YAU TONG
		CITY:			KOWLOON
		PROVINCE COUNTRY:   	K3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Hong Kong Pharma Digital Technology Holdings Ltd
		DATE OF NAME CHANGE:	20240110
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>ea0283730-f1_cellyan.htm
<DESCRIPTION>REGISTRATION STATEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As
filed with the U.S. Securities and Exchange Commission on March 27, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
No. 333- &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
F-1&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REGISTRATION
STATEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES ACT OF 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLYAN
BIOTECHNOLOGY CO., LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of Registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman
    Islands</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5122</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 30.25in; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Not
    applicable</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
    or other jurisdiction of<BR>
    incorporation or organization)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Primary
    Standard Industrial<BR>
    Classification Code Number)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
    Employer<BR>
    Identification No.)</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Room
B1, 5/F., Well Town Industrial Building,<BR>
13 Ko Fai Road, Yau Tong, Kowloon</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong
Kong</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>+852&nbsp;2618-9289</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
including zip code, and telephone number, including area code, of Registrant&rsquo;s principal executive offices)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cogency
Global Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>122
East 42nd Street, 18th Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10168</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
212-947-7200</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Name,
address, including zip code, and telephone number, including area code, of agent for service)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Copies
of all communications, including communications sent to agent for service, should be sent to:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Zhaocong
&ldquo;Richard&rdquo; Xu, Esq.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>McLaughlin
&amp; Stern, LLP</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>260
Madison Avenue, 18<SUP>th</SUP> Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>New
York, NY 10016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tel:
(212) 448-1100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximate
date of commencement of proposed sale to the public: From time to time after the effective date of this Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, check the following box.&ensp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following
box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&ensp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&ensp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the
Securities Act registration statement number of the earlier effective registration statement for the same offering.&ensp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&ensp;&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards&dagger; provided
pursuant to Section 7(a)(2)(B) of the Securities Act.&ensp;&#9744;&dagger;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The term &ldquo;new
    or revised financial accounting standard&rdquo; refers to any update issued by the Financial Accounting Standards Board to its Accounting
    Standards Codification after April 5, 2012.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the
Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this Registration Statement shall become effective
on such date as the SEC, acting pursuant to said Section 8(a), may determine.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>The
information in this preliminary prospectus is not complete and may be changed. The selling shareholders named in this preliminary prospectus
may not sell these securities until the Registration Statement filed with the U.S. Securities and Exchange Commission, of which this
preliminary prospectus is a part, is effective. This preliminary prospectus is not an offer to sell these securities and the selling
shareholders named in this preliminary prospectus are not soliciting an offer to buy these securities in any state where the offer or
sale is not permitted.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>SUBJECT
TO COMPLETION, DATED MARCH 27, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>PRELIMINARY
PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to 12,499,986 Class A Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLYAN
BIOTECHNOLOGY CO., LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus relates to the offer and sale by the selling shareholders named in this prospectus (the &ldquo;Selling Shareholders&rdquo;)
from time to time of up to an aggregate of 12,499,986 Class A ordinary shares, par value US$0.001 per share (the &ldquo;Class A Ordinary
Shares&rdquo;), offered by the Selling Shareholders (the &ldquo;Offered Shares&rdquo;). The Offered Shares were originally issued to
the Selling Shareholders in a private placement transaction consummated in March 25, 2026 (&ldquo;March 2026 Private Placement&rdquo;)
pursuant to certain securities purchase agreements, dated as of March 24, 2026, between Cellyan Biotechnology and the Selling Shareholders
(the &ldquo;Securities Purchase Agreements&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology will not receive any of the proceeds from the sale of the Offered Shares by the Selling Shareholders. All Offered Shares
subject to resale hereunder will have been issued by Cellyan Biotechnology and acquired by the Selling Shareholders prior to any such
resale pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Shareholders and any of their respective pledgees, assignees, and successors-in-interest may offer or resell the Offered Shares
from time to time through public or private transactions at prevailing market prices, at prices related to prevailing market prices,
or at privately negotiated prices. The Selling Shareholders will bear all commissions, discounts, and fees of underwriters, selling brokers,
dealer managers, and similar expenses, if any, attributable to the sale of the Offered Shares. Cellyan Biotechnology will bear all costs,
expenses, and fees in connection with the registration of the Offered Shares. For additional information on the methods of sale that
may be used by the Selling Shareholders, see &ldquo;Plan of Distribution&rdquo; beginning on page 34 of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should carefully
read this entire prospectus and any amendments or supplements thereto before making your investment decision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class A Ordinary Shares are listed on the Nasdaq Stock Market, or Nasdaq, under the symbol &ldquo;HKPD.&rdquo; On March 26, 2026, the
last reported sale price of the Class A Ordinary Shares on Nasdaq was $0.65 per Class A Ordinary Share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investing
in Cellyan Biotechnology&rsquo;s Class A Ordinary Shares, including the Offered Shares, involves a high degree of risk, including the
risk of losing your entire investment. Before making an investment decision, please read the information under the heading &ldquo;Risk
Factors&rdquo; of this prospectus, and risk factors set forth in Cellyan Biotechnology&rsquo;s most recent annual report on Form 20-F
(the &ldquo;2025 Annual Report&rdquo;) and in other reports incorporated herein by reference.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is considered a &ldquo;controlled company&rdquo; under Nasdaq corporate governance rules as more than 50% of the Company&rsquo;s
voting power is held by an individual, an entity or a group immediately following the consummation of this offering. As of the date of
this prospectus, our largest shareholder, Ms. Liying Wang, the beneficial owner of 7,150,000 Class B Ordinary Shares of the Company,
held approximately 95.63% of the voting power of the outstanding share capital of the Company and Cellyan Biotechnology meets the definition
of a &ldquo;controlled company&rdquo; under the corporate governance standards for Nasdaq listed companies. As a &ldquo;controlled company,&rdquo;
Cellyan Biotechnology is eligible to utilize certain exemptions from the corporate governance requirements of the Nasdaq Stock Market.
Cellyan Biotechnology currently follows certain Cayman Islands corporate governance practices in lieu of the Nasdaq corporate governance
listing standards as follows: (i) Cellyan Biotechnology is not required to seek shareholders&rsquo; approval of any issuance of securities
in connection with a transaction other than a public offering where such transaction involves the issuance of securities representing
20% or more of the voting power outstanding before the issuance at a price lower than the &ldquo;Minimum Price,&rdquo; in lieu of the
corporate governance requirements of Nasdaq Listing Rule 5635(d) with respect to shareholder approval; (ii) Cellyan Biotechnology is
not required to seek shareholders&rsquo; approval for the establishment of or any material amendments to its equity compensation plans,
in lieu of the corporate governance requirements of Nasdaq Listing Rule 5635(c) with respect to shareholder approval; (iii) Cellyan Biotechnology
is not required to seek shareholders&rsquo; approval for the issuance of securities to external consultants, in lieu of the corporate
governance requirements of Nasdaq Listing Rule 5635(c) with respect to shareholder approval; and (iv) Cellyan Biotechnology is not required
to hold annual shareholders&rsquo; meetings. See &ldquo;Prospectus Summary &mdash; Implications of Being a Controlled Company.&rdquo;
Additionally, Ms. Liying Wang is able to control Cellyan Biotechnology&rsquo;s management and matters requiring an ordinary resolution
of shareholders, including the appointment and removal of directors and approval of significant corporate transactions such as a change
in control, merger, consolidation or sale of assets. However, Cellyan Biotechnology&rsquo;s controlling shareholder, Ms. Liying Wang,
does not have the ability to determine matters requiring a special resolution of shareholders such as amending Cellyan Biotechnology&rsquo;s
memorandum and articles of association. For more information, please see &ldquo;Item 3. D. Risk Factors &mdash; Risks Related to Ownership
of Our Securities &mdash;Our largest shareholder, Ms. Liying Wang, holds a majority of the voting power of the Company&rsquo;s outstanding
share capital, which will limit or preclude your ability to influence corporate matters&rdquo; on page 17 of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is not a Chinese operating company, but rather a holding company incorporated in the Cayman Islands. As a holding company
with no material operations of its own, Cellyan Biotechnology conducts its operations through its operating subsidiaries established
in the Hong Kong Special Administrative Region (&ldquo;Hong Kong&rdquo;), Joint Cross Border Logistics Company Limited and V-Alliance
Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong (together, the &ldquo;HK Subsidiaries&rdquo;).
As such, Cellyan Biotechnology&rsquo;s corporate structure involves unique risks to investors. Investors of Cellyan Biotechnology&rsquo;s
Class A Ordinary Shares do not directly own any equity interests in the HK Subsidiaries, but will instead own shares of a Cayman Islands
holding company. The Chinese regulatory authorities could intervene or influence the operations of the HK Subsidiaries, including disallowing
Cellyan Biotechnology&rsquo;s corporate structure, which would likely result in a material change in Cellyan Biotechnology&rsquo;s operations
and/or a material change in the value of Cellyan Biotechnology&rsquo;s Class A Ordinary Shares. For details, see &ldquo;Item 3. Key Information
&mdash; D. Risk Factors &mdash; Risks Related to Doing Business in Hong Kong &mdash; Substantially all our operations are in Hong Kong.
However, the legal and operational risks associated with operations in China may also apply to our operations in Hong Kong. The Chinese
government may exercise significant oversight and control over the conduct of our business and may intervene in or influence our operations
at any time, which could result in a material change in our operations and may significantly limit or completely hinder Cellyan Biotechnology&rsquo;s
ability to offer or continue to offer Class A Ordinary Shares to investors and cause the value of the Class A Ordinary Shares to significantly
decline or be worthless. Changes in the policies, regulations, rules, and the enforcement of laws of the Chinese government may also
be quick and the risks related to the PRC legal and regulatory system may materialize&rdquo; beginning on page 19 of the 2025 Annual
Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
holding company structure involves unique risks to investors, and you may never directly hold equity interests in the HK Subsidiaries.
While Cellyan Biotechnology has been advised by its People&rsquo;s Republic of China (&ldquo;PRC&rdquo;) legal counsel, Guangdong Jishi
Furen Law Firm, that as of the date of this prospectus, the HK Subsidiaries&rsquo; operations in Hong Kong and the offering of the Offered
Shares in the United States are not subject to the review or prior approval of the Cyberspace Administration of China (the &ldquo;CAC&rdquo;)
or the China Securities Regulatory Commission (the &ldquo;CSRC&rdquo;), Cellyan Biotechnology faces various legal and operational risks
and uncertainties associated with being based in or having operations in Hong Kong, having clients who are PRC individuals or companies
whose shareholders or directors are PRC individuals, and the complex and evolving PRC laws and regulations. The legal and operational
risks associated with operations in China apply to the HK Subsidiaries&rsquo; operations in Hong Kong. Should recent statements and regulatory
actions by the PRC government apply to Cellyan Biotechnology in the future, Cellyan Biotechnology might face risks associated with regulatory
approvals on foreign investment in Hong Kong-based issuers, anti-monopoly regulatory actions, and oversight on cybersecurity, data privacy
and personal information pursuant to PRC laws and regulations. The PRC government may also intervene or impose restrictions on the HK
Subsidiaries&rsquo; ability to transfer cash out of Hong Kong for the purpose of distributing earnings and paying dividends. Furthermore,
PRC regulatory authorities may in the future promulgate laws, regulations or rules that require Cellyan Biotechnology to obtain regulatory
approval from PRC authorities before this or any future securities offering. These risks could result in a material adverse change in
the HK Subsidiaries&rsquo; business operations and the value of the Class A Ordinary Shares, restrictions on the HK Subsidiaries&rsquo;
ability to accept foreign investments, significant limitations on or a complete inability by Cellyan Biotechnology to continue to offer
securities to investors or to maintain the listing of the Class A Ordinary Shares on a U.S. or other foreign exchange, or cause the value
of such securities to significantly decline or become worthless. See &ldquo;Item 3. Key Information &mdash; D. Risk Factors &mdash; Risks
Related to Doing Business in Hong Kong&rdquo; beginning on page 19 of the 2025 Annual Report for a discussion of these legal and operational
risks that should be considered before making a decision to purchase the Class A Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specifically,
on February 17, 2023, the CSRC issued the Notice on Filing Arrangements for Overseas Securities Offering and Listing by Domestic Companies,
stating that the CSRC has published the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies
and five supporting guidelines (collectively, the &ldquo;New Overseas Listing Rules&rdquo;). Among others, the New Overseas Listing Rules
provide that PRC domestic companies seeking to offer and list securities (which, for the purposes of the New Overseas Listing Rules,
are defined thereunder as equity shares, depository receipts, corporate bonds convertible to equity shares, and other equity securities
that are offered and listed overseas, either directly or indirectly, by PRC domestic companies) in overseas markets, either via direct
or indirect means, must file with the CSRC within three working days after an application for an overseas listing is submitted. The New
Overseas Listing Rules came into effect on March 31, 2023. As advised by Cellyan Biotechnology&rsquo;s PRC legal counsel, Guangdong Jishi
Furen Law Firm, based on relevant facts and current PRC laws, as of the date of this prospectus, Cellyan Biotechnology believes that
this offering is not an indirect or direct offering and listing of securities in overseas markets as prescribed in the New Overseas Listing
Rules, and thus, Cellyan Biotechnology does not need to fulfil the CSRC filling procedure. However, there remain substantial uncertainties
surrounding the enforcement thereof, Cellyan Biotechnology cannot assure you that, if required, it would be able to complete the filings
and/or fully comply with the relevant new rules on a timely basis, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
as more stringent standards have been imposed by the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and the Public Company
Accounting Oversight Board (the &ldquo;PCAOB&rdquo;), Cellyan Biotechnology&rsquo;s securities may be prohibited from trading if its
auditor cannot be fully inspected by the PCAOB for two consecutive years. Pursuant to the Holding Foreign Companies Accountable Act (the
&ldquo;HFCA Act&rdquo;) enacted in 2020, if the auditor of a U.S.-listed company&rsquo;s financial statements is not subject to PCAOB
inspections for three consecutive &ldquo;non-inspection&rdquo; years, the SEC is required to prohibit the securities of such issuer from
being traded on a U.S. national securities exchange, such as NYSE and Nasdaq, or in U.S. over-the-counter markets. On December 23, 2022,
the U.S. Senate passed the Accelerating Holding Foreign Companies Accountable Act, and on December 29, 2022, legislation entitled &ldquo;Consolidated
Appropriations Act, 2023&rdquo; (the &ldquo;Consolidated Appropriations Act&rdquo;) was signed into law, which contained, among other
things, an identical provision to the Accelerating Holding Foreign Companies Accountable Act and amended the HFCA Act by requiring the
SEC to prohibit an issuer&rsquo;s securities from trading on any U.S. stock exchange if its auditor is not subject to PCAOB inspections
for two consecutive years instead of three, thereby reducing the time period for triggering the prohibition on trading. Pursuant to the
HFCA Act, on December 16, 2021, the PCAOB issued its determination that it was unable to inspect or investigate completely PCAOB-registered
public accounting firms headquartered in Mainland China or in Hong Kong, because of positions taken by authorities in those jurisdictions,
and the PCAOB included in the report of its determination a list of the accounting firms so headquartered. This list does not include
Cellyan Biotechnology&rsquo;s auditor, Onestop Assurance PAC, as Cellyan Biotechnology&rsquo;s auditor is headquartered in Singapore
and is registered with the PCAOB and subject to PCAOB inspection. On August 26, 2022, the CSRC, the Ministry of Finance of the PRC (the
&ldquo;MOF&rdquo;), and the PCAOB signed a Statement of Protocol (the &ldquo;Protocol&rdquo;) governing inspections and investigations
of accounting firms based in Mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate
registered public accounting firms headquartered in Mainland China and Hong Kong. On December 15, 2022, the PCAOB announced that it was
able, in 2022, to inspect and investigate completely issuer audit engagements of PCAOB-registered public accounting firms headquartered
in Mainland China and Hong Kong and, as a result, vacated its previous 2021 determination. However, uncertainties still exist as to whether
the PCAOB will have continued access for complete inspections and investigations. The PCAOB has indicated that it will act immediately
to consider the need to issue new determinations if necessary. While Cellyan Biotechnology&rsquo;s auditor is based in Singapore and
is subject to PCAOB inspection, in the event the PCAOB subsequently determines that it is unable to inspect or investigate completely
Cellyan Biotechnology&rsquo;s auditor, such lack of inspection could cause Cellyan Biotechnology&rsquo;s securities to be delisted from
the U.S. stock exchange. See &ldquo;Item 3. Key Information &mdash; D. Risk Factors &mdash; Risks Related to Doing Business in Hong Kong
&mdash; The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and acts passed by the U.S. Senate and the
U.S. House of Representatives, all call for additional and more stringent criteria to be applied to U.S.-listed companies with significant
operations in China and Hong Kong. These developments could add uncertainties to our business operations, share price and reputation&rdquo;
on page 21 of the 2025 Annual Report. In addition, Cellyan Biotechnology cannot assure you that Nasdaq or other regulatory agencies will
not impose additional or more stringent requirements on Cellyan Biotechnology. Such uncertainty could cause the market price of the Class
A Ordinary Shares to be materially and adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Companies Act and our memorandum and articles of association, as amended, our board of directors may authorize and declare a dividend
to shareholders at such time and of such an amount as they think fit if they are satisfied, on reasonable grounds, that immediately following
the payment of such dividend, we will be able to pay our debts as they become due in the ordinary course of business. We may provide
funding to the HK Subsidiaries through loans or capital contributions without restrictions on the amount of the funds. As a holding company,
we may rely on dividends and other distributions on equity paid by the HK Subsidiaries for our cash and financing requirements. Under
Hong Kong law, the HK Subsidiaries are permitted to provide funding to Cellyan Biotechnology through dividend distributions without restrictions
on the amount of the funds, provided that dividends may only be paid out of distributable profits (that is, accumulated realized profits
less accumulated realized losses) or other distributable reserves, and not out of share capital. Under the current practice of the Inland
Revenue Department of Hong Kong, no tax is payable in Hong Kong in respect of dividends paid by the HK Subsidiaries. The HK Subsidiaries
have not made any dividends or other distributions to us as of the date of this prospectus. In the future, cash proceeds raised from
financings conducted outside of Hong Kong, including this offering, may be transferred by Cellyan Biotechnology to the HK Subsidiaries
via capital contribution or shareholder loans, as the case may be. As of the date of this prospectus, neither Cellyan Biotechnology nor
the HK Subsidiaries have paid any dividends or made any distributions to their respective shareholder(s), including any U.S. investors.
In addition, as of the date of this prospectus, the transfer of cash or other types of assets between Cellyan Biotechnology and any of
the HK Subsidiaries totaled $810,000. This amount represented the subscription price for the Class B Ordinary Shares paid by the holder
of such shares and was remitted directly to Joint Cross Border as an interest-free loan payable on demand from us. The HK Subsidiaries,
which carry out substantive operations, maintain the cash. Each of the HK Subsidiaries has established strict internal cash management
policies, which stipulate, among other things, that (i) with respect to cash, the entity shall not hold more than HK$100,000 in cash
on a single day and any excess cash shall be deposited into bank accounts, and (ii) with respect to bank accounts, including online banking,
each entity maintains layered authorization for accessing and using bank accounts. Cellyan Biotechnology and the HK Subsidiaries do not
currently have plans to distribute earnings or declare cash dividends in the foreseeable future. We intend to retain any future earnings
to finance the expansion of the HK Subsidiaries&rsquo; business. Any future determination related to our dividend policy will be made
at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements, contractual
requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in
any future financing instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Currently,
there are no restrictions on foreign exchange, nor limitations on Cellyan Biotechnology&rsquo;s ability to transfer cash to or from HK
Subsidiaries or to investors under Hong Kong laws. However, if certain PRC laws and regulations, including existing laws and regulations
and those enacted or promulgated in the future, were to become applicable to the HK Subsidiaries, to the extent Cellyan Biotechnology&rsquo;s
cash or assets are in Hong Kong or with a Hong Kong entity, such funds or assets may not be available to fund operations or for other
use outside of Hong Kong due to interventions in or the imposition of restrictions and limitations on HK Subsidiaries&rsquo; ability
to transfer funds or assets by the PRC government. Cellyan Biotechnology cannot assure you that the PRC government will not intervene
or impose restrictions on Cellyan Biotechnology or HK Subsidiaries regarding the transfer or distribution of cash within the organization
or to U.S. investors, which could result in an inability of or prohibition on HK Subsidiaries from making transfers or distributions
to Cellyan Biotechnology or U.S. investors. Any limitation on the ability of HK Subsidiaries to pay dividends or make other distributions
to Cellyan Biotechnology could materially and adversely limit Cellyan Biotechnology&rsquo;s ability to grow, make investments or acquisitions
that could be beneficial to its business, pay dividends, or otherwise fund and conduct its business. In addition, if HK Subsidiaries
incur debt on their own behalf in the future, the instruments governing such debt may restrict their abilities to pay dividends. See
&ldquo;Prospectus Summary &mdash; Transfer of Cash Through Our Organization&rdquo; beginning on page 4, &ldquo;Item 3. Key Information
&mdash; D. Risk Factors &mdash; Risks Related to Our Business and Industry &mdash; Hong Kong Pharma relies on dividends and other distributions
on equity paid by its HK Subsidiaries to fund any cash and financing requirements Hong Kong Pharma may have, and any limitation on the
ability of its HK Subsidiaries to make payments to Hong Kong Pharma could have a material adverse effect on our ability to conduct our
business. Additionally, while currently there are no restrictions on foreign exchange, nor limitations on the ability of Hong Kong Pharma
to transfer cash to or from HK Subsidiaries or to investors under Hong Kong laws, if certain PRC laws and regulations, including existing
laws and regulations and those enacted or promulgated in the future, were to become applicable to our HK Subsidiaries, to the extent
our cash or assets are in Hong Kong or with a Hong Kong entity, such funds or assets may not be available to fund operations or for other
use outside of Hong Kong due to interventions in or the imposition of restrictions and limitations on HK Subsidiaries&rsquo; ability
to transfer funds or assets by the PRC government&rdquo; on page 17 of the 2025 Annual Report, &ldquo;Dividend Policy&rdquo; on page
20 of this prospectus and the consolidated financial statements and the accompanying footnotes incorporated by reference into
this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cellyan
Biotechnology is a &ldquo;foreign private issuer&rdquo; and an &ldquo;emerging growth company&rdquo; under the federal securities laws
and will be subject to reduced public company reporting requirements. See &ldquo;Prospectus Summary&thinsp;&mdash;&thinsp;Implications
of Being an Emerging Growth Company&rdquo; for additional information.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this prospectus and any prospectus supplement or amendment carefully before you invest in any of our securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Neither
the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed
upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
date of this prospectus is&nbsp;March 27, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_001">About This Prospectus</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_002">Disclosure Regarding Forward-Looking Statements</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iv</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_003">Prospectus Summary</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_004">The Offering</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_005">Risk Factors</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_006">Enforceability of Civil Liabilities</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_007">Use of Proceeds</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_008">Dividend Policy</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">20</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_009">Capitalization</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_010">Description of Share Capital</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">22</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_011">Selling Shareholders</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_012">Plan of Distribution</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">34</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_013">Expenses</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_014">Legal Matters</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_015">Experts</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_016">Incorporation of Certain Information by Reference</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#a_017">Where You Can Find Additional Information</A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>ABOUT
THIS PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus describes the general manner in which the Selling Shareholders identified in this prospectus may offer from time to time up
to 12,499,986 Class A Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information contained in this prospectus and any related exhibits, any prospectus supplement or amendment thereto,
and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor
the Selling Shareholders have authorized any other person to provide you with different or additional information. If anyone provides
you with different or inconsistent information, you should not rely on it. This prospectus is not an offer to sell, nor are the Selling
Shareholders seeking an offer to buy, the Class A Ordinary Shares offered by this prospectus in any jurisdiction where the offer or sale
is not permitted. You should assume that the information contained in this prospectus or in any applicable prospectus supplement is accurate
only as of the date on the front cover thereof or the date of the document incorporated by reference, regardless of the time of delivery
of this prospectus or any applicable prospectus supplement, or any sales of the Class A Ordinary Shares offered hereby or thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
necessary, the specific manner in which the Class A Ordinary Shares may be offered and sold will be described in a supplement to this
prospectus, which supplement may also add, update or change any of the information contained in this prospectus. To the extent there
is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information
in such prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document
having a later date &mdash; for example, a document incorporated by reference in this prospectus or any prospectus supplement &mdash;
the statement in the document having the later date modifies or supersedes the earlier statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neither
the delivery of this prospectus nor any distribution of the Class A Ordinary Shares pursuant to this prospectus shall, under any circumstances,
create any implication that there has been no change in the information set forth or incorporated by reference into this prospectus or
in our affairs since the date of this prospectus. Our business, financial condition, results of operations, and prospects may have changed
since such date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMONLY
USED DEFINED TERMS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context requires otherwise, references in this prospectus or in a prospectus supplement to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;API&rdquo;
are to application programming interface;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cellyan
Biotechnology&rdquo; are to Cellyan Biotechnology, a holding company incorporated in the Cayman Islands as an exempted company;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Chinese
government&rdquo; or &ldquo;PRC government&rdquo; are to the government of Mainland China for the purposes of this prospectus only;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Class&nbsp;A
Ordinary Share(s)&rdquo; are to Cellyan Biotechnology&rsquo;s Class&nbsp;A ordinary shares, par value $0.001 per share;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Class&nbsp;B
Ordinary Share(s)&rdquo; are to Cellyan Biotechnology&rsquo;s Class&nbsp;B ordinary shares, par value $0.001 per share;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HK
Subsidiaries&rdquo; are to Cellyan Biotechnology&rsquo;s direct wholly-owned subsidiaries, Joint Cross Border Logistics Company Limited,
V-Alliance Technology Supplies Limited and New Ben Global Enterprises Limited, each a Hong&nbsp;Kong corporation; each, an HK Subsidiary;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;HK$,&rdquo;
&ldquo;HK Dollars&rdquo; or &ldquo;Hong&nbsp;Kong dollar(s)&rdquo; are to the legal currency of Hong&nbsp;Kong;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Hong&nbsp;Kong&rdquo;
and &ldquo;Hong&nbsp;Kong SAR&rdquo; are to the Hong&nbsp;Kong Special Administrative Region of the People&rsquo;s Republic of China;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;IFRS&rdquo;
are to the International Financial Reporting Standards, as issued by the International Accounting Standards Board;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Joint
Cross Border&rdquo; are to Joint Cross Border Logistics Company Limited, a Hong Kong subsidiary of Cellyan Biotechnology;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;V-Alliance&rdquo;
are to&nbsp;V-Alliance Technology Supplies Limited, a Hong Kong subsidiary of Cellyan Biotechnology;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;New
Ben&rdquo; are to&nbsp;New Ben Global Enterprises Limited, a Hong Kong subsidiary of V-Alliance;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">&ldquo;Mainland China&rdquo; are to the Mainland China of
the PRC, excluding Taiwan, the special administrative regions of Hong&nbsp;Kong and Macau for the purposes of this prospectus only;</TD>
</TR></TABLE>


<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Ordinary
Shares&rdquo; are to our Class A Ordinary Shares and our Class B Ordinary Shares, collectively;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PRC&rdquo;
and &ldquo;China&rdquo; are to the People&rsquo;s Republic of China, including the special administrative regions of Hong&nbsp;Kong and
Macau for the purposes of this prospectus only;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PRC
laws and regulations&rdquo; or &ldquo;PRC laws&rdquo; are to the laws and regulations of Mainland China for the purposes of this prospectus
only;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;RMB&rdquo;
or &ldquo;Renminbi&rdquo; are to the legal currency of China;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Share
Split&rdquo; are to a 1-for-10 forward split effected on October 24, 2024, of the Company&rsquo;s Class A and Class B Ordinary Shares,
by way of a share subdivision of its issued and unissued shares, with each of its issued and unissued shares subdivided into ten (10)
shares. Immediately after the Share Split, the number of issued and outstanding shares of Cellyan Biotechnology increased from 1,000,000
to 10,000,000&nbsp;shares, comprising (i) 9,501,000 Class A Ordinary Shares issued and outstanding, par value $0.001 each and (ii) 499,000
Class B Ordinary Shares issued and outstanding, par value $0.001 each. All share and per share data set forth in this prospectus have
been retroactively adjusted to reflect the Share Split;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Selling
    Shareholders&rdquo; are to the nineteen (19) investors who engaged in the March 2026 Private Placement, including Jiamei Qin, Yun
    Zhou, Yawen Zhang, Xiuhua Wang, Shunzeng Chen, Junqing Wang, Chunxia Wang, Huanyin Wang, Guojun Liu, Yundie Chi, Guorui Liu, Fuping
    Lin, Liuqin Bao, Xuanrui Chi, Xincun Li, Jindong Sun, Xiangyang Xu, Fengjun Xue and Xiangdie Liu;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;U.S.&nbsp;dollars,&rdquo;
&ldquo;dollars,&rdquo; &ldquo;USD&rdquo; or &ldquo;$&rdquo; are to the legal currency of the United&nbsp;States; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;the Company,&rdquo; &ldquo;our&rdquo; or &ldquo;our company&rdquo; are to the combined business of Cellyan Biotechnology
and its consolidated subsidiaries.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>DISCLOSURE
REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains forward-looking statements that reflect our current expectations and views of future events, all of which are subject
to risks and uncertainties. Forward-looking statements give our current expectations or forecasts of future events. You can identify
these statements by the fact that they do not relate strictly to historical or current facts. You can find many (but not all) of these
statements by the use of words such as &ldquo;approximates,&rdquo; &ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;expects,&rdquo;
&ldquo;anticipates,&rdquo; &ldquo;estimates,&rdquo; &ldquo;projects,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo; &ldquo;will,&rdquo;
&ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;may,&rdquo; or other similar expressions in this prospectus. These
statements are likely to address our growth strategy, financial results, and product and development programs. You must carefully consider
any such statements and should understand that many factors could cause actual results to differ from our forward-looking statements.
These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known
and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially. Factors that could
cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">assumptions
    about our future financial and operating results, including revenue, income, expenditures, cash balances, and other financial items;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to execute our growth and expansion plans, including our ability to meet our goals;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">current and
    future economic and political conditions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our capital
    requirements and our ability to raise any additional financing that we may require;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to attract clients and further enhance our brand recognition;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability
    to hire and retain qualified management personnel and key employees to enable us to develop our business; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">other assumptions
    described in this prospectus underlying or relating to any forward-looking statements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
describe certain material risks, uncertainties, and assumptions that could affect our business, including our financial condition and
results of operations, under &ldquo;Risk Factors&rdquo; elsewhere in this prospectus and under the heading &ldquo;Item 3. Key Information
&mdash; D. Risk Factors&rdquo; in the 2025 Annual Report, which is incorporated in this prospectus by reference. We base our forward-looking
statements on our management&rsquo;s beliefs and assumptions based on information available to our management at the time such statements
are made. We caution you that actual outcomes and results may, and are likely to, differ materially from what is expressed, implied or
forecast by our forward-looking statements. Accordingly, you should be careful about relying on any forward-looking statements. Except
as required under the federal securities laws, we undertake no intention or obligation to publicly update any forward-looking statements
after the distribution of this prospectus, whether as a result of new information, future events, changes in assumptions, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Industry
Data and Forecasts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
prospectus contains market data and industry forecasts and projections that were obtained or derived from publicly available information,
reports of governmental agencies, market research reports, and industry publications and surveys. These sources generally state that
the information contained therein has been obtained from sources believed to be reliable, but that the accuracy and completeness of such
information is not guaranteed. Although we believe such information to be accurate, we have not independently verified the data from
these sources. We acknowledge our responsibility for all disclosures in this prospectus. Forecasts and other forward-looking information
obtained from these sources are subject to the same qualifications and the additional uncertainties and risks applicable to the other
forward-looking statements in this prospectus due to a variety of factors, including those described in this section, the section entitled
&ldquo;Risk Factors,&rdquo; elsewhere in this prospectus, and the section entitled &ldquo;Item 3. Key Information &mdash; D. Risk Factors&rdquo;
in the 2025 Annual Report. These and other factors could cause results to differ materially from those expressed in such forecasts and
estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>PROSPECTUS
SUMMARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following summary is qualified in its entirety by, and should be read in conjunction with, the more detailed information and financial
statements appearing elsewhere in this prospectus. In addition to this summary, we urge you to read the entire prospectus and other information
incorporated by reference in this prospectus from our other filings with the SEC before deciding whether to invest in our Class A Ordinary
Shares.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business comprises two main divisions: (i)&nbsp;OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted
through our Hong&nbsp;Kong subsidiary, Joint Cross Border, which we refer to as the &ldquo;Supply Chain Services&rdquo; division; and
(ii)&nbsp;OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong&nbsp;Kong subsidiary,&nbsp;V-Alliance,
which we refer to as the &ldquo;Procurement and Distribution&rdquo; division. Based in Hong&nbsp;Kong, Joint Cross Border has established
itself as a leading provider of third-party supply chain services in Mainland China&rsquo;s OTC pharmaceutical cross-border e-commerce
market. Through our engagement with OTC pharmaceutical suppliers, logistics companies, and merchants who operate stores on Chinese e-commerce
platforms, Joint Cross Border offers a convenient one-stop solution for Mainland Chinese customers seeking to access cross-border OTC
pharmaceutical products. Joint Cross Border&rsquo;s service offering includes a comprehensive array of services, such as pre-consultation,
product information review, procurement of overseas OTC pharmaceutical products, registration of OTC pharmaceutical products with the
HKDOH, obtaining import and export permits and clearances, warehousing, packaging, and arranging logistics and end-to-end delivery services
for consumers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
regulations and policies governing the cross-border supply chain for OTC pharmaceutical products vary from country to country. We believe
that the traditional supply chain is inefficient in navigating the intricate regulatory landscape and thus unable to meet the significant
and growing demand for overseas OTC pharmaceuticals among Mainland Chinese consumers. To capture this opportunity, Joint Cross Border
offers its clients a suite of supply chain solutions designed to address the unique requirements of handling cross-border OTC pharmaceutical
products. We believe our advanced technological capabilities, extensive experience in the OTC pharmaceutical supply chain service industry,
and e-commerce insights can further entrench our position as an increasingly important participant in Mainland China&rsquo;s OTC pharmaceutical
cross-border e-commerce market. Our main customers are (i)&nbsp;e-commerce platform logistics partners, such as CaiNiao, that engage
our supply chain services in connection with cross-border OTC pharmaceutical products, and (ii)&nbsp;merchants on established Chinese
e-commerce platforms, such as Tmall, Meituan, Pinduoduo, JD.com, Xiaohongshu, and Youzan, that offer popular OTC pharmaceutical products
sourced from Hong&nbsp;Kong, Taiwan, Japan, and certain European countries, including the United Kingdom and Germany. As of the date
of this prospectus, our system has cataloged more than 6,000 SKUs, including over 4,000 HKDOH-registered OTC SKUs. The OTC pharmaceutical
products we manage or distribute include traditional OTC Chinese medicine manufactured in Hong&nbsp;Kong and outside China, as well as
non-Chinese OTC medicine registered in Hong&nbsp;Kong and outside China. While on average over 90% of the products we handle are OTC
pharmaceutical products, our portfolio also includes non-pharmaceutical items such as health supplements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received industry recognition, including membership in The H.K. Medicine Dealers&rsquo; Guild and the China Medical Pharmaceutical
Material Association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of certain recent developments in our business and corporate affairs since the date of our most recently filed
annual report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Management
Changes</I>. On October 6, 2025, the Board of Directors (the &ldquo;Board&rdquo;) received and accepted the resignations of Mr. Lap Sun
Wong as Chief Executive Officer, Mr. Zhifang Zhang as Executive Director, and Mr. Kwok Man Bun as Chief Financial Officer, each effective
immediately and each for personal reasons unrelated to any disagreement with the Company or the Board. Effective on the same date, the
Board appointed Mr. Chenyu Liang as Director and Chief Executive Officer, Ms. Shu Liu as Chief Financial Officer, and Mr. Zifeng Wang
as Chief Strategy Officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Changes
to Board Composition</I>. On November 6, 2025, the Board received and accepted the resignations of Ms. Raina Zou as Independent Director
and chairperson of the audit committee, and Dr. King Yin Lai as Independent Director and chairperson of the compensation committee, each
for personal reasons unrelated to any disagreement with the Company or the Board. To fill the vacancy created by Ms. Zou&rsquo;s resignation,
the Board appointed Ms. Jingyan Wu as an independent director and chairperson of the audit committee, effective November 6, 2025. In
addition, effective September 9, 2025, the Board had appointed Mr. Mike Yao Zhou as an independent director and member of the nomination
committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2025
Annual General Meeting</I>. On December 12, 2025, the Company held its annual general meeting of shareholders (the &ldquo;2025 AGM&rdquo;),
at which the shareholders approved, among other things: (i) the re-election of five directors; (ii) the re-appointment of Onestop Assurance
PAC as the Company&rsquo;s independent registered public accounting firm for the fiscal year ending March 31, 2026; (iii) an increase
of the authorized share capital of the Company from US$100,000 divided into 100,000,000 ordinary shares to US$1,000,000 divided into
1,000,000,000 ordinary shares (the &ldquo;Increase of Share Capital&rdquo;); (iv) an amendment of the authorized share capital to create
two classes of ordinary shares, comprising 940,000,000 Class A Ordinary Shares and 60,000,000 Class B Ordinary Shares (the &ldquo;Implementation
of the Dual Class Structure&rdquo;); (v) authorization for the Board to effect a reverse share split and share consolidation at a ratio
of between one-for-ten and one-for-one hundred; (vi) the change of the Company&rsquo;s name; (vii) the adoption of the Fourth Amended
and Restated Memorandum and Articles of Association; (viii) the repurchase of 7,150,000 Class A Ordinary Shares registered in the name
of TUTU Business Services Limited and the concurrent issuance of 7,150,000 Class B Ordinary Shares (the &ldquo;Share Repurchase&rdquo;);
and (ix) the adoption of the Company&rsquo;s 2025 Equity Incentive Plan. The amendment to the authorized share capital and the repurchase
of the 7,150,000 Class A Ordinary Shares were fully completed as of February 8, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Change
of Company Name</I>. On December 31, 2025, the English name of the Company was changed from &ldquo;Hong Kong Pharma Digital Technology
Holdings Limited&rdquo; to &ldquo;Cellyan Biotechnology Co., Ltd,&rdquo; and the Chinese name of &ldquo;&#29983;&#30740;&#29983;&#29289;&#20844;&#21496;&rdquo;
was adopted as the dual foreign name of the Company in replacement of its existing Chinese name of &ldquo;&#28207;&#33647;&#25968;&#23383;&#31185;&#25216;&#25511;&#32929;&#26377;&#38480;&#20844;&#21496;,&rdquo;
with effect from the date on which the Registrar of Companies in the Cayman Islands issued the Certificate of Incorporation on Change
of Name confirming registration of the new name.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nasdaq
Minimum Bid Price Deficiency</I>. On January 12, 2026, the Company received a notification letter from the Listings Qualifications Department
of The Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;) indicating that the closing bid price of the Company&rsquo;s Class A Ordinary Shares
had been below the minimum requirement of US$1.00 per share for 30 consecutive business days, and that the Company was therefore not
in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notification letter does not result
in the immediate delisting of the Company&rsquo;s Class A Ordinary Shares, which continue to trade on Nasdaq under the symbol &ldquo;HKPD.&rdquo;
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until July 13, 2026, to regain
compliance. The Company is currently evaluating available options to regain compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption
of Fund Investment</I>. On November 10, 2025, the Company submitted an early redemption application in respect of its investment in an
open-ended fund, with total redemption proceeds of US$2,331,925. Pursuant to an agreed installment payment schedule, the first installment
of US$500,000 was paid on or around November 18, 2025, and the second installment of US$400,000 was paid on or around January 12, 2026.
As of March 18, 2026, the Company had received the first two installments of the redemption proceeds in full, with the remaining balance
of US$1,431,925 to be settled in one to three installments on or before March 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Repayment
of Bank Loan</I>. The Company&rsquo;s loan with Livi Bank, which was originally scheduled to mature on January 10, 2030, was repaid in
full, including all outstanding principal and accrued interest, as of January 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Structure</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following diagram illustrates our corporate structure as of the date of this prospectus, and assuming the completion of the Reclassification.
The blue box indicates the entity in which investors are purchasing their interests. The green boxes indicate the entities in which the
Company&rsquo;s operations are conducted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028373001_img1.jpg" ALT="" STYLE="height: 346px; width: 680px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
above holding company structure involves unique risks to investors, and you may never directly hold equity interests in the HK Subsidiaries.
You are specifically cautioned that, as we conduct substantially all of our operations in Hong Kong, there are significant legal and
operational risks associated with our operations in Hong Kong, including risks related to the legal, political, and economic policies
of the Chinese government, the relations between China and the United States, and applicable Chinese and United States regulations. These
risks could result in a material change in our operations and/or cause the value of Cellyan Biotechnology&rsquo;s Class A Ordinary Shares
to significantly decline or become worthless, and could affect Cellyan Biotechnology&rsquo;s ability to offer or continue to offer securities
to investors. Although we believe our operating structure is legal and permissible under Hong Kong laws and Chinese laws and regulations
currently in effect, Chinese regulatory authorities could take a different position on the interpretation and enforcement of applicable
laws and regulations and disallow our holding company structure, which would likely result in a material adverse change in our operations.
We are aware that the PRC government has initiated a series of regulatory actions and issued statements to regulate business operations
in certain areas in China, including cracking down on illegal activities in the securities market, enhancing supervision over China-based
companies listed overseas using a VIE structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding efforts
in anti-monopoly enforcement. We currently do not have, nor intend to have in the future, a VIE structure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 18, 2026, V-Alliance acquired 100% share ownership of New Ben Global Enterprises Limited (&#29275;&#29319;&#29615;&#29699;&#23454;&#19994;&#26377;&#38480;&#20844;&#21496;),
a company incorporated in Hong Kong from WAN FENG, an individual. As of the date of this prospectus, New Ben has not commenced operations
and has not generated any revenues. The Company expects that the subsidiary may be used to support its future business expansion; however,
no specific business activities have been initiated as of the date hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
of Cash Through Our Organization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the fiscal&nbsp;years ended March&nbsp;31, 2025, 2024 and 2023, and up to the date of this prospectus, the transfer of cash or other
types of assets between Cellyan Biotechnology and any of its HK Subsidiaries totaled $810,000. This amount represented the subscription
price for the Class B Ordinary Shares paid by the holder of such shares and was remitted to Joint Cross Border directly as an interest-free,
payable on demand loan from Cellyan Biotechnology. See our consolidated financial statements and related notes incorporated by reference
into this prospectus. Additionally, no dividends or distributions have been made by any of our HK Subsidiaries or Cellyan Biotechnology
to date, including to any U.S. investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we decide to pay dividends on our Ordinary Shares in the future, as a holding company, we will be dependent on the receipt of funds from
our HK Subsidiaries by way of dividend payments made by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is permitted under the laws of the Cayman Islands to provide funding to our HK Subsidiaries through loans or capital contributions
without restrictions on the amount of the funds. Currently, the HK Subsidiaries are permitted under the laws of Hong&nbsp;Kong to provide
funding to Cellyan Biotechnology through dividend distributions without restrictions on the amount of the funds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently intend to retain all available funds and future earnings, if any, for the operation and expansion of our business and do not
anticipate declaring or paying any dividends in the foreseeable future. Any future determination related to our dividend policy will
be made at the discretion of our board of directors after considering our financial condition, results of operations, capital requirements,
contractual requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions
contained in any future financing instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the Companies Act (As Revised) of the Cayman Islands, which we refer to as the Companies Act below, and our memorandum and articles
of association, our board of directors may authorize and declare a dividend to shareholders at such time and of such an amount as they
think fit if they are satisfied, on reasonable grounds, that immediately following the payment of the dividend, we will be able to pay
our debts as they become due in the ordinary course of business. Any dividend shall be paid out of profits and/or out of amounts credited
to the share premium account. There is no other statutory restriction on the amount of funds which may be distributed by us by dividend
under the laws of the Cayman Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Hong&nbsp;Kong laws, dividends may only be paid out of distributable profits (that is, accumulated realized profits less accumulated
realized losses) or other distributable reserves. Dividends cannot be paid out of share capital. Under the current practice of the Inland
Revenue Department of Hong&nbsp;Kong, no tax is payable in Hong&nbsp;Kong in respect of dividends paid by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is a Cayman Islands exempted company, and each of the HK Subsidiaries is a Hong&nbsp;Kong company. Currently, there are
no restrictions or limitations under the laws of Hong Kong on (i) foreign exchange or the conversion of HK dollars into foreign currencies
and the remittance of currencies out of Hong&nbsp;Kong, (ii) the transfer of cash or other assets between Cellyan Biotechnology and any
of the HK Subsidiaries, across borders, or to U.S. investors, or (iii) the distribution of earnings from the HK Subsidiaries to Cellyan
Biotechnology or U.S.&nbsp;investors. However, if certain PRC laws and regulations, including existing laws and regulations and those
enacted or promulgated in the future, were to become applicable to our HK Subsidiaries, to the extent our cash or assets are in Hong
Kong or with a Hong Kong entity, such funds or assets may not be available to fund operations or for other use outside of Hong Kong due
to interventions in or the imposition of restrictions and limitations on the HK Subsidiaries&rsquo; ability to transfer funds or assets
by the PRC government. We cannot assure you that the PRC government will not intervene or impose restrictions on the HK Subsidiaries
regarding the transfer or distribution of cash within the organization or to U.S. investors, which could result in an inability of or
prohibition on the HK Subsidiaries from making transfers or distributions to Cellyan Biotechnology or U.S. investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the HK Subsidiaries has established strict internal cash management policies, which stipulate that, among other things, (i) regarding
cash, the entity should not hold more than HK$100,000 cash on a single day and excess cash should be deposited into bank accounts, and
(ii) regarding bank accounts, including online banking, each entity has layered authorization for accessing and using bank accounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
&ldquo;Dividend Policy&rdquo; and &ldquo;Item 3. Key Information &mdash; D. Risk Factors &mdash; Risks Related to Our Business and Industry
&mdash; Hong Kong Pharma relies on dividends and other distributions on equity paid by its HK Subsidiaries to fund any cash and financing
requirements Hong Kong Pharma may have, and any limitation on the ability of its HK Subsidiaries to make payments to Hong Kong Pharma
could have a material adverse effect on our ability to conduct our business. Additionally, while currently there are no restrictions
on foreign exchange, nor limitations on the ability of Hong Kong Pharma to transfer cash to or from HK Subsidiaries or to investors under
Hong Kong laws, if certain PRC laws and regulations, including existing laws and regulations and those enacted or promulgated in the
future, were to become applicable to our HK Subsidiaries, to the extent our cash or assets are in Hong Kong or with a Hong Kong entity,
such funds or assets may not be available to fund operations or for other use outside of Hong Kong due to interventions in or the imposition
of restrictions and limitations on HK Subsidiaries&rsquo; ability to transfer funds or assets by the PRC government&rdquo; on page 17
of the 2025 Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Regulatory Developments in China</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is a holding company incorporated in the Cayman Islands, with all of its operations conducted by the HK Subsidiaries in
Hong&nbsp;Kong. Cellyan Biotechnology and its subsidiaries are not based in Mainland China and do not have operations in Mainland China,
as of the date of this prospectus. Cellyan Biotechnology currently does not have any subsidiary in Mainland China, nor does it foresee
the need to enter into any contractual arrangements with a VIE to establish a VIE structure in Mainland China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong
is a special administrative region of the PRC and the basic policies of the PRC regarding Hong&nbsp;Kong are reflected in the Basic Law,
which is a national law of the PRC and serves as Hong Kong&rsquo;s constitutional document. Pursuant to the Basic Law, national laws
of the PRC shall not be applied in Hong&nbsp;Kong except for those listed in Annex&nbsp;III of the Basic Law and applied locally by promulgation
or local legislation. The Basic Law expressly provides that the national laws of the PRC which may be listed in Annex&nbsp;III shall
be confined to those relating to defense and foreign affairs as well as other matters outside the autonomy of Hong&nbsp;Kong. The Basic
Law provides Hong&nbsp;Kong with a high degree of autonomy and executive, legislative and independent judicial powers, including that
of final adjudication, under the principle of &ldquo;one country, two systems.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
light of China&rsquo;s recent expansion of authority in Hong&nbsp;Kong, there are risks and uncertainties which we cannot foresee for
the time being, and rules, regulations and the enforcement of laws in China can change quickly. If there is a significant change to current
political arrangements between Mainland China and Hong&nbsp;Kong, Cellyan Biotechnology will be subject to uncertainty about any future
actions of the PRC government or authorities in Hong&nbsp;Kong, and it is possible that all the legal and operational risks associated
with being based in and having operations in the PRC may also apply to operations in Hong&nbsp;Kong in the future. There is no assurance
that there will not be any changes in the economic, political and legal environment in Hong&nbsp;Kong in the future. The PRC government
may intervene or influence Cellyan Biotechnology&rsquo;s current and future operations in Hong&nbsp;Kong at any time, or may exert more
control over offerings conducted overseas and/or foreign investment in issuers like Cellyan Biotechnology. Such governmental actions,
if and when they occur: (i)&nbsp;could significantly limit or completely hinder Cellyan Biotechnology&rsquo;s ability to continue its
operations; (ii)&nbsp;could significantly limit or hinder Cellyan Biotechnology&rsquo;s ability to offer or continue to offer its Class
A Ordinary Shares to investors; and (iii)&nbsp;may cause the value of Cellyan Biotechnology&rsquo;s Class A Ordinary Shares to significantly
decline or become worthless.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the PRC government initiated a series of regulatory actions and statements to regulate business operations in certain areas in China
with little advance notice, including cracking down on illegal activities in the securities market, enhancing supervision over China-based
companies listed overseas using VIE structures, adopting new measures to extend the scope of cybersecurity reviews, and expanding efforts
in anti-monopoly enforcement. For example, on July 6, 2021, the General Office of the Communist Party of China Central Committee and
the General Office of the State Council jointly issued a document to crack down on illegal activities in the securities market and promote
the high-quality development of the capital market, which, among other things, requires the relevant governmental authorities to strengthen
cross-border oversight of law enforcement and judicial cooperation, in order to enhance supervision over China-based companies listed
overseas, and to establish and improve the system of extraterritorial application of the PRC securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 17, 2023, the CSRC issued the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Enterprises,
or the Trial Measures, which became effective on March 31, 2023. On the same date of the issuance of the Trial Measures, the CSRC circulated
No.1 to No.5 Supporting Guidance Rules, the Notes on the Trial Measures, the Notice on Administration Arrangements for the Filing of
Overseas Listings by Domestic Enterprises and the relevant CSRC Answers to Reporter Questions on the official website of the CSRC (collectively,
and together with the Trial Measures, the &ldquo;New Overseas Listing Rules&rdquo;). Pursuant to the New Overseas Listing Rules, where
a PRC domestic company submits an application for initial public offerings or listings in overseas markets, such issuer shall file with
the CSRC within three working days after such application is submitted. Article 15 of the Trial Measures provides that if the issuer
meets both of the following criteria, the overseas securities offering and listing conducted by such issuer will be deemed an indirect
overseas offering by a Mainland China company and such issuer shall fulfill the CSRC filing procedure prior to its listing on the foreign
stock markets: (i) 50% or more of any of the issuer&rsquo;s operating revenue, total profit, total assets or net assets as documented
in its audited consolidated financial statements for the most recent fiscal year is accounted for by Mainland China companies; and (ii)
the main parts of the issuer&rsquo;s business activities are conducted in Mainland China, or its main place(s) of business are located
in Mainland China, or the majority of senior management staff in charge of its business operations and management are PRC citizens or
have their usual place(s) of residence located in Mainland China.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
advised by Cellyan Biotechnology&rsquo;s PRC counsel, based on the facts that (i) more than 99% of the Company&rsquo;s operating revenue,
total profit, total assets and net assets as documented in its audited consolidated financial statements for the most recent fiscal year
are accounted for by Cellyan Biotechnology&rsquo;s subsidiaries located outside Mainland China; (ii) our core business activities are
not conducted in Mainland China, and our principal places of business are located outside Mainland China; and (iii) as of the date of
this prospectus, Cellyan Biotechnology does not directly or indirectly have any equity or similar interest in any domestic company or
entity registered in Mainland China, we believe that we do not meet the criteria as set forth in Article 15 of the Trial Measures, and
this offering is not an indirect offering and listing of securities in overseas markets as prescribed in the New Overseas Listing Rules
and thus Cellyan Biotechnology is not required to fulfill the CSRC filing procedure in connection with the offering of the Offered Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
as of the date of this prospectus, in respect of the New Overseas Listing Rules, as advised by Guangdong Jishi Furen Law Firm, Cellyan
Biotechnology&rsquo;s PRC counsel, Cellyan Biotechnology believes it is not required to obtain permission from any PRC authorities (including
those in Hong Kong) to issue its Class A Ordinary Shares to investors, including the CSRC or any other PRC governmental authority. However,
as the New Overseas Listing Rules were recently promulgated and there exists uncertainty with respect to the implementation and interpretation
of the principle of &ldquo;substance over form,&rdquo; it remains uncertain whether Cellyan Biotechnology&rsquo;s offering and listing
will be deemed as &ldquo;indirect overseas offering and listing by companies in Mainland China&rdquo; and subject to the filing procedures.
See &ldquo;Item 3. Key Information&mdash;D. Risk Factors &mdash; Risks Related to Doing Business in Hong Kong &mdash; We may become subject
to a variety of PRC laws and other obligations regarding cyber security, data protection, overseas offerings and/or foreign investment
in China-based issuers, and any failure to comply with applicable laws and obligations could have a material adverse effect on our business,
financial condition, and results of operations and may hinder our ability to offer or continue to offer Ordinary Shares to investors
and cause the value of our Ordinary Shares to significantly decline or be worthless&rdquo; on page 19 of the 2025 Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 28, 2021, the CAC and other authorities of Mainland China promulgated the Cybersecurity Review Measures (the &ldquo;CRM&rdquo;),
which took effect on February 15, 2022. Pursuant to the CRM, the purchase of network products and services by a critical information
infrastructure operator (the &ldquo;CIIO&rdquo;) and the data processing activities carried out by online platform operators that affect
or may affect national security shall be subject to cybersecurity review. In addition, an online platform operator that possesses the
personal information of more than one million users and seeks to go public abroad shall apply to the Office of Cybersecurity Review for
a cybersecurity review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
advised by Guangdong Jishi Furen Law Firm, Cellyan Biotechnology&rsquo;s PRC counsel, Cellyan Biotechnology does not believe it is obligated
to apply for a cybersecurity review pursuant to the CRM, considering that (i) we do not possess personal information of more than one
million individuals in Mainland China, and we do not possess any core data or important data of the PRC or any information that affects
or may affect the national security of the PRC; (ii) the CRM provides no further explanation or interpretation for &ldquo;online platform
operator&rdquo; or &ldquo;affect or may affect national security&rdquo;; (iii) as of the date of this prospectus, we have not received
any notice or determination from applicable PRC governmental authorities identifying any of Cellyan Biotechnology&rsquo;s subsidiaries
as a CIIO or any of its systems as critical information infrastructure; and (iv) Cellyan Biotechnology has not received any notification
of cybersecurity review from relevant PRC governmental authorities due to the impact or potential impact on national security.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
HK Subsidiaries may collect and store certain data from their clients in Mainland China and Hong Kong during their conduct of business.
Given that (1) each of the HK Subsidiaries was incorporated and located in Hong Kong; (2) as of the date of this prospectus, Cellyan
Biotechnology has no subsidiary, VIE structure, nor any direct operations in Mainland China; and (3) pursuant to the Basic Law, which
is a national law of the PRC and the constitutional document for Hong Kong, national laws of the PRC shall not be applied in Hong Kong
except for those listed in Annex III of the Basic Law (which is confined to laws relating to defense and foreign affairs, as well as
other matters outside the autonomy of Hong Kong), Cellyan Biotechnology does not currently expect the CRM, the PRC Personal Information
Protection Law, (as defined below), the PRC Data Security Law (as defined below), and the New Overseas Listing Rules to have an impact
on its business, operations, or this offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Permission
Required from Hong&nbsp;Kong and Chinese Authorities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology has been advised by SH Wong &amp; Co, its Hong&nbsp;Kong counsel, that based on their understanding of the current Hong&nbsp;Kong
laws, as of the date of this prospectus, neither Cellyan Biotechnology nor any of the HK Subsidiaries is required to obtain any permission
or approval from Hong&nbsp;Kong authorities to maintain listing in the U.S.&nbsp;or to issue Class A Ordinary Shares to foreign investors.
Cellyan Biotechnology has been advised by Guangdong Jishi Furen Law Firm, its PRC legal counsel, that based on their understanding of
the current PRC laws, as of the date of this prospectus, neither Cellyan Biotechnology nor any of the HK Subsidiaries is required to
obtain any permission or approval from any PRC authorities to maintain listing in the U.S. or to issue Class A Ordinary Shares to foreign
investors, including from the CSRC or the CAC, because (i)&nbsp;this offering is not an indirect offering and listing of securities in
overseas markets as prescribed in the New Overseas Listing Rules and the CSRC has not, as of the date of this prospectus, issued any
definitive rule or interpretation concerning whether offerings like ours pursuant to this prospectus are subject to the New Overseas
Listing Rules; and (ii) the HK Subsidiaries were established and operate in Hong&nbsp;Kong and are not included in the categories of
industries and companies whose foreign securities offerings are subject to review by the CSRC or the CAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, the HK Subsidiaries have&nbsp;received from Hong&nbsp;Kong authorities all requisite licenses, permissions
and approvals needed to engage in the businesses currently conducted by them in Hong&nbsp;Kong, and no such permission or approval&nbsp;has
been denied. As of the date of this prospectus, neither Cellyan Biotechnology nor any of the HK Subsidiaries is required to obtain any
license, permission or approval from authorities of Mainland China to operate our business. The following table summarizes the licenses,
permissions and approvals held by the HK Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License/Permit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuing
    Authority</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuance
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Cross Border Logistics Company Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Registration Ordinance (Chapter&nbsp;310)&nbsp;&ndash;Business
    Registration Certificate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;18, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;17, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Medicine Company (as business/branch Name for
    Joint Cross Border Logistics Company Limited)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Registration Ordinance (Chapter&nbsp;310)&nbsp;&ndash;Business
    Registration Certificate</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;18, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;17, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Medicine Company/Joint Cross Border Logistics
    Company Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chinese Medicine Ordinance (Chapter&nbsp;549)&nbsp;&ndash;Wholesaler
    Licence in Proprietary Chinese Medicines</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR Chinese Medicines Traders Committee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July 25, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;16, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Medicine Company/Joint Cross Border Logistics
    Company Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Antibiotics Ordinance (Chapter&nbsp;137)&nbsp;&ndash;Permit</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR Director of Health</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">October&nbsp;1, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">September&nbsp;30, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Medicine Company/Joint Cross Border Logistics
    Company Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Waste Disposal Ordinance (Chapter&nbsp;354)&nbsp;&ndash;Registration
    of Waste Producer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR Director of Environmental Protection</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August 2, 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">N/A</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Medicine Company/Joint Cross Border Logistics
    Company Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmacy and Poisons Ordinance (Chapter&nbsp;138)&nbsp;&ndash;Wholesale
    Dealer Licence</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR Pharmacy and Poisons Board</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 1, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May&nbsp;31, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>License/Permit</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuing
    Authority</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issuance
    Date</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiration
    Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint Cross Border Logistics Company Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pesticides Ordinance (Chapter&nbsp;133)&nbsp;&ndash;Pesticides
    Licence</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR Director of Agriculture, Fisheries
    and Conservation</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">December&nbsp;18, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&nbsp;13, 2027</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V-Alliance Technology Supplies Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chinese Medicine Ordinance (Chapter&nbsp;549)&nbsp;&ndash;Wholesaler
    Licence in Proprietary Chinese Medicines</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR Chinese Medicines Traders Committee</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&nbsp;4, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">January&nbsp;3, 2027</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V-Alliance Technology Supplies Limited</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Food Safety Ordinance (Chapter&nbsp;612)&nbsp;&ndash;Registration
    as Food Importer/Food Distributor</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong SAR<BR>
    Food Importer/ Distributor Registration and Import Licensing Office</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;21, 2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">July&nbsp;20, 2026</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Cellyan
Biotechnology has also been advised by Guangdong Jishi Furen Law Firm, its PRC legal counsel, that uncertainties still exist, due to
the possibility that laws, regulations, or policies in the PRC could change rapidly in the future. In the event that (i) the PRC government
expanded the categories of industries and companies whose foreign securities offerings are subject to review by the CSRC or the CAC and
we were required to obtain such permissions or approvals; or (ii) we inadvertently concluded that relevant permissions or approvals were
not required, or we failed to receive or maintain any such permissions or approvals, our operations in Hong Kong and our ability to offer
or continue to offer securities to investors could be significantly limited or completely hindered, and the value of such securities
could significantly decline or become worthless. In addition, if we do not receive or maintain our existing licenses, or we inadvertently
conclude that governmental approvals are not required, or applicable laws, regulations, or interpretations change such that we are required
to obtain approval in the future and we fail to obtain such approval on a timely basis, we may be subject to governmental investigations,
fines, penalties, orders to suspend operations and rectify any non-compliance, or prohibitions from conducting certain business or any
financing, which could result in a material adverse change in our operations, significantly limit or completely hinder our ability to
offer or continue to offer securities to investors, or cause our securities to significantly decline in value or become worthless.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
PCAOB Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Class A Ordinary Shares may be prohibited from trading on a national exchange under the HFCA Act if the PCAOB is unable to inspect our
auditors fully for two consecutive years. Pursuant to the HFCA Act, enacted in 2020, if the auditor of a U.S.&nbsp;-listed company&rsquo;s
financial statements is not subject to PCAOB inspections for three consecutive &ldquo;non-inspection&rdquo; years, the SEC is required
to prohibit the securities of such issuer from being traded on a U.S.&nbsp;national securities exchange, such as NYSE and Nasdaq, or
in U.S.&nbsp;over-the-counter markets. On December&nbsp;23, 2022, the U.S.&nbsp;Senate passed the Accelerating Holding Foreign Companies
Accountable Act, and on December&nbsp;29, 2022, legislation entitled &ldquo;Consolidated Appropriations Act, 2023&rdquo; was signed into
law, which contained, among other things, a provision identical to the Accelerating Holding Foreign Companies Accountable Act that amended
the HFCA Act by requiring the SEC to prohibit an issuer&rsquo;s securities from trading on any U.S.&nbsp;stock exchange if its auditor
is not subject to PCAOB inspections for two consecutive&nbsp;years instead of three, thereby reducing the period for triggering the trading
prohibition. The delisting of our Class A Ordinary Shares, or the threat of their being delisted, may materially and adversely affect
the value of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
auditor, Onestop Assurance PAC, the independent registered public accounting firm that issues the audit report included elsewhere in
this prospectus, is an auditor of publicly traded companies in the United States and a firm registered with the PCAOB, and is therefore
subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess compliance with applicable professional
standards. Onestop Assurance PAC has been inspected by the PCAOB on a regular basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 16, 2021, the PCAOB issued a report on its determinations that it was unable to inspect or investigate completely PCAOB-registered
public accounting firms headquartered in Mainland China and Hong Kong, because of positions taken by PRC authorities in those jurisdictions.
The PCAOB made its determinations pursuant to PCAOB Rule 6100, which provides a framework for how the PCAOB fulfills its responsibilities
under the HFCA Act. The report further identified, in Appendix A and Appendix B, the registered public accounting firms subject to the
Mainland China determination and the Hong Kong determination, respectively. Our auditor, Onestop Assurance PAC, is headquartered in Singapore
and was not included in the report or listed under Appendix A or Appendix B.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 26, 2022, the CSRC, the MOF, and the PCAOB signed a Protocol governing inspections and investigations of accounting firms based
in Mainland China and Hong Kong, taking the first step toward opening access for the PCAOB to inspect and investigate registered public
accounting firms headquartered in Mainland China and Hong Kong. Pursuant to the fact sheet disclosed by the SEC with respect to the Protocol,
the PCAOB shall have independent discretion to select any issuer audits for inspection or investigation and the unfettered ability to
transfer information to the SEC. On December 15, 2022, the PCAOB issued a new determination report which: (1) vacated the December 16,
2021 determination report; and (2) concluded that the PCAOB was able, in 2022, to inspect and investigate completely issuer audit engagements
of PCAOB-registered public accounting firms headquartered in Mainland China and Hong Kong. However, uncertainties still exist as to whether
the PCAOB will continue to have access for complete inspections and investigations. The PCAOB has also indicated that it will act immediately
to consider the need to issue new determinations under the HFCA Act if warranted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more detailed information, see &ldquo;Item 3. Key Information &mdash; D. Risk Factors &mdash; Risks Related to Doing Business in Hong
Kong &mdash; The recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and acts passed by the U.S. Senate and
the U.S. House of Representatives, all call for additional and more stringent criteria to be applied to U.S.-listed companies with significant
operations in China and Hong Kong. These developments could add uncertainties to our business operations, share price and reputation&rdquo;
on page 21 of the 2025 Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Summary
of Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing
in Cellyan Biotechnology&rsquo;s Class A Ordinary Shares involves significant risks. You should carefully consider all of the information
in this prospectus before making an investment in Cellyan Biotechnology&rsquo;s Class A Ordinary Shares. Below please find a summary
of the principal risks we face, organized under relevant headings. These risks are discussed more fully under &ldquo;Item 3. Key Information&mdash;D.
Risk Factors&rdquo; beginning on page 5 of the 2025 Annual Report and in the section titled &ldquo;Risk Factors&rdquo; of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to Our Business and Industry</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risks
and uncertainties related to the Company&rsquo;s business and industry include, without limitation, the following. For details of each
of these bulleted risk factors, see &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks Related to Our Business
and Industry&rdquo; under the same subheadings beginning on page 5 of the 2025 Annual Report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face intense
    competition in the broader supply chain services industry, especially if large logistics service providers who hire our expertise
    decide to expand their offerings to include OTC pharmaceutical related supply chain services in-house, which could adversely affect
    our results of operations and market share. (see page 5 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our OTC pharmaceutical
    cross-border procurement and distribution business operates in highly competitive and evolving markets. (see page 6 of the 2025 Annual
    Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain customers
    contributed to a significant percentage of our total revenue during the fiscal&nbsp;years ended March&nbsp;31, 2024 and 2025, and
    losing one or more of them could result in a material adverse impact on our financial performance and business prospects. (see page
    6 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail
    to cost-efficiently attract new customers to use our solutions and services, or to maintain relationships with existing customers,
    our business and results of operations could be adversely affected. (see page 7 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business
    and growth are significantly affected by the development of international commerce and the e-commerce industry, as well as macroeconomic
    and other factors that affect demand for OTC pharmaceutical products and related supply chain services, in Hong&nbsp;Kong, Mainland
    China, and globally. (see page 7 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current and
    future trade restrictions could materially and adversely affect our business, financial condition, and results of operations. (see
    page 8 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face risks
    associated with the OTC pharmaceutical inventories handled through our logistics networks, including real or perceived quality or
    health issues with the products that are handled through our logistics networks, and risks inherent in the logistics industry, including
    personal injury, product damage, and transportation-related incidents. (see page 8 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to
    successfully implement our business strategy, effectively respond to changes in market dynamics and satisfactorily meet customer
    demands may cause our future financial results to suffer. (see page 9 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any disruption
    to the operation of our warehousing and logistics facilities, or to the development of new warehousing and logistics facilities,
    could have a material adverse effect on our business, financial condition, and results of operations. (see page 10 of the 2025 Annual
    Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our suppliers
    include OTC pharmaceutical producers and distributors, logistics service subcontractors, packaging service providers, etc., and any
    loss of our suppliers or if our suppliers fail to deliver products or services according to schedules, prices, quality and volumes
    that are acceptable to us, our operation may suffer. (see page 10 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our insurance
    coverage may not be adequate, which could expose us to significant costs and business disruptions. (see page 11 of the 2025 Annual
    Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail
    to comply with applicable laws and regulations, many of which are highly complex, we could be subject to significant adverse regulatory
    actions, including monetary penalties, or suffer brand and reputational harm. (see page 11 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to
    obtain certain filings, approvals, licenses, permits and certificates required for our business operations may materially and adversely
    affect our business, financial condition and results of operations. (see page 12 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The failure
    or disruption of our information technology systems or the failure of our information technology infrastructure to support our businesses
    could adversely affect our reputation, business, operating results, and cash flows. (see page 13 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data governance
    failures can adversely affect our reputation, businesses, and prospects. Our use and disclosure of customers&rsquo; sensitive information
    is subject to complex regulations at multiple levels. We would be adversely affected if we or our business associates or other vendors
    fail to adequately protect customers&rsquo; or other sensitive information. (see page 14 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our business
    depends on the continued efforts of our senior management. If any of our key executives and employees was unable or unwilling to
    continue in their present positions, our business may be severely disrupted. (see page 15 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan Biotechnology
    relies on dividends and other distributions on equity paid by its HK Subsidiaries to fund any cash and financing requirements Cellyan
    Biotechnology may have, and any limitation on the ability of its HK Subsidiaries to make payments to Cellyan Biotechnology could
    have a material adverse effect on our ability to conduct our business. Additionally, while currently there are no restrictions on
    foreign exchange, nor limitations on the ability of Cellyan Biotechnology to transfer cash to or from HK Subsidiaries or to investors
    under Hong Kong laws, if certain PRC laws and regulations, including existing laws and regulations and those enacted or promulgated
    in the future, were to become applicable to our HK Subsidiaries, to the extent our cash or assets are in Hong Kong or with a Hong
    Kong entity, such funds or assets may not be available to fund operations or for other use outside of Hong Kong due to interventions
    in or the imposition of restrictions and limitations on HK Subsidiaries&rsquo; ability to transfer funds or assets by the PRC government.
    (see page 17 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure to
    achieve and maintain effective internal controls could adversely affect our business and price of our securities. (see page 18 of
    the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are exposed
    to foreign currency risk. (see page 18 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to Doing Business in Hong&nbsp;Kong</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
    all our operations are in Hong&nbsp;Kong. However, the legal and operational risks associated with operations in China may also apply
    to our operations in Hong&nbsp;Kong. The Chinese government may exercise significant oversight and control over the conduct of our
    business and may intervene in or influence our operations at any time, which could result in a material change in our operations
    and may significantly limit or completely hinder our ability to offer or continue to offer Class A Ordinary Shares to investors and
    cause the value of the Class A Ordinary Shares to significantly decline or be worthless. Changes in the policies, regulations, rules,
    and the enforcement of laws of the Chinese government may also be quick and the risks related to the PRC legal and regulatory system
    may materialize. See &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks Related to Doing Business in
    Hong Kong&nbsp;&mdash;&nbsp;Substantially all our operations are in Hong Kong. However, the legal and operational risks associated
    with operations in China may also apply to our operations in Hong Kong. The Chinese government may exercise significant oversight
    and control over the conduct of our business and may intervene in or influence our operations at any time, which could result in
    a material change in our operations and may significantly limit or completely hinder our ability to offer or continue to offer Ordinary
    Shares to investors and cause the value of the Ordinary Shares to significantly decline or be worthless. Changes in the policies,
    regulations, rules, and the enforcement of laws of the Chinese government may also be quick and the risks related to the PRC legal
    and regulatory system may materialize&rdquo; beginning on page 19 of the 2025 Annual Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The enactment
    of Law of the PRC on Safeguarding the Hong&nbsp;Kong National Security Law could impact our Hong&nbsp;Kong operating subsidiaries.
    See &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks Related to Doing Business in Hong Kong&nbsp;&mdash;&nbsp;The
    enactment of Law of the PRC on Safeguarding the Hong Kong National Security Law could impact our Hong Kong operating subsidiaries&rdquo;
    beginning on page 20 of the 2025 Annual Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in
    Hong&nbsp;Kong&rsquo;s economic, political or social conditions or government policies could have a material adverse effect on the
    Company&rsquo;s business and operations. See &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks Related
    to Doing Business in Hong Kong&nbsp;&mdash;&nbsp;Changes in Hong Kong&rsquo;s economic, political or social conditions or government
    policies could have a material adverse effect on the Company&rsquo;s business and operations&rdquo; beginning on page 20 of the 2025
    Annual Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There are political
    risks associated with conducting business in Hong&nbsp;Kong. See &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks
    Related to Doing Business in Hong Kong&nbsp;&mdash;&nbsp;There are political risks associated with conducting business in Hong Kong&rdquo;
    beginning on page 20 of the 2025 Annual Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The recent
    joint statement by the SEC, proposed rule changes submitted by Nasdaq, and acts passed by the U.S.&nbsp;Senate and the U.S.&nbsp;House
    of Representatives, all call for additional and more stringent criteria to be applied to U.S.-listed companies with significant operations
    in China and Hong&nbsp;Kong. These developments could add uncertainties to our business operations, share price and reputation. See
    &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks Related to Doing Business in Hong Kong&nbsp;&mdash;&nbsp;The
    recent joint statement by the SEC, proposed rule changes submitted by Nasdaq, and acts passed by the U.S. Senate and the U.S. House
    of Representatives, all call for additional and more stringent criteria to be applied to U.S.-listed companies with significant operations
    in China and Hong Kong. These developments could add uncertainties to our business operations, share price and reputation&rdquo;
    beginning on page 21 of the 2025 Annual Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Hong&nbsp;Kong
    and China legal systems are evolving and embody uncertainties which could limit the legal protections available to us. Uncertainties
    with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes
    in laws and regulations in China could adversely affect us. See &ldquo;Item 3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks
    Related to Doing Business in Hong Kong&nbsp;&mdash;&nbsp;The Hong Kong and China legal systems are evolving and embody uncertainties
    which could limit the legal protections available to us. Uncertainties with respect to the PRC legal system, including uncertainties
    regarding the enforcement of laws, and sudden or unexpected changes in laws and regulations in China could adversely affect us&rdquo;
    beginning on page 23 of the 2025 Annual Report.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may become
    subject to a variety of PRC laws and other obligations regarding cyber security, data protection, overseas offerings and/or foreign
    investment in China-based issuers, and any failure to comply with applicable laws and obligations could have a material adverse effect
    on our business, financial condition, and results of operations and may hinder our ability to offer or continue to offer Class A
    Ordinary Shares to investors and cause the value of the Class A Ordinary Shares to significantly decline or be worthless. See &ldquo;Item
    3. Key Information &mdash; D. Risk Factors&nbsp;&mdash;&nbsp;Risks Related to Doing Business in Hong Kong&nbsp;&mdash;&nbsp;We may
    become subject to a variety of PRC laws and other obligations regarding cyber security, data protection, overseas offerings and/or
    foreign investment in China-based issuers, and any failure to comply with applicable laws and obligations could have a material adverse
    effect on our business, financial condition, and results of operations and may hinder our ability to offer or continue to offer Ordinary
    Shares to investors and cause the value of our Ordinary Shares to significantly decline or be worthless&rdquo; beginning on page
    19 of the 2025 Annual Report. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Risks
Related to Ownership of Our Securities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price of the
    Class A Ordinary Shares has been volatile or may decline regardless of our operating performance. (see page 24 of the 2025 Annual
    Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to maintain
    a listing of the Class A Ordinary Shares on Nasdaq. (see page 26 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If securities or industry
    analysts publish unfavorable research, or do not continue to cover us, the Company&rsquo;s share price and trading volume could decline.
    (see page 26 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have not historically
    declared or paid dividends on our shares and, consequently, your ability to achieve a return on your investment will depend on appreciation
    in the price of the Class A Ordinary Shares. (see page 26 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may issue additional
    equity or debt securities, which are senior to the Class A Ordinary Shares as to distributions and in liquidation, which could materially
    adversely affect the market price of the Class A Ordinary Shares. (see page 26 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will be subject to ongoing
    public reporting requirements that are less rigorous than Exchange&nbsp;Act rules for companies that are not emerging growth companies,
    and the shareholders could receive less information than they might expect to receive from more mature public companies. (see page
    27 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are a foreign private
    issuer within the meaning of the rules under the Exchange&nbsp;Act, and as such we are exempt from certain provisions applicable
    to U.S.&nbsp;domestic public companies. We plan to take advantage of the exemptions available to us as a foreign private issuer.
    (see page 28 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As a foreign private issuer,
    we are permitted to rely on exemptions from certain Nasdaq corporate governance standards applicable to domestic U.S.&nbsp;issuers.
    This may afford less protection to holders of the Class A Ordinary Shares. (see page 28 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may lose our foreign
    private issuer status in the future, which could result in significant additional costs and expenses. (see page 29 of the 2025 Annual
    Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You may be unable to present
    proposals before annual general meetings or extraordinary general meetings not called by shareholders. (see page 29 of the 2025 Annual
    Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain judgments obtained
    against us and the Selling Shareholders by Cellyan Biotechnology&rsquo;s shareholders may not be enforceable. (see page 29 of the
    2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You may face difficulties
    in protecting your interests, and your ability to protect your rights through U.S.&nbsp;courts may be limited, because Cellyan Biotechnology
    was incorporated under Cayman Islands law. (see page 29 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan Biotechnology&rsquo;s
    amended and restated memorandum and articles of association contain anti-takeover provisions that could discourage a third party
    from acquiring us, which could limit Cellyan Biotechnology&rsquo;s shareholders&rsquo; opportunity to sell their shares at a premium.
    (see page 30 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman Islands economic
    substance requirements may have an effect on our business and operations. (see page 30 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is a risk that we
    will be a passive foreign investment company for any taxable year, which could result in adverse U.S.&nbsp;federal income tax consequences
    to U.S.&nbsp;investors in the Class A Ordinary Shares. (see page 30 of the 2025 Annual Report)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable
    to continue to meet the listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted. For details, see the risk factor
    on page 17 of this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our largest shareholder,
    Ms. Liying Wang, holds a majority of the voting power of the Company&rsquo;s outstanding share capital, which will limit or preclude
    your ability to influence corporate matters. For details, see the risk factor on page 17 of this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The sale of a substantial
    amount of our Class A Ordinary Shares by the Selling Shareholders in the public market could adversely affect the prevailing market
    price of our Class A Ordinary Shares. For details, see the risk factor on page 17 of this prospectus.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal executive offices are located at Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon, Hong Kong.
Our telephone number at this address is +852 2618-9289. Our registered office in the Cayman Islands is located at 4<SUP>th</SUP> Floor,
Harbour Place, 103 South Church Street, P.O. Box 10240, Grand Cayman KY1-1002, Cayman Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
should submit any inquiries to the address and telephone number of our principal executive offices. Our corporate website is http://
www.9zt.hk. The information contained on our websites is not a part of this prospectus. Our agent for service of process in the United
States is located at 122 East 42nd St 18th Floor, New York, NY 10168.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains a website at www.sec.gov that contains reports, proxy, and information statements, and other information regarding issuers
that file electronically with the SEC using its EDGAR system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being an Emerging Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a company with less than US$1.235 billion in gross revenues during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012, and may take advantage of reduced reporting
requirements that are otherwise applicable to public companies. These provisions include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted
    to present only two years of audited financial statements and only two years of related Management&rsquo;s Discussion and Analysis
    of Financial Condition and Results of Operations in our filings with the SEC;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required
    to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure
    obligations regarding executive compensation in periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions
    from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute
    payments not previously approved.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of our initial public offering.
However, if certain events occur before the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo;
our annual gross revenues exceed US$1.235 billion or we issue more than US$1.0 billion of non-convertible debt in any three-year period,
we will cease to be an emerging growth company before the end of such five-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Section 107 of the JOBS Act provides that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition
period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. We have elected to
take advantage of the extended transition period for complying with new or revised accounting standards and acknowledge such election
is irrevocable pursuant to Section 107 of the JOBS Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Implications
of Being a Foreign Private Issuer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a foreign private issuer within the meaning of the rules under the Exchange Act. As such, we are exempt from certain provisions applicable
to United States domestic public companies. For example:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not
    required to provide as many Exchange Act reports, or as frequently, as a domestic public company;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for interim
    reporting, we are permitted to comply solely with our home country&rsquo;s requirements, which are less rigorous than the rules that
    apply to domestic public companies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not
    required to provide the same level of disclosure on certain issues, such as executive compensation;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are exempt
    from provisions of Regulation FD aimed at preventing issuers from making selective disclosures of material information;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not
    required to comply with the sections of the Exchange Act regulating the solicitation of proxies, consents, or authorizations in respect
    of a security registered under the Exchange Act; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are not
    required to comply with Section 16 of the Exchange Act requiring insiders to file public reports of their trading activities and
    establishing insider liability for profits realized from any &ldquo;short-swing&rdquo; trading transaction.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<DIV STYLE="padding: 5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_004"></A>THE
OFFERING</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities offered by the Selling
    Shareholders</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 74%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This prospectus
    covers the resale of a total of up to 12,499,986 Class A Ordinary Shares, from time to time after the registration statement that
    includes this prospectus is declared effective.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Terms of the Offering</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Shareholders,
    including their respective transferees, donees, pledgees or successors-in-interest, may sell, transfer or otherwise dispose of any
    or all of the Class A Ordinary Shares offered by this prospectus from time to time on the Nasdaq Capital Market or any other stock
    exchange, market or trading facility on which the Class A Ordinary Shares are traded or in private transactions. The Class A Ordinary
    Shares may be sold at fixed prices, at prevailing market prices, at prices related to prevailing market prices or at negotiated prices.
    See &ldquo;Plan of Distribution&rdquo; on page 34 of this prospectus.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Selling Shareholders</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All of the Offered Shares
    are being offered by the Selling Shareholders named herein. See &ldquo;Selling Shareholders&rdquo; of this prospectus for more information
    on the Selling Shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Use of proceeds</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Shareholders
    will receive all of the proceeds from the sale of Offered Shares for sale by them under this prospectus. We will not receive proceeds
    from the sale of the Offered Shares by the Selling Shareholders. See the section of this prospectus titled &ldquo;Use of Proceeds.&rdquo;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plan of Distribution</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Selling Shareholders,
    and any of their respective pledgees, and successors-in-interest, may offer or sell the Offered Shares from time to time through
    public or private transactions at prevailing market prices, at prices related to prevailing market prices or at privately negotiated
    prices. The Selling Shareholders may also resell the Offered Shares to or through underwriters, broker-dealers or agents, who may
    receive compensation in the form of discounts, concessions or commissions. See &ldquo;Plan of Distribution&rdquo; beginning on page
    34 of this prospectus for additional information on the methods of sale that may be used by the Selling Shareholders.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk factors</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investing in our securities
    involves significant risks. You should read the section titled &ldquo;Risk Factors,&rdquo; elsewhere in this prospectus, and under
    similar headings in other documents or incorporated by reference into this prospectus for a discussion of the factors you should
    carefully consider before deciding to purchase the Class A Ordinary Shares.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Class A Ordinary Shares
    are listed on the Nasdaq Capital Market under the symbol &ldquo;HKPD.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_005"></A>RISK
FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in Cellyan Biotechnology&rsquo;s securities involves significant risk. Before making an investment in Cellyan Biotechnology&rsquo;s
securities, you should carefully consider the risk factors set forth in the 2025 Annual Report on file with the SEC, which is incorporated
by reference into this prospectus, as well as the following risk factors. Before making an investment decision, you should carefully
consider these risks as well as other information we include or incorporate by reference in this prospectus. The risks and uncertainties
not presently known to us or that we currently deem immaterial may also materially harm our business, operating results, and financial
condition and could result in a complete loss of your investment.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Ownership of Our Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are unable to continue to meet the listing requirements of Nasdaq, our Class A Ordinary Shares will be delisted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 12, 2026, the Company received a notification letter from the Listing Qualifications Department of Nasdaq indicating that the
closing bid price of the Company&rsquo;s Class A Ordinary Shares had been below the minimum requirement of US$1.00 per share for 30 consecutive
business days, and that the Company was therefore not in compliance with the minimum bid price requirement set forth in Nasdaq Listing
Rule 5550(a)(2). The notification letter does not result in the immediate delisting of the Company&rsquo;s Class A Ordinary Shares. Pursuant
to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until July 13, 2026, to regain compliance.
The Company is currently evaluating available options to regain compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to achieve and maintain compliance with such listing standards or other Nasdaq listing requirements in the future, our
Class A Ordinary Shares could be delisted from Nasdaq. A delisting of our Class A Ordinary Shares and our inability to list on another
national securities market could negatively impact us by: (i) reducing the liquidity and market price of our Class A Ordinary Shares;
(ii) reducing the number of investors willing to hold or acquire our Class A Ordinary Shares, which could negatively impact our ability
to raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradable securities,
thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our
employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B><I>Our
largest shareholder, Ms. Liying Wang, holds a majority of the voting power of the Company&rsquo;s outstanding share capital, which will
limit or preclude your ability to influence corporate matters.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">As
of the date of this prospectus, Ms. Liying Wang, the beneficial owner of 7,150,000 Class&nbsp;B Ordinary Shares of the Company, held
approximately 95.63% of the voting power of our outstanding share capital. Therefore, Ms. Liying Wang is able to control all matters
requiring approval by shareholders. Ms. Liying Wang&rsquo;s interests may not be the same as or may even conflict with your interests.
For example, she could attempt to delay or prevent a change in control of us, even if such change in control would benefit our other
shareholders, which could deprive our shareholders of an opportunity to receive a premium for their Ordinary Shares as part of a sale
of us or our assets, and might affect the prevailing market price of the Class A Ordinary Shares due to investors&rsquo; perceptions
that conflicts of interest may exist or arise. As a result, Ms. Liying Wang&rsquo;s majority voting power over our outstanding share
capital may not align with the best interests of our other shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
sale of a substantial amount of our Class A Ordinary Shares by the Selling Shareholders in the public market could adversely affect the
prevailing market price of our Class A Ordinary Shares.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is registering for resale of up to 12,499,986 Class A Ordinary Shares. As of the date of this prospectus, there are 16,349,986
Class A Ordinary Shares issued and outstanding, including shares issued in the March 2026 Private Placement. Sales of substantial amounts
of the Class A Ordinary Shares in the public market, or the perception that such sales might occur, could adversely affect the market
price of the Class A Ordinary Shares. Cellyan Biotechnology cannot predict if and when the Selling Shareholders may sell such Class A
Ordinary Shares in the public market. Furthermore, in the future, Cellyan Biotechnology may issue additional Class A Ordinary Shares
or other equity or debt securities convertible into Class A Ordinary Shares. Any such issuance could result in substantial dilution to
our existing shareholders and could cause the price of the Class A Ordinary Shares to decline.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_006"></A>ENFORCEABILITY
OF CIVIL LIABILITIES</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Cayman Islands</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is incorporated under the laws of the Cayman Islands as an exempted company with limited liability. It is incorporated
in the Cayman Islands because of certain benefits associated with being a Cayman Islands exempted company, such as political and economic
stability, an effective judicial system, a favorable tax system, the absence of foreign exchange control or currency restrictions and
the availability of professional and support services. However, the Cayman Islands has a less developed body of securities laws as compared
to the United&nbsp;States and provides less protection for investors. In addition, Cayman Islands companies may not have standing to
sue before the federal courts of the United&nbsp;States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology&rsquo;s constitutional documents do not contain provisions requiring that disputes, including those arising under the securities
laws of the United&nbsp;States, between the company, its officers, directors and shareholders, be subject to arbitration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Substantially
all of our assets are located outside the United&nbsp;States. In addition, all of our executive officers, including Mr. Chenyu Liang,
our Director and Chief Executive Officer, Ms. Shu Liu, our Chief Financial Officer, and Mr. Zifeng Wang, our Chief Strategy Officer,
are nationals or residents of the PRC. All or a substantial portion of their assets are located outside the United&nbsp;States. As a
result, it may be difficult for investors to effect service of process within the United&nbsp;States upon us or these persons, or to
enforce judgments obtained in U.S.&nbsp;courts against us or them, including judgments predicated upon the civil liability provisions
of the securities laws of the United&nbsp;States or any state in the United&nbsp;States. It may also be difficult for you to enforce
judgments obtained in U.S.&nbsp;courts based on the civil liability provisions of the U.S.&nbsp;federal securities laws against us and
the officers and directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have appointed Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168, as our agent upon whom process may
be served in any action brought against us under the federal or state securities laws of the United&nbsp;States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harney
Westwood &amp; Riegels, our counsel as to Cayman Islands law, has advised us that there is uncertainty as to whether the courts of the
Cayman Islands would: (i) recognize or enforce judgments of courts of the United States obtained against us or our directors or officers
that are predicated upon the civil liability provisions of the federal securities laws of the United States or the securities laws of
any state in the United States, or (ii) entertain original actions brought in the Cayman Islands against us or our directors or officers
that are predicated upon the federal securities laws of the United States or the securities laws of any state in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been advised by Harney Westwood&nbsp;&amp; Riegels, our counsel as to Cayman Islands law, that although there is no statutory enforcement
in the Cayman Islands of judgments obtained in the federal or state courts of the United&nbsp;States (and the Cayman Islands are not
a party to any treaties for the reciprocal enforcement or recognition of such judgments), the Grand Court of the Cayman Islands will
at common law enforce final and conclusive&nbsp;<I>in personam&nbsp;</I>judgments of state and/or federal courts of the United&nbsp;States
of America (the &ldquo;Foreign Court&rdquo;) of a debt or definite sum of money against the Company (other than a sum of money payable
in respect of taxes or other charges of a like nature, or in respect of a fine or other penalty (which may include a multiple damages
judgment in an anti-trust action) or where enforcement would be contrary to public policy). The Grand Court of the Cayman Islands will
also at common law enforce final and conclusive&nbsp;<I>in personam</I>&nbsp;judgments of the Foreign Court that are non-monetary against
the Company, for example, declaratory judgments ruling upon the true legal owner of shares in a Cayman Islands company. The Grand Court
will exercise its discretion in the enforcement of non-money judgments by having regard to the circumstances, such as considering whether
the principles of comity apply. To be treated as final and conclusive, any relevant judgment must be regarded as <I>res judicata</I>
by the Foreign Court. A debt claim on a foreign judgment must be brought within 6&nbsp;years of the date of the judgment, and arrears
of interest on a judgment debt cannot be recovered after six&nbsp;years from the date on which the interest was due. The courts of the
Cayman Islands are unlikely to enforce a judgment obtained from the Foreign Court under civil liability provisions of U.S.&nbsp;federal
securities law if such a judgment is found by the courts of the Cayman Islands to give rise to obligations to make payments that are
penal or punitive in nature. Such a determination has not yet been made by the Grand Court of the Cayman Islands. A court of the Cayman
Islands may stay enforcement proceedings if concurrent proceedings are being brought elsewhere. A judgment entered in default of appearance
by a defendant who has had notice of the Foreign Court&rsquo;s intention to proceed may be final and conclusive notwithstanding that
the Foreign Court has power to set aside its own judgment and despite the fact that it may be subject to an appeal the time-limit for
which has not yet expired. The Grand Court of the Cayman Islands may safeguard the defendant&rsquo;s rights by granting a stay of execution
pending any such appeal and may also grant interim injunctive relief as appropriate for the purpose of enforcement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong&nbsp;Kong</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of our executive officers, including Mr. Chenyu Liang, our Director and Chief Executive Officer, Ms. Shu Liu, our Chief Financial Officer,
and Mr. Zifeng Wang, our Chief Strategy Officer, are nationals or residents of the PRC. All or a substantial portion of their assets
are located outside the United&nbsp;States. As a result, it may be difficult for investors to effect service of process within the U.S.&nbsp;upon
us or these persons, or to enforce against us or them judgments obtained in U.S.&nbsp;courts, including judgments predicated upon the
civil liability provisions of the U.S.&nbsp;federal securities laws or securities laws of any U.S.&nbsp;state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SH
Wong &amp; Co, our counsel with respect to Hong&nbsp;Kong law, has advised us that there is uncertainty as to whether the courts of Hong&nbsp;Kong
would recognize or enforce judgments of U.S.&nbsp;courts obtained against us or our directors or officers predicated upon the civil liability
provisions of the securities laws of the United&nbsp;States or any state in the United&nbsp;States, but Hong&nbsp;Kong courts do not
entertain original actions brought in Hong&nbsp;Kong against us or our directors or officers predicated upon the securities laws of the
United&nbsp;States or any state in the United&nbsp;States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
judgment of a court in the United&nbsp;States predicated upon U.S.&nbsp;federal or state securities laws may be enforced in Hong&nbsp;Kong
at common law by bringing an action in a Hong&nbsp;Kong court on that judgment for the amount due thereunder and then seeking summary
judgment on the strength of the foreign judgment, provided that the foreign judgment, among other things, is (1)&nbsp;for a monetary
sum (not being taxes or similar charges to a foreign government taxing authority or a fine or other penalty), and (2)&nbsp;final and
conclusive on the merits of the claim, but not otherwise. Such a judgment may not, in any event, be so enforced in Hong&nbsp;Kong if
(a)&nbsp;it was obtained by fraud, (b)&nbsp;the proceedings in which the judgment was obtained were opposed to natural justice, (c)&nbsp;its
enforcement or recognition would be contrary to the public policy of Hong&nbsp;Kong, (d)&nbsp;the court of the United&nbsp;States was
not jurisdictionally competent, or (e)&nbsp;the judgment was in conflict with a prior Hong&nbsp;Kong judgment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong&nbsp;Kong
has no arrangement for the reciprocal enforcement of judgments with the United&nbsp;States. As a result, there is uncertainty as to the
enforceability in Hong&nbsp;Kong in actions for enforcement of judgments of U.S.&nbsp;courts of civil liabilities predicated solely upon
the federal securities laws of the United&nbsp;States or the securities laws of any state or territory within the United&nbsp;States,
whereas original actions predicated solely upon the federal securities laws of the United&nbsp;States or the securities laws of any state
or territory within the United&nbsp;States would not be entertained by Hong&nbsp;Kong courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_007"></A>USE
OF PROCEEDS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will not receive any proceeds from the sale by the Selling Shareholders of the Offered Shares. The Selling Shareholders will receive
all net proceeds from the sale of the Offered Shares covered by this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will incur all costs associated with this prospectus and the registration statement of which it is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_008"></A>DIVIDEND
POLICY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not previously declared or paid any cash dividends on our Class A Ordinary Shares, and we do not anticipate declaring or paying
any cash dividends in the foreseeable future. We currently intend to retain all, or substantially all, of our available funds and future
earnings, if any, to fund the operation and expansion of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology&rsquo;s board of directors has complete discretion as to whether to distribute dividends, subject to certain restrictions
under Cayman Islands law. In particular, Cellyan Biotechnology may only pay dividends out of its profits or share premium account, and
provided always that in no circumstances may a dividend be paid if this would result in Cellyan Biotechnology being unable to pay its
debts as they fall due in the ordinary course of business immediately following the date on which the distribution or dividend is paid,
or would be in violation of the relevant provisions, if any, of Cellyan Biotechnology&rsquo;s memorandum and articles of association,
as amended. Even if the board of directors of Cellyan Biotechnology decides to pay dividends, the form, frequency and amount will depend
upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and
other factors that the board of directors may deem relevant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology is a holding company incorporated in the Cayman Islands and it relies principally on dividends from the HK Subsidiaries
for its cash requirements, including any payment of dividends to its shareholders. According to the Companies Ordinance of Hong&nbsp;Kong,
a Hong&nbsp;Kong company may only make a distribution out of profits available for distribution. Under the current practice of the Inland
Revenue Department of Hong&nbsp;Kong, no tax is payable in Hong&nbsp;Kong in respect to dividends paid by HK Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
dividends, if any, on the Class A Ordinary Shares will be paid in U.S.&nbsp;dollars. Holders of record of Class A Ordinary Shares on
the applicable record date will be entitled to receive any such dividends.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_009"></A>CAPITALIZATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth our cash and cash equivalents and capitalization as of September 30, 2025:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an actual
    basis as of September 30, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on an as adjusted
    basis to reflect the following equity adjustment transactions occurring after September 30, 2025 and prior to the Offering.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            repurchase of 7,150,000 Class A ordinary shares of the Company (the &ldquo;Repurchased Shares&rdquo;)
                                            registered in the name of TUTU Business Services Limited (the &ldquo;Shareholder&rdquo;)
                                            for an aggregate nominal purchase price of US$1. Such purchase price will be paid to the
                                            Shareholder upon completion of the repurchase and will be funded solely from the proceeds
                                            of a concurrent private placement of 7,150,000 Class B ordinary shares of the Company issued
                                            exclusively to finance such repurchase;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
                                            issuance of 12,499,986 Class A ordinary shares and 24,999,972 warrants of the Company in
                                            connection with the closing of a PIPE financing, for an aggregate gross proceeds of US$6,750,014,
                                            paid via Tether (USDT).</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">certain
                                            offering expenses incurred in respect of the PIPE financing and this Offering.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this table in conjunction with our consolidated financial statements and the related notes appearing elsewhere in this prospectus,
and other financial information included elsewhere in this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">September 30, 2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Actual</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>As Adjusted<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-align: center; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(US$, except share and<BR> per share data)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; width: 76%; text-align: left; text-indent: -0.125in">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">190,912</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,875,059</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Short term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">355,466</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">355,466</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Long-term debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,334,565</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,334,565</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Due to related parties</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">337,610</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">337,610</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Total debt</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,027,641</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,027,641</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Share Capital*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in">Ordinary shares, 1,000,000,000 shares authorized, consisting of&nbsp;940,000,000 Class A ordinary shares of par value of US$0.001 each and&nbsp;60,000,000 Class B ordinary shares of par value of US$0.001 each, with 49,501,000 Class&nbsp;A ordinary shares of $0.001 par value per share and 499,000 Class&nbsp;B ordinary shares of $0.001 par value per share issued and outstanding</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Class A Ordinary Shares, 11,000,000 shares issued and outstanding, actual; 16,349,986 shares issued and outstanding, as adjusted basis *</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,350</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Class B Ordinary Shares, nil shares issued and outstanding, actual; 7,150,000 shares issued and outstanding, as adjusted basis *</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Additional paid in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,463,898</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10,135,545</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Retained earnings</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,657,787</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,657,787</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Accumulated other comprehensive (loss) income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Total shareholder&rsquo;s equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,143,431</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">11,827,578</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.125in; font-weight: bold; text-align: left; text-indent: -0.125in">Total capitalization</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">7,171,072</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">13,855,219</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As adjusted
    information discussed above is illustrative only. Our additional paid-in capital, retained earnings, accumulative other comprehensive
    (loss) income, total shareholder&rsquo;s equity and total capitalization following the completion of this offering are subject to
    the actual number of Offered Shares sold.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The shares issued and outstanding
    and per share number presented here are adjusted retrospectively to reflect the Increase of Share Capital, the Implementation of
    the Dual Class Structure, and the Share Repurchase. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_010"></A>DESCRIPTION
OF SHARE CAPITAL</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description of Cellyan Biotechnology&rsquo;s share capital and provisions of its amended and restated memorandum and articles
of association, as amended from time to time, are summaries and do not purport to be complete. Reference is made to Cellyan Biotechnology&rsquo;s
Fourth Amended and Restated Memorandum and Articles of Association (adopted by Special Resolution on December 12, 2025), which are referred
to in this section as the &ldquo;Fourth Amended and Restated Articles of Association.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, Cellyan Biotechnology&rsquo;s authorized share capital is US$1,000,000, divided into 1,000,000,000 ordinary
shares of par value US$0.001 each, comprising (i) 940,000,000 Class&nbsp;A Ordinary Shares, par value US$0.001 each; and (ii) 60,000,000
Class&nbsp;B Ordinary Shares, par value US$0.001 each.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this prospectus, Cellyan Biotechnology has issued and outstanding 23,499,986 ordinary shares, par value US$0.001 per share,
comprising an aggregate of (i) 16,349,986 Class&nbsp;A Ordinary Shares, including shares issued in the March 2026 Private Placement,
and (ii) 7,150,000 Class&nbsp;B Ordinary Shares. Each Class A Ordinary Share entitles the holder thereof to one (1) vote on all matters
subject to vote at general meetings of the Company, and each Class&nbsp;B Ordinary Share entitles the holder thereof to fifty (50) votes
on all matters subject to vote at general meetings of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of Cellyan Biotechnology&rsquo;s Class A Ordinary Shares and Class B Ordinary Shares issued and outstanding as of the date of this prospectus
are fully paid. Save and except for voting rights and conversion rights as set out in the Fourth Amended and Restated Articles of Association,
the Class A Ordinary Shares and the Class B Ordinary Shares rank pari passu with one another and have the same rights, preferences, privileges
and restrictions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ordinary
Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are summaries of certain provisions of the Fourth Amended and Restated Articles of Association that relate to the material
terms of the Ordinary Shares. A copy of the Fourth Amended and Restated Articles of Association is filed as an exhibit to the registration
statement of which this prospectus forms a part. Capitalized terms used but not otherwise defined herein shall have the meanings ascribed
to such terms in the Fourth Amended and Restated Memorandum and Articles of Association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights.</I> Holders of Class A Ordinary Shares and Class B Ordinary Shares shall at all times vote together as one class on all resolutions
submitted to a vote by the Members. Each Class A Ordinary Share entitles the holder thereof to one (1) vote on all matters subject to
vote at general meetings of Cellyan Biotechnology, and each Class&nbsp;B Ordinary Share entitles the holder thereof to fifty (50) votes
on all matters subject to vote at general meetings of Cellyan Biotechnology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Conversion.</I>
Each Class B Ordinary Share is convertible into one (1) Class A Ordinary Share at any time at the option of the holder thereof. The right
to convert is exercisable by the holder of the Class B Ordinary Share delivering a written notice to Cellyan Biotechnology electing to
convert a specified number of Class B Ordinary Shares into Class A Ordinary Shares. Any conversion pursuant to the foregoing shall become
effective forthwith upon receipt by Cellyan Biotechnology of such written notice (or at such later date as may be specified therein),
and Cellyan Biotechnology shall make the appropriate entries in its register of members to record the re-designation of the relevant
Class B Ordinary Shares as Class A Ordinary Shares. In addition, upon any sale, transfer, assignment or disposition of any Class&nbsp;B
Ordinary Share to any person who is not the Designated Person or an Affiliate of the Designated Person, or upon a change of ultimate
beneficial ownership of any Class B Ordinary Share to any person who is not the Designated Person or an Affiliate of the Designated Person,
such Class B Ordinary Share shall be automatically and immediately converted into the same number of Class A Ordinary Shares. For the
avoidance of doubt, the creation of any pledge, charge, encumbrance or other third party right over any Class&nbsp;B Ordinary Shares
to secure a holder&rsquo;s contractual or legal obligations shall not be deemed a sale, transfer, assignment or disposition, or a change
of ultimate beneficial ownership, unless and until such pledge, charge, encumbrance or other third party right is enforced and results
in the third party holding legal title to the relevant Class B Ordinary Shares, in which case all such Class B Ordinary Shares shall
be automatically converted into the same number of Class A Ordinary Shares. Save as aforesaid, no share may be converted or redesignated
from one class to another without the sanction of a Special Resolution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Automatic
Conversion.</I> Upon any sale, transfer, assignment or disposition of any Class B Ordinary Share by a Member to any person who is not
the Designated Person or an Affiliate of the Designated Person, or upon a change of ultimate beneficial ownership of any Class B Ordinary
Share to any person who is not the Designated Person or an Affiliate of the Designated Person, such Class B Ordinary Share shall be automatically
and immediately converted into the same number of Class&nbsp;A Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Modification
of Rights.</I> Whenever the capital of Cellyan Biotechnology is divided into different classes, the rights attached to any such class
may, subject to any rights or restrictions for the time being attached to any class, only be materially and adversely varied with the
consent in writing of the holders of two-thirds of the issued shares of that class or with the sanction of a Special Resolution passed
at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares of any class issued
with preferred or other rights shall not be deemed to be materially and adversely varied by, inter alia, the creation, allotment or issue
of further shares ranking pari passu with or subsequent to them or the redemption or purchase of any shares of any class by Cellyan Biotechnology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Fourth Amended and Restated Memorandum and Articles of Association</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Fourth Amended and Restated Memorandum and Articles of Association of Cellyan Biotechnology were adopted by Special Resolution on December
12, 2025. The following are summaries of material provisions of the Fourth Amended and Restated Articles of Association and of the Companies
Act, insofar as they relate to the material terms of the Ordinary Shares. Capitalized terms used but not otherwise defined herein shall
have the meanings ascribed to such terms in the Fourth Amended and Restated Memorandum and Articles of Association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Objects
of the Company.&nbsp;</I>Under the Fourth Amended and Restated Memorandum of Association, the objects of Cellyan Biotechnology are unrestricted,
and Cellyan Biotechnology is capable of exercising all the functions of a natural person of full capacity irrespective of any question
of corporate benefit, as provided by the Companies Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Ordinary
Shares.&nbsp;</I>The Ordinary Shares are issued in registered form and are issued when registered in Cellyan Biotechnology&rsquo;s register
of members. Cellyan Biotechnology may not issue shares to bearer. Cellyan Biotechnology&rsquo;s shareholders who are non-residents of
the Cayman Islands may freely hold and vote their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends.&nbsp;</I>The
holders of the Ordinary Shares are entitled to such dividends as may be declared by the board of directors. The Fourth Amended and Restated
Articles of Association provide that dividends may be declared and paid out of the funds of Cellyan Biotechnology lawfully available
therefor. Under the laws of the Cayman Islands, Cellyan Biotechnology may pay a dividend out of either profit or share premium account;
provided that in no circumstances may a dividend be paid out of its share premium if this would result in Cellyan Biotechnology being
unable to pay its debts as they fall due in the ordinary course of business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights. </I>Holders of Class A Ordinary Shares and Class B Ordinary Shares shall at all times vote together as one class on all resolutions
submitted to a vote by the Members. Each Class A Ordinary Share entitles the holder thereof to one (1) vote, and each Class B Ordinary
Share entitles the holder thereof to fifty (50) votes, on all matters subject to vote at general meetings of Cellyan Biotechnology. Voting
at any meeting of shareholders is by way of a poll save that in the case of a physical meeting, the chairman of the meeting may decide
that a vote be on a show of hands unless a poll is demanded by:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">at least three
    shareholders present in person or by proxy for the time being entitled to vote at the meeting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shareholder(s)&nbsp;present
    in person or by proxy representing not less than one-tenth of the total voting rights of all shareholders having the right to vote
    at the meeting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">shareholder(s)&nbsp;present
    in person or by proxy and holding shares in us conferring a right to vote at the meeting being shares on which an aggregate sum has
    been paid up equal to not less than one-tenth of the total sum paid up on all shares conferring that right.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes cast
by such shareholders as, being entitled to do so, vote at a general meeting of Cellyan Biotechnology, while a special resolution requires
the affirmative vote of not less than two-thirds of the votes cast by such shareholders as, being entitled to do so, vote at a general
meeting of Cellyan Biotechnology. A special resolution will be required for important matters such as a change of name, making changes
to the Fourth Amended and Restated Articles of Association, a reduction of share capital and the winding up of Cellyan Biotechnology.
The shareholders may, among other things, divide or combine their shares by ordinary resolutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General
Meetings of Shareholders.&nbsp;</I>As a Cayman Islands exempted company, Cellyan Biotechnology is not obliged by the Companies Act to
call shareholders&rsquo; annual general meetings. The Fourth Amended and Restated Articles of Association provide that Cellyan Biotechnology
may, if required by the Companies Act, in each calendar year hold a general meeting as its annual general meeting, and shall specify
the meeting as such in the notices calling it, and the annual general meeting shall be held at such time and place as may be determined
by its directors. All general meetings (including an annual general meeting, any adjourned general meeting or postponed meeting) may
be held as a physical meeting at such times and in any part of the world, as a hybrid meeting or as a Virtual Meeting by means of Communication
Facilities, as may be determined by the board of directors in its absolute discretion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shareholders&rsquo;
general meetings may be convened by the Chairman of the board of directors or by a majority of the board of directors. Advance notice
of at least ten (10) clear&nbsp;days is required for the convening of any general meeting of the shareholders. A quorum required for
any general meeting of shareholders consists of, at the time when the meeting proceeds to business, two shareholders holding shares which
carry in aggregate (or representing by proxy) not less than one-third of all votes attaching to issued and outstanding shares in Cellyan
Biotechnology entitled to vote at such general meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Act does not provide shareholders with any right to requisition a general meeting or to put any proposal before a general meeting.
These rights may be provided in a company&rsquo;s articles of association. However, Cellyan Biotechnology&rsquo;s Fourth Amended and
Restated Articles of Association do not provide its shareholders with any right to requisition a general meeting or to put any proposals
before annual general meetings or extraordinary general meetings not called by such shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transfer
of Ordinary Shares.&nbsp;</I>Subject to the restrictions set out below, any of the shareholders may transfer all or any of his or her
Ordinary Shares by an instrument of transfer in the usual or common form or in a form prescribed by the Designated Stock Exchange or
any other form approved by the board of directors. Notwithstanding the foregoing, the Ordinary Shares may also be transferred in accordance
with the applicable rules and regulations of the Designated Stock Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may, in its absolute discretion, decline to register any transfer of any Ordinary Share which is not fully paid up
or on which Cellyan Biotechnology has a lien. The board of directors may also decline to register any transfer of any Ordinary Share
unless:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument
    of transfer is lodged with us, accompanied by the certificate for the Ordinary Shares to which it relates and such other evidence
    as the board of directors may reasonably require to show the right of the transferor to make the transfer;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument
    of transfer is in respect of only one class of Ordinary Shares;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the instrument
    of transfer is properly stamped, if required;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the case
    of a transfer to joint holders, the number of joint holders to whom the Ordinary Share is to be transferred does not exceed four;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a fee of such
    maximum sum as the Nasdaq may determine to be payable or such lesser sum as the directors may from time to time require is paid to
    us in respect thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the directors refuse to register a transfer they shall, within two calendar months after the date on which the instrument of transfer
was lodged, send to each of the transferor and the transferee notice of such refusal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registration of transfers may, after compliance with any notice required in accordance with the Designated Stock Exchange Rules, be suspended
and the register closed at such times and for such periods as the board of directors may from time to time determine; provided, however,
that the registration of transfers shall not be suspended nor the register closed for more than thirty (30) calendar days in any calendar
year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Liquidation.&nbsp;</I>On
the winding up of Cellyan Biotechnology, if the assets available for distribution amongst the shareholders shall be more than sufficient
to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst the shareholders
in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares
in respect of which there are monies due, of all monies payable to Cellyan Biotechnology for unpaid calls or otherwise. If the assets
available for distribution are insufficient to repay all of the paid-up capital, such assets will be distributed so that, as nearly as
may be, the losses are borne by the shareholders in proportion to the par value of the shares held by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Calls
on Shares and Forfeiture of Shares.&nbsp;</I>The board of directors may from time to time make calls upon shareholders for any amounts
unpaid on their shares in a notice served to such shareholders at least fourteen (14) calendar days prior to the specified time and place
of payment. The shares that have been called upon and remain unpaid are subject to forfeiture.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Redemption,
Repurchase and Surrender of Shares.</I> Cellyan Biotechnology may issue shares on terms that such shares are subject to redemption, at
its option or at the option of the holders of these shares, on such terms and in such manner as may be determined by the board of directors
before the issue of such shares. Cellyan Biotechnology may also repurchase any of its shares on such terms and in such manner as have
been approved by the board of directors. Under the Companies Act, the redemption or repurchase of any share may be paid out of Cellyan
Biotechnology&rsquo;s profits, or out of Cellyan Biotechnology&rsquo;s share premium account, or out of the proceeds of a new issue of
shares made for the purpose of such redemption or repurchase, or out of capital if Cellyan Biotechnology can, immediately following such
payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be
redeemed or repurchased (a)&nbsp;unless it is fully paid up, (b)&nbsp;if such redemption or repurchase would result in there being no
shares outstanding or (c)&nbsp;if Cellyan Biotechnology has commenced liquidation. In addition, Cellyan Biotechnology may accept the
surrender of any fully paid share for no consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Variations
of Rights of Shares.&nbsp;</I>Whenever the capital of Cellyan Biotechnology is divided into different classes the rights attached to
any such class may, subject to any rights or restrictions for the time being attached to any class, only be materially and adversely
varied with the consent in writing of the holders of two-thirds of the issued shares of that class or with the sanction of a Special
Resolution passed at a separate meeting of the holders of the shares of that class. The rights conferred upon the holders of the shares
of any class issued with preferred or other rights shall not, unless otherwise expressly provided by the terms of issue of the shares
of that class, be deemed to be materially and adversely varied by the creation, allotment or issue of further shares ranking pari passu
with such existing class of shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Issuance
of Additional Shares.&nbsp;</I>The Fourth Amended and Restated Articles of Association authorize the board of directors to issue additional
Ordinary Shares from time to time as the board of directors shall determine, to the extent of available authorized but unissued shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Fourth Amended and Restated Articles of Association also authorize the board of directors to establish from time to time one or more
series of preference shares and to determine, with respect to any series of preference shares, the terms and rights of that series, including,
among other things:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation
    of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number
    of shares of the series;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dividend
    rights, dividend rates, conversion rights and voting rights; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the rights
    and terms of redemption and liquidation preferences.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors may issue preference shares without action by the shareholders to the extent of available authorized but unissued
shares. Issuance of these shares may dilute the voting power of holders of Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inspection
of Books and Records.&nbsp;</I>Holders of the Ordinary Shares will have no general right under Cayman Islands law to inspect or obtain
copies of the list of shareholders or the corporate records. However, the Fourth Amended and Restated Articles of Association provide
the shareholders with the right to inspect the register of shareholders without charge, and to receive the annual audited financial statements
of Cellyan Biotechnology. See &ldquo;Where You Can Find Additional Information.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Anti-Takeover
Provisions.&nbsp;</I>Some provisions of the Fourth Amended and Restated Articles of Association may discourage, delay or prevent a change
of control of Cellyan Biotechnology or management that shareholders may consider favorable, including provisions that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">authorize the
    board of directors to issue preference shares in one or more series and to designate the price, rights, preferences, privileges and
    restrictions of such preference shares without any further vote or action by the shareholders; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">limit the ability
    of shareholders to requisition and convene general meetings of shareholders.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">However,
under Cayman Islands law, the directors may only exercise the rights and powers granted to them under the Fourth Amended and Restated
Articles of Association for a proper purpose and for what they believe in good faith to be in the best interests of Cellyan Biotechnology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Exempted
Company.</I> Cellyan Biotechnology is an exempted company with limited liability under the Companies Act. The Companies Act distinguishes
between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business
mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are
essentially the same as for an ordinary company except that an exempted company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have
    to file an annual return of its shareholders with the Registrar of Companies;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">is not required
    to open its register of members for inspection;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">does not have
    to hold an annual general meeting;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may issue shares
    with no par value;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may obtain
    an undertaking against the imposition of any future taxation (such undertakings are usually given for 30&nbsp;years in the first
    instance);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register
    by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register
    as an exempted limited duration company; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">may register
    as a segregated portfolio company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Limited
liability&rdquo; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder&rsquo;s
shares of Cellyan Biotechnology (except in exceptional circumstances, such as involving fraud, the establishment of an agency relationship
or an illegal or improper purpose or other circumstances in which a court may be prepared to pierce or lift the corporate veil).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Differences
in Corporate Law</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Act is derived, to a large extent, from the older Companies Acts of England but does not follow recent English statutory enactments
and accordingly there are significant differences between the Companies Act and the current Companies Act&nbsp;of&nbsp;England. In addition,
the Companies Act differs from laws applicable to U.S.&nbsp;corporations and their shareholders. Set forth below is a summary of the
significant differences between the provisions of the Companies Act applicable to Cellyan Biotechnology and the laws applicable to companies
incorporated in the United&nbsp;States and their shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Mergers
and Similar Arrangements.&nbsp;</I>The Companies Act permits mergers and consolidations between Cayman Islands companies and between
Cayman Islands companies and non-Cayman Islands companies. For these purposes, (a)&nbsp;&rdquo;merger&rdquo; means the merging of two
or more constituent companies and the vesting of their undertaking, property and liabilities in one of such companies as the surviving
company, and (b)&nbsp;a &ldquo;consolidation&rdquo; means the combination of two or more constituent companies into a consolidated company
and the vesting of the undertaking, property and liabilities of such companies to the consolidated company. In order to effect such a
merger or consolidation, the directors of each constituent company must approve a written plan of merger or consolidation, which must
then be authorized by (a)&nbsp;a special resolution of the shareholders of each constituent company, and (b)&nbsp;such other authorization,
if any, as may be specified in such constituent company&rsquo;s articles of association. The plan must be filed with the Registrar of
Companies of the Cayman Islands together with a declaration as to the solvency of the consolidated or surviving company, a list of the
assets and liabilities of each constituent company and an undertaking that a copy of the certificate of merger or consolidation will
be given to the members and creditors of each constituent company and that notification of the merger or consolidation will be published
in the Cayman Islands Gazette. Court approval is not required for a merger or consolidation which is effected in compliance with these
statutory procedures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
merger between a Cayman parent company and its Cayman subsidiary or subsidiaries does not require authorization by a resolution of shareholders
of that Cayman subsidiary if a copy of the plan of merger is given to every member of that Cayman subsidiary to be merged unless that
member agrees otherwise. For this purpose, a company is a &ldquo;parent&rdquo; of a subsidiary if it holds issued shares that together
represent at least ninety percent (90%) of the votes at a general meeting of the subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consent of each holder of a fixed or floating security interest over a constituent company is required unless this requirement is waived
by a court in the Cayman Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Save
in certain limited circumstances, a shareholder of a Cayman constituent company who dissents from the merger or consolidation is entitled
to payment of the fair value of his shares (which, if not agreed between the parties, will be determined by the Cayman Islands court)
upon dissenting to the merger or consolidation, provided the dissenting shareholder complies strictly with the procedures set out in
the Companies Act. The exercise of dissenter rights will preclude the exercise by the dissenting shareholder of any other rights to which
he or she might otherwise be entitled by virtue of holding shares, save for the right to seek relief on the grounds that the merger or
consolidation is void or unlawful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Separate
from the statutory provisions relating to mergers and consolidations, the Companies Act also contains statutory provisions that facilitate
the reconstruction and amalgamation of companies by way of schemes of arrangement, provided that the arrangement is approved, in the
case of a shareholder scheme, by seventy-five percent in value of the members or class of members, as the case may be, with whom the
arrangement is to be made and, in the case of a creditor scheme, a majority in number of each class of creditors with whom the arrangement
is to be made, and who must in addition represent seventy-five per cent in value of each such class of creditors, as the case may be,
that are present and voting either in person or by proxy at a meeting, or meetings, convened for that purpose. The convening of the meetings
and subsequently the arrangement must be sanctioned by the Grand Court of the Cayman Islands. While a dissenting shareholder has the
right to express to the court the view that the transaction ought not to be approved, the court can be expected to approve the arrangement
if it determines that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the statutory
    provisions as to the required majority vote have been met;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the shareholders
    have been fairly represented at the meeting in question and the statutory majority are acting bona fide without coercion of the minority
    to promote interests adverse to those of the class;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the arrangement
    is such that may be reasonably approved by an intelligent and honest man of that class acting in respect of his interest; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the arrangement
    is not one that would more properly be sanctioned under some other provision of the Companies Act.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Act also contains a statutory power of compulsory acquisition which may facilitate the &ldquo;squeeze out&rdquo; of a dissentient
minority shareholder upon a tender offer. When a tender offer is made and accepted by holders of 90% of the shares affected within four&nbsp;months
after the making of the offer, the offeror may, within a two-month period commencing on the expiration of such four-month period, require
the holders of the remaining shares to transfer such shares to the offeror on the terms of the offer. An objection can be made to the
Grand Court of the Cayman Islands but this is unlikely to succeed in the case of an offer which has been so approved unless there is
evidence of fraud, bad faith or collusion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an arrangement and reconstruction by way of scheme of arrangement is thus approved and sanctioned, or if a tender offer is made and accepted,
in accordance with the foregoing statutory procedures, a dissenting shareholder would have no rights comparable to appraisal rights,
save that objectors to a takeover offer may apply to the Grand Court of the Cayman Islands for various orders that the Grand Court of
the Cayman Islands has a broad discretion to make, which would otherwise ordinarily be available to dissenting shareholders of Delaware
corporations, providing rights to receive payment in cash for the judicially determined value of the shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Act also contains statutory provisions which provide that a company may present a petition to the Grand Court of the Cayman
Islands for the appointment of a restructuring officer on the grounds that the company (a)&nbsp;is or is likely to become unable to pay
its debts within the meaning of section 93 of the Companies Act; and (b)&nbsp;intends to present a compromise or arrangement to its creditors
(or classes thereof) either, pursuant to the Companies Act, the law of a foreign country or by way of a consensual restructuring. The
petition may be presented by a company acting by its directors, without a resolution of its members or an express power in its articles
of association. On hearing such a petition, the Cayman Islands court may, among other things, make an order appointing a restructuring
officer or make any other order as the court thinks fit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholders&rsquo;
Suits.&nbsp;</I>In principle, we will normally be the proper plaintiff and as a general rule a derivative action may not be brought by
a minority shareholder. However, based on English authorities, which would in all likelihood be of persuasive authority in the Cayman
Islands, the Cayman Islands courts can be expected to follow and apply the common law principles (namely the rule in&nbsp;<I>Foss v.
Harbottle</I>&nbsp;and the exceptions thereto) so that a non-controlling shareholder may be permitted to commence a class action against
or derivative actions in the name of the company to challenge actions where:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a company acts
    or proposes to act illegally or ultra vires;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the act complained
    of, although not ultra vires, could only be effected duly if authorized by more than the number of votes which have actually been
    obtained; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">those who control
    the company are perpetrating a &ldquo;fraud on the minority.&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
shareholder may have a direct right of action against us where the individual rights of that shareholder have been infringed or are about
to be infringed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Indemnification
of Directors and Executive Officers and Limitation of Liability.&nbsp;</I>Cayman Islands law does not limit the extent to which a company&rsquo;s
memorandum and articles of association may provide for indemnification of officers and directors, except to the extent any such provision
may be held by the Cayman Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the
consequences of committing a crime. The Fourth Amended and Restated Articles of Association provide that Cellyan Biotechnology shall
indemnify its directors and officers, and their personal representatives, against all actions, proceedings, costs, charges, expenses,
losses, damages or liabilities incurred or sustained by such persons, other than by reason of such person&rsquo;s own dishonesty, willful
default or fraud, in or about the conduct of Cellyan Biotechnology&rsquo;s business or affairs (including as a result of any mistake
of judgment) or in the execution or discharge of his duties, powers, authorities or discretions, including without prejudice to the generality
of the foregoing, any costs, expenses, losses or liabilities incurred by such director or officer in defending (whether successfully
or otherwise) any civil proceedings concerning Cellyan Biotechnology or its affairs in any court whether in the Cayman Islands or elsewhere.
This standard of conduct is generally the same as permitted under the Delaware General Corporation Law for a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, Cellyan Biotechnology has entered into indemnification agreements with the directors and executive officers that provide such
persons with additional indemnification beyond that provided in the Fourth Amended and Restated Articles of Association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to the directors, officers or persons controlling
us under the foregoing provisions, we have been informed that in the opinion of the SEC, such indemnification is against public policy
as expressed in the Securities Act and is therefore unenforceable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Directors&rsquo;
Fiduciary Duties.&nbsp;</I>Under Delaware corporate law, a director of a Delaware corporation has a fiduciary duty to the corporation
and its shareholders. This duty has two components: the duty of care and the duty of loyalty. The duty of care requires that a director
act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director
must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction.
The duty of loyalty requires that a director acts in a manner he reasonably believes to be in the best interests of the corporation.
He must not use his corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that
the best interest of the corporation and its shareholders take precedence over any interest possessed by a director, officer or controlling
shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed
basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation. However, this presumption
may be rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by
a director, the director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a matter of Cayman Islands law, a director of a Cayman Islands exempted company is in the position of a fiduciary with respect to the
company and therefore it is considered that he owes the following duties to the company&nbsp;&mdash;&nbsp;a duty to act in good faith
in the best interests of the company, a duty not to make a personal profit based on his position as director (unless the company permits
him to do so), a duty not to put himself in a position where the interests of the company conflict with his personal interest or his
duty to a third party and a duty to exercise powers for the purpose for which such powers were intended. A director of a Cayman Islands
exempted company owes to the company a duty to act with skill and care. It was previously considered that a director need not exhibit
in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience.
However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these
authorities are likely to be followed in the Cayman Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
Action by Written Consent.&nbsp;</I>Under the Delaware General Corporation Law, a corporation may eliminate the right of shareholders
to act by written consent by amendment to its certificate of incorporation. Cellyan Biotechnology&rsquo;s Fourth Amended and Restated
Articles of Association provide that any action required or permitted to be taken at any general meetings may be taken upon the vote
of shareholders at a general meeting duly noticed and convened in accordance with the Fourth Amended and Restated Articles of Association
or may be taken by written consent of all the shareholders entitled to vote at a general meeting of Cellyan Biotechnology in one or more
instruments each signed by one or more of the shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Shareholder
Proposals.&nbsp;</I>Under the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting
of shareholders, provided it complies with the notice provisions in the governing documents. A special meeting may be called by the board
of directors or any other person authorized to do so in the governing documents, but shareholders may be precluded from calling special
meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Companies Act does not provide shareholders with any right to requisition a general meeting or to put any proposal before a general meeting.
However, these rights may be provided in a company&rsquo;s articles of association. Cellyan Biotechnology&rsquo;s Fourth Amended and
Restated Articles of Association do not provide its shareholders with such right. As a Cayman Islands exempted company, Cellyan Biotechnology
is not obliged by law to call shareholders&rsquo; annual general meetings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Cumulative
Voting.&nbsp;</I>Under the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the
corporation&rsquo;s certificate of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation
of minority shareholders on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder
is entitled on a single director, which increases the shareholder&rsquo;s voting power with respect to electing such director. There
are no prohibitions in relation to cumulative voting under the laws of the Cayman Islands but the Fourth Amended and Restated Articles
of Association do not provide for cumulative voting. As a result, the shareholders are not afforded any less protections or rights on
this issue than shareholders of a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal
of Directors.&nbsp;</I>Under the Delaware General Corporation Law, a director of a corporation with a classified board may be removed
only for cause with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides
otherwise. Under Cellyan Biotechnology&rsquo;s Fourth Amended and Restated Articles of Association, subject to certain restrictions as
contained therein, directors may be removed with or without cause, by an Ordinary Resolution of the shareholders. An appointment of a
director may be on terms that the director shall automatically retire from office (unless he has sooner vacated office) at the next or
a subsequent annual general meeting or upon any specified event or after any specified period in a written agreement between Cellyan
Biotechnology and the director, if any; but no such term shall be implied in the absence of express provision. Under Cellyan Biotechnology&rsquo;s
Fourth Amended and Restated Articles of Association, a director&rsquo;s office shall be vacated if the director (i)&nbsp;becomes bankrupt
or has a receiving order made against him or suspends payment or compounds with his creditors; (ii)&nbsp;is found to be or becomes of
unsound mind or dies; (iii)&nbsp;resigns his office by notice in writing to Cellyan Biotechnology; (iv)&nbsp;without special leave of
absence from the board of directors, is absent from three consecutive meetings of the board and the board resolves that his office be
vacated; (v)&nbsp;is prohibited by law from being a director; or (vi)&nbsp;is removed from office pursuant to any other provision of
the Fourth Amended and Restated Articles of Association.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transactions
with Interested Shareholders.&nbsp;</I>The Delaware General Corporation Law contains a business combination statute applicable to Delaware
corporations whereby, unless the corporation has specifically elected not to be governed by such statute by amendment to its certificate
of incorporation, it is prohibited from engaging in certain business combinations with an &ldquo;interested shareholder&rdquo; for three&nbsp;years
following the date that such person becomes an interested shareholder. An interested shareholder generally is a person or a group who
or which owns or owned 15% or more of the target&rsquo;s outstanding voting share within the past three&nbsp;years. This has the effect
of limiting the ability of a potential acquirer to make a two-tiered bid for the target in which all shareholders would not be treated
equally. The statute does not apply if, among other things, prior to the date on which such shareholder becomes an interested shareholder,
the board of directors approves either the business combination or the transaction which resulted in the person becoming an interested
shareholder. This encourages any potential acquirer of a Delaware corporation to negotiate the terms of any acquisition transaction with
the target&rsquo;s board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman
Islands law has no comparable statute. As a result, Cellyan Biotechnology cannot avail itself of the types of protections afforded by
the Delaware business combination statute. However, although Cayman Islands law does not regulate transactions between a company and
its significant shareholders, it does provide that such transactions must be entered into bona fide in the best interests of the company
and not with the effect of constituting a fraud on the minority shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dissolution;
Winding up.&nbsp;</I>Under the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution
must be approved by shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the
board of directors may it be approved by a simple majority of the corporation&rsquo;s outstanding shares. Delaware law allows a Delaware
corporation to include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated
by the board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Cayman Islands law, a company may be wound up by either an order of the courts of the Cayman Islands or by a special resolution of its
members or, if the company is unable to pay its debts, by an ordinary resolution of its members. The court has authority to order winding
up in a number of specified circumstances including where it is, in the opinion of the court, just and equitable to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Variation
of Rights of Shares.&nbsp;</I>Under the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with
the approval of a majority of the outstanding shares of such class, unless the certificate of incorporation provides otherwise. Under
Cellyan Biotechnology&rsquo;s Fourth Amended and Restated Articles of Association, if its share capital is divided into more than one
class of shares, the rights attached to any such class may only be materially and adversely varied with the consent in writing of the
holders of two-thirds of the issued shares of that class or with the sanction of a Special Resolution passed at a separate meeting of
the holders of the shares of that class.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment
of Governing Documents.&nbsp;</I>Under the Delaware General Corporation Law, a corporation&rsquo;s governing documents may be amended
with the approval of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise.
Under Cayman Islands law, Cellyan Biotechnology&rsquo;s Fourth Amended and Restated Memorandum and Articles of Association may only be
amended with a Special Resolution of its shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Rights
of Non-resident or Foreign Shareholders.&nbsp;</I>There are no limitations imposed by Cellyan Biotechnology&rsquo;s Fourth Amended and
Restated Articles of Association on the rights of non-resident or foreign shareholders to hold or exercise voting rights on its shares.
In addition, there are no provisions in Cellyan Biotechnology&rsquo;s Fourth Amended and Restated Articles of Association governing the
ownership threshold above which shareholder ownership must be disclosed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>History
of Securities Issuances</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
Cellyan Biotechnology&rsquo;s incorporation on August&nbsp;17, 2023, it had an authorized share capital of $50,000 divided into 50,000,000
ordinary shares of a single class, par value $0.001 per share. Upon incorporation, ten ordinary shares were allotted and issued to the
initial subscriber, Harneys Fiduciary (Cayman) Limited, who transferred the share to Lap Sun Wong, on the same&nbsp;day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&nbsp;1, 2023, an additional 9,500,990 ordinary shares in total, par value $0.001 each, were allotted and issued to Lap Sun Wong
and new shareholders, including among others, 1,710,170 ordinary shares to Lap Sun Wong; 4,448,520 ordinary shares to Fame Overseas Supply
Chain Limited; 190,020 ordinary shares to Profit Seeker Limited; 617,850 ordinary shares to Pacific Health Century International Group
Limited; and 617,850 ordinary shares to Atlantic Health Century International Group Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&nbsp;15, 2023, Cellyan Biotechnology amended its share capital to secure an $800,000 investment from an investor. As a result
of such amendment, our authorized share capital changed to $50,000 divided into 50,000,000 shares, par value $0.001 per share, comprising
(i)&nbsp;49,501,000 Class&nbsp;A Ordinary Shares, par value $0.001 each; and (ii)&nbsp;499,000 Class&nbsp;B Ordinary Shares, par value
$0.001 each. The 9,501,000 ordinary shares that were previously issued and outstanding were redesignated as 9,501,000 Class&nbsp;A Ordinary
Shares. Cellyan Biotechnology issued 499,000 Class&nbsp;B Ordinary Shares to the new investor in consideration of $800,000 in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 16, 2025, Cellyan Biotechnology consummated its initial public offering of 1,403,685 ordinary shares, par value $0.001 per share,
at a public offering price of US$4.0 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with its initial public offering, Cellyan Biotechnology also issued warrants to purchase up to 70,184 ordinary shares (the
&ldquo;Representative&rsquo;s Warrants&rdquo;) to Bancroft Capital, LLC, as representative of the underwriters. The Representative&rsquo;s
Warrants are exercisable at any time and from time to time from July 15, 2025 to July 15, 2028 at an exercise price of $4.80 per share.
Cellyan Biotechnology undertakes to maintain an effective registration statement on Form&nbsp;F-1 (or Form&nbsp;F-3, if the Company is
eligible to use such form) until such date that is the earlier of the date when all of the ordinary shares underlying the Representative&rsquo;s
Warrants have been publicly sold by holder of such warrants or such time as Rule&nbsp;144 or another similar exemption under the Securities
Act of 1933, as amended (the &ldquo;Securities Act&rdquo;) is available for the sale of all of such ordinary shares underlying the Representative&rsquo;s
Warrants without registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 9, 2025, TUTU Business Services Limited, a company controlled by Ms. Liying Wang, entered into a Share Purchase Agreement with Lap
Sun Wong, Fame Overseas Supply Chain Limited, Profit Seeker Limited, HongKong Profit Fields Group Limited and Pacific Health Century
International Group Limited (the &ldquo;Sellers&rdquo;), pursuant to which the Reporting Persons acquired 7,150,000 ordinary shares,
par value $0.001 per share, of Cellyan Biotechnology from the Sellers. The aggregate purchase price was HK$53,820,000 (equivalent to
approximately US$6,900,000).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2025, Cellyan Biotechnology held the 2025 AGM, at which the shareholders approved, among other things: (i) an increase of
the authorized share capital of Cellyan Biotechnology from US$100,000 divided into 100,000,000 ordinary shares to US$1,000,000 divided
into 1,000,000,000 ordinary shares (the &ldquo;Increase of Share Capital&rdquo;); (ii) an amendment of the authorized share capital to
create two classes of ordinary shares, comprising 940,000,000 Class A Ordinary Shares, par value US$0.001 each, and 60,000,000 Class
B Ordinary Shares, par value US$0.001 each (the &ldquo;Implementation of the Dual Class Structure&rdquo;); (iii) the adoption of the
Fourth Amended and Restated Memorandum and Articles of Association; and (iv) the repurchase of 7,150,000 Class A Ordinary Shares registered
in the name of TUTU Business Services Limited and the concurrent issuance of 7,150,000 Class B Ordinary Shares (the &ldquo;Share Repurchase&rdquo;).
The amendment to the authorized share capital and the repurchase of the 7,150,000 Class A Ordinary Shares were fully completed as of
February 8, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2026, we entered into certain Securities Purchase Agreements with the Selling Shareholders, pursuant to which we issued and
sold an aggregate of 12,499,986 Class A Ordinary Shares to the Selling Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Listing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class A Ordinary Shares are listed on the Nasdaq Capital Market under the symbol &ldquo;HKPD.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Transfer
Agent and Registrar</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
transfer agent and registrar for the Class A Ordinary Shares is Vstock Transfer, LLC. The transfer agent and registrar&rsquo;s address
is 18 Lafayette Pl, Woodmere, NY 11598, telephone 212-828-8436.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_011"></A>SELLING
SHAREHOLDERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>March
2026 Private Placement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2026, Cellyan Biotechnology entered into Securities Purchase Agreements with the Selling Shareholders, pursuant to which the
Company agreed to issue and sell an aggregate of 12,499,986 Class A Ordinary Shares&rdquo;) included in 12,499,986 units (the &ldquo;Units&rdquo;),
each consisting of one Class A Ordinary Share, and two warrants, each exercisable to purchase one Class A Ordinary Share (each, a &ldquo;Warrant&rdquo;),
at a purchase price of $0.52 per Unit, for gross proceeds of approximately $6,500,000. The Company plans to use the process for business
expansion, working capital and general corporate purposes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Warrants have a three-year term and a $0.01 per share exercise price. The Warrants also provide for cashless exercise if and only if
at the time of any exercise thereof there is no effective registration statement registering. Subject to limited exceptions, a holder
of Warrants will not have the right to exercise any portion of its Warrants if the holder, together with its affiliates, would beneficially
own in excess of 4.99% (or, at the election of the holder, such limit may be increased to up to 9.99%) of the number of Class A Ordinary
Shares outstanding immediately after giving effect to such exercise.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the March 2026 Private Placement, the Company also entered into a registration rights agreement with the Investors (the
&ldquo;Registration Rights Agreement&rdquo;), pursuant to which the Company agreed to file one or more registration statements with the
Commission to register the resale of the Class A Ordinary Shares to be issued in the March 2026 Private Placement and the Class A Ordinary
Shares issuable upon exercise of the Warrants. Pursuant to the Registration Rights Agreement, the Company is required to file the initial
registration statement no later than the 30th calendar day following the closing date of the March 2026 Private Placement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
March 2026 Private Placement closed on March 25, 2026. The Units were issued and sold by the Company to the Investors in reliance upon
the exemptions from the registration requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant
to Section 4(a)(2) thereof, and Regulation S promulgated thereunder. Each Investor was required to represent that it is not a &ldquo;U.S.
person&rdquo; in accordance with Regulation S under the Securities Act. The Company did not engage in general solicitation or advertising
and did not offer securities to the public in connection with the issuance and sale of the Units, the Class A Ordinary Shares or the
Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Relationships
with the Selling Shareholders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Except
for ownership of the Class A Ordinary Shares we issued and sold in the March 2026 Private Placement , and as described in this prospectus,
none of the Selling Shareholders has had any material relationship with us within the past three years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Information
About This Offering</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Offered Shares offered by the Selling Shareholders are those issued in the March 2026 Private Placement as described above. We are registering
the Offered Shares in order to permit the Selling Shareholders to offer the Offered Shares for resale from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
this prospectus, when we refer to the Selling Shareholders, we are referring to the Selling Shareholders identified below, and, as applicable,
permitted transferees or other successors-in-interest of the Selling Shareholders that may be identified in a supplement to this prospectus
or, if required, a post-effective amendment to the registration statement of which this prospectus is a part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below provides information regarding the beneficial ownership of the Offered Shares by the Selling Shareholders. The second column
lists the number of Class A Ordinary Shares beneficially owned by the Selling Shareholders. The fourth column lists the maximum number
of Class A Ordinary Shares being offered in this prospectus by the Selling Shareholders. The fifth and sixth columns list the number
of Class A Ordinary Shares beneficially owned after the offering of the Offered Shares and the percentage of outstanding Class A Ordinary
Shares, assuming the sale of all of the Offered Shares offered by such Selling Shareholders pursuant to this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Shareholders may sell some, all or none of their respective Offered Shares. We do not know when or whether the Selling Shareholders
will sell their respective Offered Shares nor do we know how long the Selling Shareholders will hold their Offered Shares before selling
them, and we currently have no agreements, arrangements or understandings with the Selling Shareholders regarding the sale or other disposition
of any of the Offered Shares. The Offered Shares covered hereby may be offered from time to time by the Selling Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated, all information contained in the table below and the footnotes thereto is based upon information provided to us
by the Selling Shareholders. The percentage of shares owned prior to the offering is based on the Selling Shareholders&rsquo; ownership
of Class A Ordinary Shares as of March 26, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class&nbsp;A Ordinary Shares Beneficially Owned Prior to this Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class&nbsp;B Ordinary Shares Beneficially Owned Prior to this Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Maximum Number of Class A Ordinary Shares to be Offered Pursuant to this Prospectus</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class&nbsp;A Ordinary Shares Beneficially Owned After this Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Class&nbsp;B Ordinary Shares Beneficially Owned After this Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Voting Power After this Offering</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold">Name&nbsp;of&nbsp;Selling&nbsp;Shareholder</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 30%; text-align: left">Jiamei Qin</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">657,894</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">4.02</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">657,894</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 4%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yun Zhou</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Yawen Zhang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Xiuhua Wang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shunzeng Chen</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Junqing Wang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Chunxia Wang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Huanyin Wang</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Guojun Liu</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Yundie Chi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Guorui Liu</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fuping Lin</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Liuqin Bao</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Xuanrui Chi</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Xincun Li</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Jindong Sun</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Xiangyang Xu</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Fengjun Xue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.02</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">657,894</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Xiangdie Liu</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">657,894</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.02</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">657,894</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beneficial
    ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities.
    The total number of Class A Ordinary Shares issued and outstanding as of March 26, 2026 was 16,349,986, which includes shares issued
    in the March 2026 Private Placement. The total number of Class B Ordinary Shares issued and outstanding as of March 26, 2026 was
    7,150,000.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_012"></A>PLAN
OF DISTRIBUTION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Shareholders may sell all or a portion of the Class A Ordinary Shares beneficially owned by them and offered hereby from time
to time directly or through one or more underwriters, broker-dealers or agents. If the Class A Ordinary Shares are sold through underwriters
or broker-dealers, the Selling Shareholders will be responsible for underwriting discounts or commissions or agent&rsquo;s commissions.
The Class A Ordinary Shares may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale,
at varying prices determined at the time of sale, or at negotiated prices. Such sales may be effected in transactions, which may involve
crosses or block transactions, by any of the following methods:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">on any national
    securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in the over-the-counter
    market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions
    otherwise than on these exchanges or systems or in the over-the-counter market;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the
    writing of options, whether such options are listed on an options exchange or otherwise;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage
    transactions and transactions in which the broker-dealer solicits purchasers;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades
    in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal
    to facilitate the transaction;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by
    a broker-dealer as principal and resale by the broker-dealer for its account;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">an exchange
    distribution in accordance with the rules of the applicable exchange;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated
    transactions;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">short sales;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">sales pursuant
    to Rule 144 under the Securities Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">broker-dealers
    may agree with the Selling Shareholders to sell a specified number of such shares at a stipulated price per share;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination
    of any such methods of sale; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method
    permitted pursuant to applicable law.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Shareholders may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available,
rather than under this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Broker-dealers
engaged by the Selling Shareholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive commissions
or discounts from the Selling Shareholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser)
in amounts to be negotiated, but, except as set forth in a supplement to this prospectus, in the case of an agency transaction not in
excess of a customary brokerage commission in compliance with FINRA Rule 2121, and in the case of a principal transaction, a markup or
markdown in compliance with FINRA Rule 2121.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the sale of the securities or interests therein, the Selling Shareholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may, in turn, engage in short sales of the securities in the course of hedging the positions they
assume. The Selling Shareholders may also sell securities short and deliver these securities to close out their short positions, or loan
or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Shareholders may also enter into options
or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the
delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Selling Shareholders and any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo;
within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers
or agents and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts
under the Securities Act. The Selling Shareholders have informed us that they do not have any written or oral agreement or understanding,
directly or indirectly, with any person to distribute the securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay certain fees and expenses incurred by us incident to the registration of the securities. We have agreed to indemnify
the Selling Shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to keep this prospectus effective until none of the Selling Shareholders owns any Class A Ordinary Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws.
In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for
sale in the applicable state or an exemption from the registration or qualification requirement is available and is complied with.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
applicable rules and regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously
engage in market-making activities with respect to the Offered Shares for the applicable restricted period, as defined in Regulation
M, prior to the commencement of the distribution. In addition, the Selling Shareholders will be subject to applicable provisions of the
Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the
Offered Shares by the Selling Shareholders or any other person. We will make copies of this prospectus available to the Selling Shareholders
and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including
by compliance with Rule 172 under the Securities Act).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offering will terminate on the date that all of the Class A Ordinary Shares offered by this prospectus have been sold by the Selling
Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Class A Ordinary Shares are currently listed on the Nasdaq Capital Market under the symbol &ldquo;HKPD.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_013"></A>EXPENSES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth the estimated costs and expenses payable by the registrant expected to be incurred in connection with the
issuance and distribution of the Offered Shares being registered hereby. All of such expenses are estimates, except for the SEC registration
fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Securities and Exchange Commission Registration Fee</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,123</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: left">Legal Fees and Other Expenses</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">51,128</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Accounting Fees and Expenses</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">14,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Miscellaneous Expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">739</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt">Total Expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">66,990</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_014"></A>LEGAL
MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are being represented by McLaughlin &amp; Stern, LLP with respect to certain legal matters as to United States federal securities and
New York State law. The validity of the Class A Ordinary Shares offered in this offering and certain other legal matters as to Cayman
Islands law will be passed upon for us by Harney Westwood &amp; Riegels, our counsel as to Cayman Islands law. Legal matters as to Hong
Kong law will be passed upon for us by SH Wong &amp; Co. Legal matters as to PRC law will be passed upon for us by Guangdong Jishi Furen
Law Firm.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_015"></A>EXPERTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements for the fiscal years ended March 31, 2025, 2024 and 2023 incorporated herein by reference to the 2025
Annual Report have been so incorporated in reliance on the report of Onestop Assurance PAC, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting. The office of Onestop Assurance PAC is located at 10
Anson Road, #13-09 International Plaza, Singapore 079903.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_016"></A>INCORPORATION
OF CERTAIN INFORMATION BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have elected to incorporate the following documents into this prospectus, together with all exhibits filed therewith or incorporated
therein by reference, to the extent not otherwise amended or superseded by the contents of this prospectus:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    annual report on&nbsp;<A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/2007702/000121390025076725/ea0252263-20f_hongkong.htm">Form 20-F</A>&nbsp;for the fiscal year ended March 31, 2025, filed with the SEC on August 14, 2025;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    current reports on&nbsp;Form 6-K&nbsp;filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025086676/ea0253921-6k_hongkong.htm">September 11, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025096731/ea0260472-6k_hongkong.htm">October 7, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025109242/ea0265263-6k_hongkong.htm">November 12, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025113878/ea0265848-01.htm">November 24, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025122811/ea0270002-6k_hongkong.htm">December 17, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025126836/ea0271326-6k_cellyan.htm">December 31, 2025</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390026005164/ea0273151-6k_cellyan.htm">January 16, 2026</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/2007702/000121390026030790/ea0282235-6k_cellyan.htm">March 18, 2026</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390026034966/ea0283677-6k_cellyan.htm">March 27, 2026</A>;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    description of our Ordinary Shares contained in our registration statement on&nbsp;<A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025001906/ea0227062-8a12b_hongkong.htm">Form 8-A</A>, filed with the SEC on January 8, 2025,
    and any amendment or report filed for the purpose of updating such description;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any future
    annual reports on Form 20-F filed with the SEC after the date of this prospectus and prior to the termination of the offering of
    the securities offered by this prospectus; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any future
    reports of foreign private issuer on Form 6-K that we furnish to the SEC after the date of this prospectus that are identified in
    such reports as being incorporated by reference into the registration statement of which this prospectus forms a part.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2025 Annual Report contains a description of our business and audited consolidated financial statements with reports by our independent
auditors. These statements were prepared in accordance with U.S. GAAP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to,
but not filed with, the SEC. Copies of all documents incorporated by reference in this prospectus, other than exhibits to those document
unless such exhibits are specially incorporated by reference in this prospectus, will be provided at no cost to each person, including
any beneficial owner, who receives a copy of this prospectus on the written or oral request of that person made to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CELLYAN
BIOTECHNOLOGY CO., LTD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Room
B1, 5/F., Well Town Industrial Building,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13
Ko Fai Road, Yau Tong, Kowloon</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
Kong</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+852
2618-9289</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should rely only on the information that we incorporate by reference or provide in this prospectus. We have not authorized anyone to
provide you with different information. We are not making any offer to sell these securities in any jurisdiction where the offer or sale
is not permitted. You should not assume that the information contained or incorporated in this prospectus by reference is accurate as
of any date other than the date of the document containing the information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_017"></A>WHERE
YOU CAN FIND ADDITIONAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed with the SEC a registration statement on Form F-1, including relevant exhibits and schedules under the Securities Act, covering
the Offered Shares offered by this prospectus. You should refer to our registration statements and their exhibits and schedules if you
would like to find out more about us and about the Offered Shares. This prospectus summarizes material provisions of contracts and other
documents that we refer you to. Since the prospectus may not contain all the information that you may find important, you should review
the full text of these documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to periodic reporting and other informational requirements of the Exchange Act, as applicable to foreign private issuers.
Accordingly, we are required to file reports, including annual reports on Form 20-F, and other information with the SEC. As a foreign
private issuer, we are exempt from the rules of the Exchange Act prescribing the furnishing and content of proxy statements to shareholders
under the federal proxy rules contained in Sections 14(a), (b) and (c) of the Exchange Act, and our executive officers, directors and
principal shareholders are exempt from the short-swing profit recovery provisions contained in Section 16 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC maintains a website that contains reports, proxy statements, and other information about issuers, such as us, who file electronically
with the SEC. The address of that website is http://www.sec.gov. The information on that website is not a part of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
dealers, salesperson, or other person is authorized to give any information or to represent anything not contained in this prospectus.
You must not rely on any unauthorized information or representations. This prospectus is an offer to sell only the securities offered
hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is
current only as of its date.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to 12,499,986 Class A Ordinary Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLYAN
BIOTECHNOLOGY CO., LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Prospectus
dated March 27, 2026</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
NOT REQUIRED IN PROSPECTUS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&thinsp;6.
Indemnification of Directors and Officers.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayman
Islands law does not limit the extent to which a company&rsquo;s memorandum and articles of association may provide for indemnification
of directors and officers, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public
policy, such as to provide indemnification against the consequences of committing a crime, or against the indemnified person&rsquo;s
own fraud or dishonesty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
Fourth Amended and Restated Articles of Association provide that we will indemnify every director, secretary, assistant secretary, or
other officer for the time being and from time to time of our Company (but not including our auditors) and the personal representatives
of the same and from: (a) all actions, proceedings, costs, charges, expenses, losses, damages, or liabilities incurred or sustained by
such person, other than by reason of such person&rsquo;s own dishonesty, willful default, or fraud, in or about the conduct of our business
or affairs (including as a result of any mistake of judgment) or in the execution or discharge of that person&rsquo;s duties, powers,
authorities, or discretions; and (b) without limitation to paragraph (a) above, all costs, expenses, losses, or liabilities incurred
by such person in defending (whether successfully or otherwise) any civil proceedings concerning us or our affairs in any court, whether
in the Cayman Islands or elsewhere.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have agreed to indemnify our directors and officers against certain liabilities and expenses incurred by such persons in connection with
claims made by reason of their being such a director or officer.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&thinsp;7.
Recent Sales of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the past three&nbsp;years, we have issued the following securities. We believe that each of the following issuances was exempted from
registration under the Securities Act in reliance on Regulation&nbsp;D under the Securities Act or pursuant to Section&nbsp;4(a)(2)&nbsp;of
the Securities Act regarding transactions not involving a public offering, or in reliance on Regulation&nbsp;S under the Securities Act
regarding sales by an issuer in offshore transactions. The underwriter was not involved in these issuances of securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
Cellyan Biotechnology&rsquo;s incorporation on August&nbsp;17, 2023, it had an authorized share capital of $50,000 divided into 50,000,000
ordinary shares of a single class, par value $0.001 per share. Upon incorporation, ten ordinary shares were allotted and issued to the
initial subscriber, Harneys Fiduciary (Cayman) Limited, who transferred the share to Lap Sun Wong, on the same&nbsp;day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&nbsp;1, 2023, an additional 9,500,990 ordinary shares in total, par value $0.001 each, were allotted and issued to Lap Sun Wong
and new shareholders, including among others, 1,710,170 ordinary shares to Lap Sun Wong; 4,448,520 ordinary shares to Fame Overseas Supply
Chain Limited; 190,020 ordinary shares to Profit Seeker Limited; 617,850 ordinary shares to Pacific Health Century International Group
Limited; and 617,850 ordinary shares to Atlantic Health Century International Group Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December&nbsp;15, 2023, Cellyan Biotechnology amended its share capital to secure an $800,000 investment from an investor. As a result
of such amendment, our authorized share capital changed to $50,000 divided into 50,000,000 shares, par value $0.001 per share, comprising
(i)&nbsp;49,501,000 Class&nbsp;A Ordinary Shares, par value $0.001 each; and (ii)&nbsp;499,000 Class&nbsp;B Ordinary Shares, par value
$0.001 each. The 9,501,000 ordinary shares that were previously issued and outstanding were redesignated as 9,501,000 Class&nbsp;A Ordinary
Shares. Cellyan Biotechnology issued 499,000 Class&nbsp;B Ordinary Shares to the new investor in consideration of $800,000 in cash.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2025, Cellyan Biotechnology held the 2025 AGM, at which the shareholders approved, among other things: (i) an increase of
the authorized share capital of Cellyan Biotechnology from US$100,000 divided into 100,000,000 ordinary shares to US$1,000,000 divided
into 1,000,000,000 ordinary shares (the &ldquo;Increase of Share Capital&rdquo;); (ii) an amendment of the authorized share capital to
create two classes of ordinary shares, comprising 940,000,000 Class A Ordinary Shares, par value US$0.001 each, and 60,000,000 Class
B Ordinary Shares, par value US$0.001 each (the &ldquo;Implementation of the Dual Class Structure&rdquo;); (iii) the adoption of the
Fourth Amended and Restated Memorandum and Articles of Association; and (iv) the repurchase of 7,150,000 Class A Ordinary Shares registered
in the name of TUTU Business Services Limited and the concurrent issuance of 7,150,000 Class B Ordinary Shares (the &ldquo;Share Repurchase&rdquo;).
The amendment to the authorized share capital and the repurchase of the 7,150,000 Class A Ordinary Shares were fully completed as of
February 8, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 24, 2026, we entered into certain Securities Purchase Agreements with the Selling Shareholders, pursuant to which we issued and
sold an aggregate of 12,499,986 Class A Ordinary Shares to the Selling Shareholders. The Class A Ordinary Shares were issued and sold
by the Company to the Investors as part of Units, together with certain Warrants, in reliance upon the exemptions from the registration
requirements of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), pursuant to Section 4(a)(2) thereof, and Regulation
S promulgated thereunder. Each Investor was required to represent that it is not a &ldquo;U.S. person&rdquo; in accordance with Regulation
S under the Securities Act. The Company did not engage in general solicitation or advertising and did not offer securities to the public
in connection with the issuance and sale of the Units, the Class A Ordinary Shares or the Warrants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&thinsp;8.
Exhibits and Financial Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Exhibit Index beginning on page II-4 of this registration statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(b)
Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
have been omitted because the information required to be set forth therein is not applicable or is shown in the Consolidated Financial
Statements or the Notes thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9. Undertakings.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Insofar
as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of
the registrant pursuant to the provisions described in Item&nbsp;6, or otherwise, the registrant has been advised that in the opinion
of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event
that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a
director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion
of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication
of such issue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned
    registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to file, during
    any period in which offers or sales are being made, a post-effective amendment to this registration statement:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to include
    any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to reflect
    in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective
    amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration
    statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of
    securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
    offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate,
    the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation
    of Registration Fee&rdquo; table in the effective registration statement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to include
    any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material
    change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i), (a)(1)(ii)&nbsp;and(a)(1)(iii)&nbsp;do
    not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed
    with or furnished to the SEC by the registrant pursuant to Section&nbsp;13 or Section&nbsp;15(d)&nbsp;of the Exchange&nbsp;Act that
    are incorporated by reference in the registration statement.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, for the
    purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration
    statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the
    initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to remove from
    registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
    of the offerings.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to file a post-effective
    amendment to the registration statement to include any financial statements required by Item&nbsp;8.A of Form&nbsp;20-F at the start
    of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by Section&nbsp;10(a)(3)&nbsp;of
    the Act (15 U.S.C. 77j(a)(3)) need not be furnished, provided that the registrant includes in the prospectus, by means of a post-effective
    amendment, financial statements required pursuant to this paragraph (a)(4)&nbsp;and other information necessary to ensure that all
    other information in the prospectus is at least as current as the date of those financial statements.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, for the
    purpose of determining liability under the Securities Act to any purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the issuer
    is relying on Rule&nbsp;430B:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 120pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each prospectus
    filed by the undersigned issuer pursuant to Rule&nbsp;424(b)(3)&nbsp;shall be deemed to be part of the registration statement as
    of the date the filed prospectus was deemed part of and included in the registration statement; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 120pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">each prospectus
    required to be filed pursuant to Rule&nbsp;424(b)(2), (b)(5), or (b)(7)&nbsp;as part of a registration statement in reliance on Rule&nbsp;430B
    relating to an offering made pursuant to Rule&nbsp;415(a)(1)(i), (vii), or (x)&nbsp;for the purpose of providing the information
    required by section 10(a)&nbsp;of the Securities Act shall be deemed to be part of and included in the registration statement as
    of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of
    securities in the offerings described in the prospectus. As provided in Rule&nbsp;430B, for liability purposes of the issuer and
    any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement
    relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at
    that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration
    statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference
    into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract
    of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus
    that was part of the registration statement or made in any such document immediately prior to such effective date; or</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if the issuer
    is relying on Rule&nbsp;430C, each prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;as part of a registration statement relating
    to an offering, other than registration statements relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule&nbsp;430A,
    shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
    however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a
    document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration
    statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that
    was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
    prior to such date of first use.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">that, for the
    purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of the securities,
    the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration
    statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold
    to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and
    will be considered to offer or sell such securities to such purchaser:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any preliminary
    prospectus or prospectus of the undersigned registrant relating to the offerings required to be filed pursuant to Rule&nbsp;424;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any free writing
    prospectus relating to the offerings prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned
    registrant;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the portion
    of any other free writing prospectus relating to the offerings containing material information about the undersigned registrant or
    its securities provided by or on behalf of the undersigned registrant; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 96pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other communication
    that is an offer in the offerings made by the undersigned registrant to the purchaser.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The undersigned
    registrant hereby undertakes that:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for purposes
    of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this
    registration statement in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to
    Rule&nbsp;424(b)(1)&nbsp;or (4)&nbsp;or 497(h)&nbsp;under the Securities Act shall be deemed to be part of this registration statement
    as of the time it was declared effective.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 49.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the purpose
    of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be
    deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
    time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
INDEX</B>&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025126836/ea027132601ex1-2_cellyan.htm">Fourth Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 1.2 of the Current Report on 6-K of the Registrant, filed with the SEC on December 31, 2025)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390025076725/ea025226301ex2-1_hongkong.htm">Description of Securities Pursuant to Section 12 of the Exchange Act (incorporated by reference to Exhibit 2.1 to the Annual Report on Form 20-F, filed by the Registrant with the SEC on August 14, 2025)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024103158/ea022259001ex4-2_hongkong.htm">Form of Representative&rsquo;s Warrants (incorporated by reference to Exhibit 4.2 of the Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390026034966/ea028367701ex4-1.htm">Form of Ordinary Share Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Current Report on Form 6-K, filed by the Registrant with the SEC on March 27, 2026)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex5-1.htm">Opinion of Harney Westwood &amp; Riegels regarding the validity of the Class A Ordinary Shares being registered</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024091775/ea021809101ex10-1_hongkong.htm">Form of Indemnification Agreement between the Registrant and its directors and executive officers (incorporated by reference to Exhibit 10.1 to Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024091775/ea021809101ex10-2_hongkong.htm">Form of Employment Agreement between the Registrant and its executive officers (incorporated by reference to Exhibit 10.2 to Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024091775/ea021809101ex10-5_hongkong.htm">End-to-End Logistics Service Agreement, effective as of April 1, 2024, between Hangzhou CaiNiao Supply Chain Management Co., Ltd. and Joint Cross Border Logistics Company Limited. (incorporated by reference to Exhibit 10.5 to Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024091775/ea021809101ex10-6_hongkong.htm">Overseas Center Warehouse Service Agreement, effective as of April 1, 2024, between Hangzhou CaiNiao Supply Chain Management Co., Ltd. and Joint Cross Border Logistics Company Limited. (incorporated by reference to Exhibit 10.6 to Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024107282/ea022355601ex10-7_hongkong.htm">Tenancy Agreement between CPL YAUTONG LIMITED and Joint Cross Border Logistics Company Limited dated August 8, 2024. (incorporated by reference to Exhibit 10.7 to Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390026034966/ea028367701ex10-1.htm">Form of Securities Purchase Agreement dated March 24, 2026 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 6-K, filed by the Registrant with the SEC on March 27, 2026)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390026034966/ea028367701ex10-2.htm">Form of Registration Rights Agreement dated March 24, 2026 (incorporated by reference to Exhibit 10.2 to the Current Report on Form 6-K, filed by the Registrant with the SEC on March 27, 2026)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex21-1.htm">List of Subsidiaries of the Registrant</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex23-1.htm">Consent of Onestop Assurance PAC</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex5-1.htm">Consent of Harney Westwood &amp; Riegels (included in Exhibit 5.1)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex23-3.htm">Consent of SH Wong &amp; Co</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.4*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex99-2.htm">Consent of Guangdong Jishi Furen Law Firm (included in Exhibit 99.2)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="#s_001">Powers of Attorney (included on signature page)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/2007702/000121390024091775/ea021809101ex99-1_hongkong.htm">Code of Business Conduct and Ethics of the Registrant (incorporated by reference to Exhibit 99.1 to Registration Statement on Form F-1, as amended, initially filed by the Registrant with the SEC on October 29, 2024)</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex99-2.htm">Legal Opinion of Guangdong Jishi Furen Law Firm Regarding Certain PRC Law Matters dated March 26, 2026</A></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea028373001ex-fee.htm">Filing Fee Table</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed herewith.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="s_001"></A>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Hong Kong, People&rsquo;s Republic of China, on March 27, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLYAN
    BIOTECHNOLOGY CO., LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Chenyu Liang</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chenyu Liang</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Power
of Attorney</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
person whose signature appears below constitutes and appoints Chenyu Liang and Shu Liu as attorneys-in-fact with full power of substitution,
for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney
and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act, and any rules, regulations, and
requirements of the U.S. Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act
of securities of the registrant, including, without limitation, the power and authority to sign the name of each of the undersigned in
the capacities indicated below to the Registration Statement on Form F-1 (the &ldquo;Registration Statement&rdquo;) to be filed with
the U.S. Securities and Exchange Commission with respect to such securities, to any and all amendments or supplements to such Registration
Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any
related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed
as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before
or after the effective date of such Registration Statement; and each of the undersigned hereby ratifies and confirms all that such attorney
and agent shall do or cause to be done by virtue hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities
and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 30%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 48%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 18%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Chenyu Liang</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    27, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Chenyu Liang</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/&nbsp;Shu
    Liu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Shu Liu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/&nbsp;Lap
    Sun Wong</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Lap Sun Wong</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/&nbsp;Jingyan
    Wu</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Jingyan Wu</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Mike
    Yao Zhou</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Mike Yao Zhou</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Dr.
    Kam Leung Chan</I></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Independent Director</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 27, 2026</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Dr. Kam Leung Chan</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE
OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Securities Act of 1933, as amended, the undersigned, the duly authorized representative in the United States of America of CELLYAN
BIOTECHNOLOGY CO., LTD, has signed this registration statement thereto in New York, NY on March 27, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cogency Global Inc.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized U.S. Representative</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Colleen
    A. De Vries</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Colleen A. De Vries</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior Vice President on behalf of <BR>
Cogency Global Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 54; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>ea028373001ex5-1.htm
<DESCRIPTION>OPINION OF HARNEY WESTWOOD & RIEGELS REGARDING THE VALIDITY OF THE CLASS A ORDINARY SHARES BEING REGISTERED
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><IMG SRC="ea028373001_ex5-1img1.jpg" ALT="" STYLE="height: 58px; width: 200px"></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Harney
                                            Westwood &amp; Riegels</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14th
    Floor, Alexandra House</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18
    Chater Road</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Central</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel:
    +852 5806 7800</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fax:
    +852 5806 7810</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26
March 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">raymond.ng@harneys.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+852
5806 7883</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">069050-0001-RLN</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology Co., Ltd &#29983;&#30740;&#29983;&#29289;&#20844;&#21496;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c/o
Harneys Fiduciary (Cayman) Limited</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4<SUP>th</SUP>
Floor, Harbour Place</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">103
South Church Street, P.O. Box 10240</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Grand
Cayman KY1-1002</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cayamn
Islands</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir or Madam</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cellyan
Biotechnology Co., Ltd &#29983;&#30740;&#29983;&#29289;&#20844;&#21496; (the <I>Company</I>)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are attorneys-at-law qualified to practise in the Cayman Islands and have acted as Cayman Islands advisers to the Company in connection
with the Company&rsquo;s registration statement on Form F-1 (the <B><I>Registration Statement</I></B>), including all amendments or supplements
thereto, and accompanying prospectus (the <B><I>Prospectus</I></B>) filed with the Securities and Exchange Commission (the <B><I>Commission</I></B>)
under the United States Securities Act of 1933, as amended (the <B><I>Securities Act</I></B>), relating to the offering by the Selling
Shareholders (as defined in the Registration Statement) of up to 12,499,986 class A ordinary shares of par value of US$0.001 each (the
<B><I>Offered Shares</I></B>). In this opinion <B><I>Companies Act</I></B> means the Companies Act (2026 Revision) of the Cayman Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are furnishing this opinion as Exhibits 5.1 and 23.2 to the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the purposes of giving this opinion, we have examined the Documents (as defined in Schedule 1) which we regard as necessary in order
to issue this opinion. We have not examined any other documents, official or corporate records or external or internal registers and
have not undertaken or been instructed to undertake any further enquiry or due diligence in relation to the transaction which is the
subject of this opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
giving this opinion we have relied upon the assumptions set out in Schedule 2 which we have not verified.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
solely upon the foregoing examinations and assumptions and having regard to legal considerations which we deem relevant, and subject
to the qualifications set out in Schedule 3, we are of the opinion that under the laws of the Cayman Islands:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Existence
                                            and Good Standing</B>. The Company is an exempted company duly incorporated with limited
                                            liability, and is validly existing and in good standing under the laws of the Cayman Islands.
                                            It is a separate legal entity and is subject to suit in its own name.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 59%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">The
                                            British Virgin Islands is Harneys Hong Kong office's main jurisdiction of practice.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Jersey
    legal services are provided through a referral arrangement with Harneys (Jersey) which <BR>
is an independently owned and controlled Jersey
    law firm.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Resident
    Partners: M Chu | Y Fan | SG Gray | IC Groark | SO Karolczuk | PM Kay | MW Kwok</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">IN
    Mann | BP McCosker | R Ng | PJ Sephton</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif; width: 39%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Anguilla
    | Bermuda | British Virgin Islands</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Cayman
    Islands | Cyprus | Dubai | Hong Kong | Jersey</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">London
    | Luxembourg | Shanghai | Singapore</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">harneys.com</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authorised
                                            Share Capital.</B> Based on our review of the M&amp;A (as defined in Schedule 1), the authorised
                                            share capital of the Company is US$1,000,000 divided into 1,000,000,000 shares comprising
                                            940,000,000 class A ordinary shares of par value of US$0.0001 each (the <B><I>Class A Ordinary
                                            Shares</I></B>) and 60,000,000 class B ordinary shares of par value of US$0.001 each.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Sale
                                            of Offered Shares.</B> The Offered Shares to be sold by the Selling Shareholders are allotted
                                            and validly issued as fully paid and non-assessable shares, and there will be no further
                                            obligation on the holders of any of the Offered Shares to make any further payment to the
                                            Company in respect of such Offered Shares.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0%"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cayman
                                            Islands Law.</B> The statements under the headings &ldquo;Enforceability of Civil Liabilities
                                            &ndash; Cayman Islands&rdquo; and &ldquo;Description of Share Capital&rdquo; in the Prospectus,
                                            to the extent that they constitute statements of Cayman Islands law, are accurate in all
                                            material respects as at the date of this opinion and such statements constitute our opinion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is confined to the matters expressly opined on herein and given on the basis of the laws of the Cayman Islands as they are in
force and applied by the Cayman Islands courts at the date of this opinion. We have made no investigation of, and express no opinion
on, the laws of any other jurisdiction. We express no opinion as to matters of fact. Except as specifically stated herein, we make no
comment with respect to any representations and warranties which may be made by or with respect to the Company in the Registration Statement.
We express no opinion with respect to the commercial terms of the transactions the subject of this opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the above opinion, we hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to
the reference made to this firm in the Registration Statement under the headings &ldquo;Enforceability of Civil Liabilities &ndash; Cayman
Islands&rdquo; and &ldquo;Legal Matters&rdquo; and elsewhere in the prospectus included in the Registration Statement. In giving such
consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Securities
Act or the Rules&nbsp;and Regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is limited to the matters referred to herein and shall not be construed as extending to any other matter or document not referred
to herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion shall be construed in accordance with the laws of the Cayman Islands.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
    faithfully</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Harney
    Westwood &amp; Riegels</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
1</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">List
of Documents Examined</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            copy of the certificate of incorporation and the certificate of incorporation on change of
                                            name of the Company dated 17 August 2023 and 19 December 2025, respectively.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            copy of the fourth amended and restated memorandum and articles of association of the Company
                                            as adopted by a special resolution passed on 12 December 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            copy of the certificate of good standing in respect of the Company issued by the Registrar
                                            of Companies dated 24 March 2026.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
                                            Register of Writs and other Originating Process of the Grand Court of the Cayman Islands
                                            (the <B><I>Court Register</I></B>) via the Court&rsquo;s Digital System (as defined in Schedule
                                            3) conducted on 26 March 2026 (the <B><I>Court Search Date</I></B>).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            copy of the register of directors and officers of the Company provided to us on 25 March
                                            2026.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            copy of the unanimous written resolutions of the board of directors of the Company dated
                                            24 March 2026 (the <B><I>Resolutions</I></B>).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            certificate from a director of the Company dated 26 March 2026, a copy of which is attached
                                            hereto (the <B><I>Director&rsquo;s Certificate</I></B>).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
                                            copy of the Registration Statement to be filed with the Commission on or about the date of
                                            this opinion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1
to 7 above are the <B><I>Corporate Documents</I></B>, and 1 to 8 above are the <B><I>Documents</I></B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
2</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Authenticity
                                            of Documents.</B> All original Documents are authentic, all signatures, initials and seals
                                            are genuine, and all copies of Documents are true and correct copies.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
                                            Documents.</B> All matters required by law to be recorded in the Corporate Documents are
                                            so recorded, and all corporate minutes, resolutions, certificates, documents and records
                                            which we have reviewed are accurate and complete, and all facts expressed in or implied thereby
                                            are accurate and complete.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Director&rsquo;s
                                            Certificate.</B> The contents of the Director&rsquo;s Certificate are true and accurate as
                                            at the date of this opinion and there is no information not contained in the Director&rsquo;s
                                            Certificate that will in any way affect this opinion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Court
                                            Search.</B> The Register of Writs and other Originating Process of the Grand Court of the
                                            Cayman Islands examined by us via the Court&rsquo;s Digital System on the Court Search Date,
                                            constitutes a complete record of the proceedings for such period before the Grand Court of
                                            the Cayman Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            Steps to Wind-up</B>. The directors and shareholders of the Company have not taken any steps
                                            to have the Company struck off or placed in liquidation, no steps have been taken to wind
                                            up the Company and no receiver has been appointed over any of the property or assets of the
                                            Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0pt"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Resolutions</B>.
                                            The Resolutions passed as written resolutions have been duly executed (and where executed
                                            by a corporate entity, such execution has been duly authorised if so required) by or on behalf
                                            of each director or shareholder (as the case may be), and the signatures and initials thereon
                                            are those of a person or persons in whose name the Resolutions have been expressed to be
                                            signed. The Resolutions remain in full force and effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Unseen
                                            Documents.</B> Save for the Documents provided to us there are no resolutions, agreements,
                                            documents or arrangements which materially affect, amend or vary the transactions envisaged
                                            in the Documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
3</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualifications</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stamp
                                            Duty</B>. Cayman Islands stamp duty may be payable if any original document is executed in,
                                            brought to, or produced before a court of, the Cayman Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Foreign
                                            Statutes.</B> We express no opinion in relation to provisions making reference to foreign
                                            statutes in the Registration Statement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commercial
                                            Terms.</B> Except as specifically stated herein, we make no comment with respect to any representations
                                            and warranties which may be made by or with respect to the Company in any of the documents
                                            or instruments cited in this opinion or otherwise with respect to the commercial terms of
                                            the transactions the subject of this opinion.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Meaning
                                            of Non-Assessable.</B> In this opinion the phrase <B><I>non-assessable</I></B> means, with
                                            respect to any Resale Share, that a shareholder shall not, in respect of the relevant Resale
                                            Shares, have any obligation to make further contributions to the Company&rsquo;s assets (except
                                            in exceptional circumstances, such as involving fraud, the establishment of an agency relationship
                                            or an illegal or improper purpose or other circumstances in which a court may be prepared
                                            to pierce or lift the corporate veil).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Good
                                            Standing.</B> The Company shall be deemed to be in good standing at any time if all fees
                                            (including annual filing fees) and penalties under the Companies Act have been paid and the
                                            Registrar of Companies has no knowledge that the Company is in default under the Companies
                                            Act.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Court
                                            Search</B>. The search of the Court has been undertaken on a digital system made available
                                            through the Grand Court of the Cayman Islands (the <B><I>Court&rsquo;s Digital System</I></B>),
                                            and through inadvertent errors or delays in updating the digital system (and/or the Register
                                            from which the digital information is drawn) may not constitute a complete record of all
                                            proceedings as at the Court Search Date and in particular may omit details of very recent
                                            filings. The Court Search of the Court Register would not reveal, amongst other things, an
                                            Originating Process filed with the Grand Court which, pursuant to the Grand Court rules or
                                            best practice of the Clerk of the Courts&rsquo; office, should have been entered in the Court
                                            Register but was not in fact entered in the Court Register (properly or at all), or any Originating
                                            Process which has been placed under seal or anonymised (whether by order of the Court or
                                            pursuant to the practice of the Clerk of the Courts&rsquo; office).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ea028373001ex21-1.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF THE REGISTRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>List
of Subsidiaries</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Jurisdiction
    of Incorporation</B></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage
    of Ownership</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">V-Alliance
    Technology Supplies Limited</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joint
    Cross Border Logistics Company Limited</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    Ben Global Enterprises Limited</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">100%</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ea028373001ex23-1.htm
<DESCRIPTION>CONSENT OF ONESTOP ASSURANCE PAC
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="ea028373001_ex23-1img1.jpg" ALT="" STYLE="height: 95px; width: 350px"></FONT></TD>
    <TD STYLE="text-align: center; width: 2%; vertical-align: top"></TD>
    <TD STYLE="width: 49%"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Onestop
                           Assurance PAC</B></FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Co.
    Registration No.: 201823302D</B></FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10
    Anson Road #21-14</B></FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>International
    Plaza</B></FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Singapore,
    079903</B></FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Email:
    audit@onestop-audit.com</B></FONT></P>
    <P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Website:
    www.onestop-audit.com&nbsp;</B></FONT></p></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>CONSENT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We hereby consent to the incorporation by reference in this Registration Statement on Form F-1 of our report dated August 14, 2025, with
respect to the consolidated financial statements of Cellyan Biotechnology Co., Ltd and its subsidiaries, appearing in its Annual Report
on Form 20-F for the year ended March 31, 2025.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo; in this Registration Statement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Onestop Assurance PAC</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><IMG SRC="ea028373001_ex23-1img2.jpg" ALT="" STYLE="height: 20px; width: 220px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Singapore</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">March 27, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.3
<SEQUENCE>5
<FILENAME>ea028373001ex23-3.htm
<DESCRIPTION>CONSENT OF SH WONG & CO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt"><B>Exhibit 23.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" ROWSPAN="3"><P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SH
WONG &amp; CO</B></FONT></P>
                                <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#29579;&#19990;&#38596;&#24459;&#24072;&#34892;</B></FONT></P>
    <P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
association with Wong &amp; Chun <BR>
Lawyers</FONT></P></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNIT
    4404, 44/F, HOPEWELL CENTRE, 183 QUEEN&rsquo;S ROAD EAST, WANCHAI, HONG KONG</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#36774;&#20844;&#23460;:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#39321;&#28207;
    &#28771;&#20180;&#30343;&#21518;&#22823;&#36947;&#26481;183&#34399; &#21512;&#21644;&#20013;&#24515;44&#27155;4404&#23460;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel
    (&#38651;&#35441;):</FONT>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2126
    7008 email: simon.wong@shwongandco.com</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 42%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Partner:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Wong
    Sai Hung</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    Ref</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 48%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="width: 35%">
    27 March 2026</TD></TR>
  <TR STYLE="font-family: Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
    Ref</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">:</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CELLYAN
BIOTECHNOLOGY CO., LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Room
B1, 5/F., Well Town Industrial Building,<BR>
13 Ko Fai Road, Yau Tong, Kowloon</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong
Kong</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Re:
Consent Letter on CELLYAN BIOTECHNOLOGY CO., LTD Form F-1</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
understand that <B>CELLYAN BIOTECHNOLOGY CO., LTD</B> (the &ldquo;Company&rdquo;), a company incorporated under the laws of the Cayman
Islands is filing a registration statement on Form&nbsp;F-1&nbsp;(the &ldquo;Registration Statement&rdquo;) with the United&nbsp;States
Securities and Exchange Commission (the &ldquo;SEC&rdquo;) in connection with the offer and sale of up to an aggregate of 12,499,986
Class A ordinary shares of the Company by the selling shareholders named therein (the &ldquo;Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
act as the Hong Kong counsel to Company in connection with the Company&rsquo;s Registration Statement on Form F-1 and the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the reference to our firm in the Registration Statement and any amendments thereto, (i)&nbsp;in the Registration Statement
and any amendments thereto, (ii)&nbsp;in any written correspondences with the SEC, (iii)&nbsp;in any other future filings with the SEC
by the Company, including, without limitation, filings on Form&nbsp;20-F&nbsp;or Form&nbsp;6-K&nbsp;or other SEC filings (collectively,
the &ldquo;SEC Filings&rdquo;), (iv) on the websites of the Company and its subsidiaries and affiliates, (v)&nbsp;in institutional and
retail road shows and other activities in connection with the Offering, and (vi)&nbsp;in other publicity materials in connection with
the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
further hereby consent to the filing of this letter as an exhibit to the Registration Statement and any amendments thereto and as an
exhibit to any other SEC Filings.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
faithfully,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
SH Wong &amp; Co</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SH
Wong &amp; Co</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>6
<FILENAME>ea028373001ex99-2.htm
<DESCRIPTION>LEGAL OPINION OF GUANGDONG JISHI FUREN LAW FIRM REGARDING CERTAIN PRC LAW MATTERS DATED MARCH 26, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028373001_ex99-2img3.jpg" ALT="" STYLE="height: 56px; width: 800px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cellyan
Biotechnology Co., Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Room
B1, 5/F., Well Town Industrial Building, </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13
Ko Fai Road, Yau Tong, Kowloon</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Hong
Kong</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
26, 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cellyan
    Biotechnology Co., Ltd</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Sir/Madam,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are acting as the PRC legal counsel to Cellyan Biotechnology Co., Ltd (the &ldquo;Company&rdquo;), a company incorporated in the Cayman
Islands and listed on the Nasdaq Capital Market (&ldquo;Nasdaq&rdquo;), in connection with the registration statement on Form F-1 filed
with the U.S. Securities and Exchange Commission (the &ldquo;Commission&rdquo;). This Registration Statement is intended to register
the resale by the selling shareholders named herein (the &ldquo;Selling Shareholders&rdquo;) of 12,499,986 Class A Ordinary Shares of
the Company (the &ldquo;Shares&rdquo;). Such Shares are Class A Ordinary Shares of the Company with a par value of US$0.001 per share
(the &ldquo;Ordinary Shares&rdquo;), which were privately placed and issued to the Selling Shareholders pursuant to certain Securities
Purchase Agreements entered into by the Company and the Selling Shareholders on March 24, 2026 (the &ldquo;Securities Purchase Agreements&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
so acting, we have examined the Registration Statement, the originals or copies, certified or otherwise identified to our satisfaction,
of documents provided to us by the Company and such other documents, corporate records, certificates, approvals and other information
and instruments as we have deemed necessary for the purpose of rendering this opinion, including, without limitation, originals or copies
of the agreements and certificates issued by PRC authorities and officers of the Company (&ldquo;Documents&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
our examination of the Documents and for the purpose of rendering this opinion, we have assumed without further inquiry or investigation:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
the truthfulness, accuracy, completeness and fairness of all the Documents, as well as the factual representations, warranties and statements
contained in such Documents;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
the genuineness of all the signatures, seals and chops, and the authenticity of the Documents submitted to us as originals and the conformity
with the originals of the Documents provided to us as copies and the authenticity of such originals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
that the Documents which have been presented to us have not been revoked, amended, varied or supplemented up to the date of this Opinion,
except as noted therein;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
that the Company have not withheld anything that, if disclosed to us, would reasonably cause us to alter this opinion in whole or in
part;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
the due compliance with, and the legality, validity, effectiveness and enforceability of the Documents under, all laws other than the
PRC Laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea028373001_ex99-2img3.jpg" ALT="" STYLE="height: 56px; width: 800px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not purport to be experts on and do not purport to be generally familiar with or qualified to express legal opinions on any laws other
than the laws of the PRC and accordingly express no legal opinion herein on any laws of any jurisdiction other than the PRC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing and subject to the confirmations and qualifications set out below, we are of the opinion that, as of the date hereof,
so far as PRC Laws are concerned:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms as used in this Opinion are defined as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CAC&rdquo;
means the Cyberspace Administration of China;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;CSRC&rdquo; means the China Securities Regulatory Commission;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Governmental
Agencies&rdquo; means any national, provincial or local court, governmental agency or body, stock exchange authorities or any other regulator
in the PRC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;the
Company&rdquo; means Cellyan Biotechnology Co., Ltd (the Company has no subsidiaries established in the Chinese mainland);</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Securities
Law&rdquo; means the Securities Law of the People&rsquo;s Republic of China which was amended on December 28, 2019, and became effective
on March 1, 2020, by the Standing Committee of the National People&rsquo;s Congress;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Measures&rdquo;
means the Measures for Cybersecurity Review promulgated jointly by the Cyberspace Administration of China, National Development and Reform
Commission, Ministry of Industry and Information Technology, The Ministry of Public Security, the Ministry of State Security, Ministry
of Finance, Ministry of Commerce, People&rsquo;s Bank of China, State Administration of Radio and Television, China Securities Regulatory
Commission, State Secrecy Administration and State Cryptography Administration on December 28, 2021, which became effective on February
15, 2022;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;The Trial Measures&rdquo; means the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic
Companies promulgated by CSRC on February 17, 2023, which became effective on March 31, 2023;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PRC
Laws&rdquo; means any and all officially published and publicly available laws, regulations, rules, and regulatory, administrative or
other governmental measures, notices or circulars, and Supreme Court judicial interpretation of the PRC currently in force and publicly
available in the PRC as of the date hereof;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;PRC
Authorities&rdquo; means any national, provincial, municipal or local governmental authority, agency or body in the PRC;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Prospectus&rdquo;
means the registration Statement Form F-1, including all amendments or supplements thereto, that forms part of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the foregoing and subject to the qualifications set out below, we are of the opinion that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
Legal and Operational Risks of Operating in the PRC.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.05pt; text-align: justify; text-indent: -14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the PRC government initiated a series of regulatory actions and statements to regulate business operations in China with little advance
notice, including cracking down on illegal activities in the securities market, enhancing supervision over China-based companies listed
overseas using a variable interest entity structure, adopting new measures to extend the scope of cybersecurity reviews, and expanding
the efforts in anti-monopoly enforcement. The Company does not conduct any business operations in the Chinese mainland and has no subsidiaries
in the Chinese mainland, and thus the Company is not subject to the cybersecurity review by the Cyberspace Administration of China (the
&ldquo;CAC&rdquo;) under the Cybersecurity Review Measures that became effective on February 15, 2022. We do not believe that the Company
is directly subject to the aforementioned PRC regulatory actions or statements, as the Company has no business activities in the Chinese
mainland and is not involved in any conduct related to monopolistic behavior, user data collection or cybersecurity in the PRC. As of
the date hereof, no relevant laws or regulations in the PRC explicitly require the Company to seek approval from the China Securities
Regulatory Commission (the &ldquo;CSRC&rdquo;) or any other PRC governmental authorities for future offerings, nor has the Company received
any inquiry, notice, warning or sanctions regarding previous offerings from the CSRC or any other PRC governmental authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea028373001_ex99-2img3.jpg" ALT="" STYLE="height: 56px; width: 800px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the
Opinions on Strictly Cracking Down on Illegal Securities Activities, which were made available to the public on July 6, 2021. The Opinions
on Strictly Cracking Down on Illegal Securities Activities emphasized the need to strengthen the administration over illegal securities
activities, and the need to strengthen the supervision over overseas listings by Chinese companies. Pursuant to the Opinions, Chinese
regulators are required to accelerate rulemaking related to the overseas issuance and listing of securities, and update the existing
laws and regulations related to data security, cross-border data flow, and management of confidential information. Numerous regulations,
guidelines and other measures are expected to be adopted under the umbrella of or in addition to the Cybersecurity Law and Data Security
Law. As of the date hereof, no official guidance or related implementation rules have been issued. As a result, the Opinions on Strictly
Cracking Down on Illegal Securities Activities remain unclear on how they will be interpreted, amended and implemented by the relevant
PRC governmental authorities. We believe that no relevant laws or regulations in the PRC explicitly require the Company to seek approval
from the CSRC for its overseas listing plan, given that the Company has no business operations in the Chinese mainland and no subsidiaries
established in the Chinese mainland. As of the date of this registration statement, the Company has not received any inquiry, notice,
warning, or sanctions regarding its planned overseas listing from the CSRC or any other PRC governmental authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company does not conduct any business operations in the Chinese mainland and has no subsidiaries in the Chinese mainland, the Company
is not required to obtain any licenses, permits, approvals or permissions from any PRC government authorities for any business activities,
nor is the Company subject to the approval or permission requirements of the CSRC, CAC or any other PRC entities in respect of securities
offerings to foreign investors under any currently effective PRC laws, regulations and regulatory rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
Business and License.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.05pt; text-align: justify; text-indent: -14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the
Opinions on Severely Cracking Down on Illegal Securities Activities According to Law, or the Opinions, which was made available to the
public on July 6, 2021. The Opinions emphasized the need to strengthen the administration over illegal securities activities, and the
need to strengthen the supervision over overseas listings by Chinese companies. Effective measures, such as promoting the construction
of relevant regulatory systems, will be taken to deal with the risks and incidents of China-concept overseas listed companies. As of
the date hereof, the Company has not received any inquiry, notice, warning, or sanctions from PRC government authorities in connection
with the Opinions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ea028373001_ex99-2img3.jpg" ALT="" STYLE="height: 56px; width: 800px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company does not conduct any business operations in the Chinese mainland and has no subsidiaries established in the Chinese mainland,
and therefore the Company is not required to obtain any business licenses, permits, approvals or permissions from any PRC government
authorities for business operations. Correspondingly, the Company is not subject to the approval or permission requirements of the CSRC,
CAC or any other PRC entities in respect of securities offerings to foreign investors under any currently effective PRC laws, regulations
and regulatory rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
PRC Regulatory Permissions.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 19.05pt; text-align: justify; text-indent: -14.05pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
business license is a permit issued by Administration for Market Regulation that allows the company to conduct specific business within
the government&rsquo;s geographical jurisdiction. Given that the Company has no subsidiaries in the Chinese mainland and does not conduct
any business operations in the Chinese mainland, the Company is not required to apply for or obtain any business licenses, permissions
or approvals from any Chinese authorities for any business activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
General Office of the Central Committee of the Communist Party of China and the General Office of the State Council jointly issued the
Opinions on Strictly Cracking Down on Illegal Securities Activities, which were made available to the public on July 6, 2021. The Opinions
on Strictly Cracking Down on Illegal Securities Activities emphasized the need to strengthen the administration over illegal securities
activities, and the need to strengthen the supervision over overseas listings by Chinese companies. Pursuant to the Opinions, Chinese
regulators are required to accelerate rulemaking related to the overseas issuance and listing of securities, and update the existing
laws and regulations related to data security, cross-border data flow, and management of confidential information. Numerous regulations,
guidelines and other measures are expected to be adopted under the umbrella of or in addition to the Cybersecurity Law and Data Security
Law. As of the date hereof, no official guidance or related implementation rules have been issued. As a result, the Opinions on Strictly
Cracking Down on Illegal Securities Activities remain unclear on how they will be interpreted, amended and implemented by the relevant
PRC governmental authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we believe that no relevant laws or regulations in the PRC explicitly require the Company to seek approval from the CSRC for
its overseas listing plan, due to the fact that the Company has no business operations in the Chinese mainland and no subsidiaries established
in the Chinese mainland. As of the date of this prospectus, the Company has not received any inquiry, notice, warning, or sanctions regarding
its planned overseas listing from the CSRC or any other PRC governmental authorities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Company does not conduct any business operations in the Chinese mainland and has no subsidiaries in the Chinese mainland, the Company
has no obligation to obtain any licenses, permissions or approvals from PRC authorities for business activities in the PRC, and there
is no circumstance of any PRC authority denying the Company any such license, permission or approval (as none is required).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ea028373001_ex99-2img3.jpg" ALT="" STYLE="height: 56px; width: 800px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is subject to the following qualifications:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
This opinion is subject to, in so far as it relates to the validity and enforceability of a contract, (i) applicable bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium or similar laws in the PRC affecting creditors&rsquo; rights generally; (ii) possible
judicial, arbitral or administrative actions or any PRC Law affecting creditors&rsquo; rights; (iii) certain equitable, legal or statutory
principles acting the validity and enforceability of contractual rights generally under the concepts of public interest, interest of
the state, national security, reasonableness, good faith and fair dealing, applicable statutes of limitation; (iv) any circumstance in
connection with formulation, execution or performance of any legal documents that would be deemed materially mistaken, clearly unconscionable,
fraudulent, or coercionary at the conclusions thereof; (v) any possible judicial discretion, discretion of arbitration tribunal or administrative
action affecting creditors&rsquo; rights or with respect to the availability of remedies, defenses or injunctive relief, the calculation
of damages, the entitlement of attorneys&rsquo; fees and other costs, and the waiver of immunity from jurisdiction of any court or from
legal process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
This opinion is subject to the discretion of any competent PRC legislative, administrative, judicial or arbitration tribunals in exercising
their authority to change any PRC Laws or the implementation, interpretation or application thereof in any form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
This opinion relates only to PRC Laws and we express no opinion as to any other laws and regulations. There is no guarantee that any
of PRC Laws, or the interpretation thereof or implementation thereof, will not be changed, amended, revoked or replaced in the immediate
future or in the longer term with or without retrospective effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
This opinion is intended to be used in the context which is specifically referred to herein and each paragraph should be looked at as
a whole regarding the same subject matter and no part should be extracted and referred to independently.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is delivered by us in our capacity as the Company&rsquo;s PRC legal advisers solely for the purpose of and in connection with
the Registration Statement publicly submitted to the SEC on the date of this opinion and may not be used for any other purpose without
our prior written consent, except as required by the applicable law or by the SEC or any regulatory agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hereby consent to the use of this Opinion in, and the filing hereof as an exhibit to, the Registration Statement, and to the reference
to our name in such Registration Statement. In giving such consent, we do not thereby admit that we fall within the category of the persons
whose consent is required under Section 7 of the U.S. Securities Act of 1933, as amended, or the regulations promulgated thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ea028373001_ex99-2img3.jpg" ALT="" STYLE="height: 56px; width: 800px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature
    page)</FONT></TD>
    <TD ROWSPAN="6" STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; width: 50%; vertical-align: bottom"><IMG SRC="ea028373001_ex99-2img1.jpg" ALT="" STYLE="height: 122px; width: 120px"></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yours
    faithfully,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/
    Guangdong Jishi Furen Law Firm</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Guangdong
    Jishi Furen Law Firm</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&nbsp;<IMG SRC="ea028373001_ex99-2img2.jpg" ALT="" STYLE="height: 49px; width: 120px"></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>7
<FILENAME>ea028373001ex-fee.htm
<DESCRIPTION>FILING FEE TABLE
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Template (c) 2024-2025 Novaworks, LLC -->
<!-- Field: Set; Name: AliasFileType; Value: Forms View; Template: Fee Exhibit\Fee Exhibit FE.xds -->
<!-- Field: Set; Name: Platform; Value: Novaworks Fee Exhibit Editor; Version: 1.4a -->
<!-- Field: Set; Name: Control; Value: VGVtcGxhdGU6IChkZWZhdWx0KQ0KQmFzZSBGb250OiBUaW1lcyBOZXcgUm9tYW4sIFRpbWVzLCBTZXJpZg0KQ2FwdGlvbiBTaXplOiAxMnB0DQpUYWJsZSBUaXRsZSBTaXplOiAxMXB0DQpUYWJsZSBIZWFkIFNpemU6IDhwdA0KVGFibGUgQm9keSBTaXplOiAxMHB0 -->
<!-- Field: Set; Name: MD5; Value: cd4a6b802c4b942d30c9288a4ea3cdd4 -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:ffd="http://xbrl.sec.gov/ffd/2025">
<head>
  <title>Filing Fee Exhibit</title>
  <meta http-equiv="Content-Type" content="text/html"/>
  </head>
<body style="font: 10pt Times New Roman, Times, Serif">

<div style="display: none">
  <ix:header>
    <ix:hidden>
      <ix:nonNumeric name="ffd:SubmissnTp" contextRef="c_report" id="fee_001">F-1</ix:nonNumeric>
      <ix:nonNumeric name="ffd:FeeExhibitTp" contextRef="c_report" id="fee_002">EX-FILING FEES</ix:nonNumeric>
      <ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="c_report" id="fee_003">0002007702</ix:nonNumeric>
      <ix:nonNumeric name="ffd:OfferingTableNa" contextRef="c_report" xs:nil="true" id="fee_004"></ix:nonNumeric>
      <ix:nonNumeric name="ffd:OffsetTableNa" contextRef="c_report" id="fee_005">N/A</ix:nonNumeric>
      <ix:nonNumeric name="ffd:CombinedProspectusTableNa" contextRef="c_report" id="fee_006">N/A</ix:nonNumeric>
      </ix:hidden>
    <ix:references>
      <link:schemaRef xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd" xlink:type="simple"/>
      </ix:references>
    <ix:resources>
      <xbrli:context id="c_offering_1">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0002007702</xbrli:identifier>
          <xbrli:segment>
            <xbrldi:typedMember dimension="ffd:OfferingAxis"><dei:lineNo>1</dei:lineNo></xbrldi:typedMember>
            </xbrli:segment>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-03-27</xbrli:startDate>
          <xbrli:endDate>2026-03-27</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:context id="c_report">
        <xbrli:entity>
          <xbrli:identifier scheme="http://www.sec.gov/CIK">0002007702</xbrli:identifier>
          </xbrli:entity>
        <xbrli:period>
          <xbrli:startDate>2026-03-27</xbrli:startDate>
          <xbrli:endDate>2026-03-27</xbrli:endDate>
          </xbrli:period>
        </xbrli:context>
      <xbrli:unit id="USD">
        <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="pure">
        <xbrli:measure>xbrli:pure</xbrli:measure>
        </xbrli:unit>
      <xbrli:unit id="shares">
        <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unit>
      </ix:resources>
    </ix:header>
  </div>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: right">Ex-Filing Fees</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center">CALCULATION OF FILING FEE TABLES</p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; text-align: center"><ix:nonNumeric name="ffd:FormTp" contextRef="c_report" id="fee_007">F-1</ix:nonNumeric></p>

<p style="font: bold 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 12pt; text-align: center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="c_report" id="fee_008">CELLYAN BIOTECHNOLOGY CO., LTD</ix:nonNumeric></p>

<p style="font: bold 11pt Times New Roman, Times, Serif; border-top: Gray 3pt double; padding-top: 6pt; text-align: center; margin-top: 0pt; margin-bottom: 4pt">Table 1: Newly Registered and Carry Forward Securities</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="font-size: 2pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="width: 12%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 6.5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 9%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 0.5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td></tr>
<tr style="font-size: 8pt; vertical-align: bottom; text-align: center; font-weight: bold">
  <td style="border-bottom: Black 1pt solid">Line Item Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Type</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Security Class Title</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Notes</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Calculation<br/> Rule</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Amount Registered</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Proposed Maximum Offering<br/> Price Per Unit</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Maximum Aggregate Offering Price</td>
  <td style="padding-bottom: 1pt">&#160;</td>
  <td style="border-bottom: Black 1pt solid">Fee Rate</td>
  <td>&#160;</td>
  <td colspan="2" style="border-bottom: Black 1pt solid">Amount of Registration Fee</td></tr>
<tr style="font-size: 2pt; vertical-align: top; text-align: left">
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="22" style="padding-top: 2pt; font-style: italic; text-align: center; padding-bottom: 2pt">Newly Registered Securities</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:PrevslyPdFlg" contextRef="c_offering_1" format="ixt:booleanfalse" id="fee_009">Fees to be Paid</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="white-space: nowrap"><ix:nonNumeric name="ffd:OfferingSctyTp" contextRef="c_offering_1" id="fee_010">Equity</ix:nonNumeric></td>
  <td>&#160;</td>
  <td><ix:nonNumeric name="ffd:OfferingSctyTitl" contextRef="c_offering_1" id="fee_011">Class A ordinary shares, par value US$0.001 per share</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: center">(1)</td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonNumeric name="ffd:Rule457aFlg" contextRef="c_offering_1" format="ixt:booleantrue" id="fee_012">457(a)</ix:nonNumeric></td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:AmtSctiesRegd" unitRef="shares" decimals="0" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_013">12,499,986</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxOfferingPricPerScty" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_014">0.65</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:MaxAggtOfferingPric" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_015">8,124,990.90</ix:nonFraction></td>
  <td>&#160;</td>
  <td style="text-align: center"><ix:nonFraction name="ffd:FeeRate" unitRef="pure" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_016">0.0001381</ix:nonFraction></td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:FeeAmt" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="c_offering_1" id="fee_017">1,123.00</ix:nonFraction></td></tr>
<tr style="font-size: 4pt; vertical-align: top; text-align: left">
  <td style="width: 11%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 15%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="width: 5%">&#160;</td>
  <td style="width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 1%">&#160;</td>
  <td style="border-bottom: Black 1pt solid; width: 8%">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Offering Amounts:</td>
  <td>&#160;</td>
  <td>$</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlOfferingAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_018">8,124,990.90</ix:nonFraction></td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right"><ix:nonFraction name="ffd:TtlFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_019">1,123.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fees Previously Paid:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="text-align: right">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Total Fee Offsets:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 1pt solid">&#160;</td>
  <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="ffd:TtlOffsetAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_020">0.00</ix:nonFraction></td></tr>
<tr style="vertical-align: top; text-align: left">
  <td colspan="14" style="text-align: right">Net Fee Due:</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td>&#160;</td>
  <td style="border-bottom: Black 3pt double">$</td>
  <td style="border-bottom: Black 3pt double; text-align: right"><ix:nonFraction name="ffd:NetFeeAmt" contextRef="c_report" decimals="INF" format="ixt:numdotdecimal" unitRef="USD" id="fee_021">1,123.00</ix:nonFraction></td></tr>
</table>

<p style="font: bold 8pt Times New Roman, Times, Serif; margin-top: 6pt; margin-bottom: 6pt">__________________________________________<br/>
Offering Note(s)</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">
<tr style="vertical-align: top; text-align: justify">
  <td style="width: 15pt; text-align: right">(1)</td><td style="width: 5pt"/>
  <td style="text-align: justify"><ix:nonNumeric name="ffd:OfferingNote" escape="1" contextRef="c_offering_1" id="fee_022">The ordinary shares will be offered for resale by certain Selling Shareholder pursuant to the prospectus contained herein. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement also covers any additional number of ordinary shares issuable upon share splits, share dividends, or other distribution, recapitalization or similar events with respect to the ordinary shares being registered pursuant to this registration statement.<br/><br/>Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the closing price per ordinary share as reported on the Nasdaq Capital Market on March 26, 2026.</ix:nonNumeric></td></tr>
  </table>


</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ea028373001_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *"!.P# 2(  A$! Q$!_\0
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M_?B+_P".5YA11_9Z_F_ /KS_ )3T_P#X:)\,?] ?7?\ OQ%_\<H_X:)\,?\
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M_P! ?7?^_$7_ ,<H_P"&B?#'_0'UW_OQ%_\ '*\PHH_L]?S?@'UY_P IZ?\
M\-$^&/\ H#Z[_P!^(O\ XY1_PT3X8_Z ^N_]^(O_ (Y7F%%']GK^;\ ^O/\
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M_P#'*\PHH_L]?S?@'UY_RGI__#1/AC_H#Z[_ -^(O_CE'_#1/AC_ * ^N_\
M?B+_ ..5YA11_9Z_F_ /KS_E/3_^&B?#'_0'UW_OQ%_\<H_X:)\,?] ?7?\
MOQ%_\<KS"BC^SU_-^ ?7G_*>G_\ #1/AC_H#Z[_WXB_^.5V?@?Q]IGCZTN[G
M3+:\@6UD$;BZ55))&>-K&OGVO1?V>O\ CP\3?]A ?R-<N(PWL4G>]SHH8CVK
M:M:Q[11117(=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\N>,O^2Q^*/K%_Z+2O
MJ.OESQE_R6/Q1]8O_1:5TX7^-$Y\3_"D5:***]\\0**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]%_9Z_
MX\/$W_80'\C7G5>B_L]?\>'B;_L(#^1KS<P^&)Z&!^*1[11117DGIA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7RYXR_Y+'XH^L7_HM*^HZ^7/&7_)8_%'UB_P#1
M:5TX7^-$Y\3_  I%6BBBO?/$"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6^H6SV\K+N"MCD>O'T-)3B]$P<)+5HI45J>'KMK76;91#;RK+*D;K/"L@P6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OESQE_P EC\4?6+_T6E?4=?+GC+_D
ML?BCZQ?^BTKIPO\ &B<^)_A2*M%%%>^>(%%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+GC+_D
ML?BCZQ?^BTKZCKY<\9?\EC\4?6+_ -%I73A?XT3GQ/\ "D5:***]\\0****
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MRVO>(;N_.-C.5CP,?(.%_3%:)-SCY(S;2@_-F/111708A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>B_L]?\ 'AXF_P"P
M@/Y&O.J]%_9Z_P"/#Q-_V$!_(UYN8?#$]# _%(]HHHHKR3TPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6D_]_P"C_A57Q)_YY:3_ -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/_?\
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M6D_]_P"C_A57Q)_YY:3_ -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/_?\
MH_X55\2?^>6D_P#?^OI*BCZQ5_F8>PI?RH^;?^%5?$G_ )Y:3_W_ */^%5?$
MG_GEI/\ W_KZ2HH^L5?YF'L*7\J/FW_A57Q)_P">6D_]_P"C_A57Q)_YY:3_
M -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/_?\ K%L/#'BW4]8DTBT:P:_B
MW;T;Y5&WK\V>?RKZL/0UX[X+_P"2NZC])OYBMJ=:I*,FY/1'/6IPC*"26K./
M_P"%5?$G_GEI/_?^C_A57Q)_YY:3_P!_Z^DJ*Q^L5?YF='L*7\J/FW_A57Q)
M_P">6D_]_P"C_A57Q)_YY:3_ -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/
M_?\ H_X55\2?^>6D_P#?^OI*BCZQ5_F8>PI?RH^;?^%5?$G_ )Y:3_W_ */^
M%5?$G_GEI/\ W_KZ2HH^L5?YF'L*7\J/FW_A57Q)_P">6D_]_P"C_A57Q)_Y
MY:3_ -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/_?\ H_X55\2?^>6D_P#?
M^OI*BCZQ5_F8>PI?RH^;?^%5?$G_ )Y:3_W_ */^%5?$G_GEI/\ W_KZ2HH^
ML5?YF'L*7\J/FW_A57Q)_P">6D_]_P"C_A57Q)_YY:3_ -_Z^DJ*/K%7^9A[
M"E_*CYM_X55\2?\ GEI/_?\ H_X55\2?^>6D_P#?^OI*BCZQ5_F8>PI?RH^;
M?^%5?$G_ )Y:3_W_ */^%5?$G_GEI/\ W_KZ2HH^L5?YF'L*7\J/FW_A57Q)
M_P">6D_]_P"C_A57Q)_YY:3_ -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/
M_?\ H_X55\2?^>6D_P#?^OI*BCZQ5_F8>PI?RH^;?^%5?$G_ )Y:3_W_ */^
M%5?$G_GEI/\ W_KZ2HH^L5?YF'L*7\J/FW_A57Q)_P">6D_]_P"C_A57Q)_Y
MY:3_ -_Z^DJ*/K%7^9A["E_*CYM_X55\2?\ GEI/_?\ H_X55\2?^>6D_P#?
M^OI*BCZQ5_F8>PI?RH^;?^%5?$G_ )Y:3_W_ */^%5?$G_GEI/\ W_KZ2HH^
ML5?YF'L*7\J/FW_A57Q)_P">6D_]_P"C_A57Q)_YY:3_ -_Z^DJ*/K%7^9A[
M"E_*CYM_X55\2?\ GEI/_?\ H_X55\2?^>6D_P#?^OI*BCZQ5_F8>PI?RH^;
M?^%5?$G_ )Y:3_W_ *](^#_@O6O!NGZO'K:VZS7ERLJ>3)O&,'/TYKTJBHG4
MG/XG<N-.$/A5@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ****  ]#7CO@O_DKNH_2;^8KV(]#7CO@O_DKN
MH_2;^8KHH_#/T.3$?'3]3V*BBBN<ZPHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ****  ]#7CO@O_DKNH_2;^8KV(]#7CO@O_DKNH_2;^8KH
MH_#/T.3$?'3]3V*BBBN<ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ****  ]#7CO@O_DKNH_2;^8KV(]#7CO@O_DKNH_2;^8KHH_#/T.3$
M?'3]3V*BBBN<ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M***  ]#7CO@O_DKNH_2;^8KV(]#7CO@O_DKNH_2;^8KHH_#/T.3$?'3]3V*B
MBBN<ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKRK_ (5GXH_Z&,_^!,O^%'_"L_%'_0QG_P "9?\ "CV</YP]M5_D9ZKYT?\
MST3_ +Z%'G1_\]$_[Z%>5?\ "L_%'_0QG_P)E_PH_P"%9^*/^AC/_@3+_A1[
M.'\X>VJ_R,]5\Z/_ )Z)_P!]"CSH_P#GHG_?0KRK_A6?BC_H8S_X$R_X4?\
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M;/\ _$T?\*]\=?\ 0SK_ .!L_P#\31[*'\Z#V]3_ )]O\#UNBO)/^%>^.O\
MH9U_\#9__B:Q?$FA>+_"]@MW>>(I9(V;:!#>2D_J!ZTU1BW931,L1.*NX/\
M ]UHK)\,2R3>&K"25VD=H\EF.2>3WK6KG:L['7%W284444AA1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6?^0'J'_7M)_Z"
M:NU2UG_D!ZA_U[2?^@FFMT3+9GGWP8_Y ^I_]?"_^@UZ=7F/P8_Y ^I_]?"_
M^@UZ=6V(_B,PPO\ !B%%%%8'2%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MGOQ>_P"19A_ZZ_U%>A5Y[\7O^19A_P"NO]16U#^(C#$_PI'4^$_^16T__KE_
M4ULUC>$_^16T_P#ZY?U-;-9S^)FE/X$%%%%26%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %4M9_Y >H?]>TG_ *":NU2UG_D!
MZA_U[2?^@FFMT3+9GGWP8_Y ^I_]?"_^@UZ=7F/P8_Y ^I_]?"_^@UZ=6V(_
MB,PPO\&(4445@=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^AIT7_P/B_\ BJ/^$[\(_P#0TZ+_ .!\7_Q5 7.@HKG_ /A._"/_ $-.B_\
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MHO\ X'Q?_%4?\)WX1_Z&G1?_  /B_P#BJ N=!17/_P#"=^$?^AIT7_P/B_\
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MO_@?%_\ %4?\)WX1_P"AIT7_ ,#XO_BJ N=!17/_ /"=^$?^AIT7_P #XO\
MXJC_ (3OPC_T-.B_^!\7_P 50%SH**Y__A._"/\ T-.B_P#@?%_\51_PG?A'
M_H:=%_\  ^+_ .*H"YT%%<__ ,)WX1_Z&G1?_ ^+_P"*H_X3OPC_ -#3HO\
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MHO\ X'Q?_%4!<Z"BN?\ ^$[\(_\ 0TZ+_P"!\7_Q5'_"=^$?^AIT7_P/B_\
MBJ N=!17/_\ "=^$?^AIT7_P/B_^*H_X3OPC_P!#3HO_ ('Q?_%4!<Z"BN?_
M .$[\(_]#3HO_@?%_P#%4?\ "=^$?^AIT7_P/B_^*H"YT%%<_P#\)WX1_P"A
MIT7_ ,#XO_BJ/^$[\(_]#3HO_@?%_P#%4!<Z"BN?_P"$[\(_]#3HO_@?%_\
M%4?\)WX1_P"AIT7_ ,#XO_BJ N=!17/_ /"=^$?^AIT7_P #XO\ XJC_ (3O
MPC_T-.B_^!\7_P 50%SH**Y__A._"/\ T-.B_P#@?%_\51_PG?A'_H:=%_\
M ^+_ .*H"YT%%<__ ,)WX1_Z&G1?_ ^+_P"*H_X3OPC_ -#3HO\ X'Q?_%4!
M<Z"BN?\ ^$[\(_\ 0TZ+_P"!\7_Q5'_"=^$?^AIT7_P/B_\ BJ N=!17/_\
M"=^$?^AIT7_P/B_^*K4TW5M-UFW:XTR_M;V%7V-);3+(H; ."5)YP1Q[T 7*
M*** ,3QC_P B/K__ &#;C_T6U?+&BZ187.D6\TULKR,#EB3SR:^I_&/_ "(^
MO_\ 8-N/_1;5\S>'O^0%:_1O_0C7)BY.---/J<N);4587^P=+_Y\T_,_XT?V
M#I?_ #YI^9_QK2HKS/:U/YG]YP\\NYF_V#I?_/FGYG_&C^P=+_Y\T_,_XUI4
M4>UJ?S/[PYY=S-_L'2_^?-/S/^-']@Z7_P ^:?F?\:TJ*/:U/YG]X<\NYF_V
M#I?_ #YI^9_QH_L'2_\ GS3\S_C6E11[6I_,_O#GEW,W^P=+_P"?-/S/^-']
M@Z7_ ,^:?F?\:TJ*/:U/YG]X<\NYF_V#I?\ SYI^9_QH_L'2_P#GS3\S_C6E
M11[6I_,_O#GEW,W^P=+_ .?-/S/^-']@Z7_SYI^9_P :TJ*/:U/YG]X<\NYF
M_P!@Z7_SYI^9_P :/[!TO_GS3\S_ (UI44>UJ?S/[PYY=S-_L'2_^?-/S/\
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M_P!@Z7_SYI^9_P :/[!TO_GS3\S_ (UI44>UJ?S/[PYY=S-_L'2_^?-/S/\
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M?-/S/^-']@Z7_P ^:?F?\:TJ*/:U/YG]X<\NYF_V#I?_ #YI^9_QH_L'2_\
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M?-/S/^-']@Z7_P ^:?F?\:TJ*/:U/YG]X<\NYF_V#I?_ #YI^9_QH_L'2_\
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M;<?^BVKYF\/?\@*U^C?^A&N/&_PUZG)BOA1IT445Y)P!1110 4444 =)X?\
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M-V+87UO;2MP@F#?,?0;0:U-?\&S>'(@;W4K+S7!:.)-Y9\=<?+COW-4?"O\
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MM[6O"5]HFG6^H336T]K<$".2!F(Y!(ZJ.PJ73O!>I:A8PW;36MK%.X2'[0[
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MK_\ V#;C_P!%M7S-X>_Y 5K]&_\ 0C7TSXQ_Y$?7_P#L&W'_ *+:OF;P]_R
MK7Z-_P"A&N/&_P ->IR8KX4:=%%%>2< 4444 %:6@W-E::U;3:C )[56_>(5
M!!'T-9M%-.SN-.SN>K:5J7A_1?$.I:Q#>V,=I-"JPVMNWS9PN?EP .0:Y[P_
MXP@L?&5[J5PCBUO-R''5 2"#C\!7%45LZ\M+:6U-75>ENAZAIFL:7X:N=<U
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M&O4Y,5\*-.BBBO). **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** -G1_#%_KJ_Z ]J[\GRFN%5\9QG:3G%,UCP
M[>Z&0MZ]J),X,23JSCZJ#D"N@^%O_(VO_P!>S?\ H2U5^(W_ ".5S_NK71R1
M]ES]3;D7L^;J<Q;6\MW<Q6\*[I96"J/4FKFLZ'?Z#=K;7\021D#C!R"#GO\
MA4OAJ&&Y\0V4$[SH))557@(#*Q/!Y!%=?XET6WF\?V.F:C?7]TEQ#&!*60.I
M9V Z+C'X5,:?-"_G8487C<\ZHKTJ?P)X>M_$]MHK7FH-+<1F089?E !.2=N#
MG;4-EX#T:;Q#>:)+?7;W,";]T> J@@$ Y7DX(.15?5YWM\A^QD<3I.D7FMWR
MV=C%YDQ!."< #W/:H;VQN-/OI;.YC*3Q.49?<'''J*[3P;HB#Q?>6)NKRVN;
M8OY<T#)]T''(93US6QX<T/3I/'FIK=O->7,!>16E(QG=R3@#)Y[<=>*<:#DE
MW;'&E=+U/+9(WAD:.5&213AE88(/H13:Z_4M'AU_QM<6&EK.DS7$AG>=E*CY
MNJ@ <?G5R\\%:7-%JT6D7-W)>:9@RK,05;KP,*/[M1[&3O8CV;UL<-&AEE2,
M,JEF"Y8X SZGL*W+_P (:KIVD_VI,L#6?&)(IE<')QQCWK1TOPG:CPO<:]K,
ML\<"G$,<#*&;W)(/4\?A76>(E@7X31BV=GAPFUFZ_P"L'6KA1]UN7:Y<:7NM
MR[7/)****YC **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "NY^ 7^O\6_]?D?_M2N&KN?@%_K_%O_ %^1_P#M
M2N_ _%(ZL+\3/:****],] **** "BBB@ HHHH **** "BBB@ HHHH **** /
M /C)_P E6T;_ +!G_L\M<[71?&3_ )*MHW_8,_\ 9Y:YVO*QO\1>AYN)^,**
M**XCG"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MKI?!?AM?$&I2&Y)6RMUW2L#^0_'G\JT] \0RWOBZSM[:&*VT]Y$B%N(PWR ]
M"3DYY]:UC3NDWU-(PO9OJ</17I?Q+U"XTS5K6WLVCAB\M9=JQ+]X,<'I["MK
M6;N6W^&@U.(1+>;4_>B)<\R 'MCI6GL%>2OL7[)7:OL>-45J6&B:GK?GW%O"
M"B?/)-(ZQH"3_>; SD]*;?:#J.FW$4-U!L,N-CAP4;(R,.#@_G6'+*U[:&7*
M[7L9M%=-)X!\11*CO:1!'^ZYN(]I_'.*RM2T+4M)OELKRU=;AONJOS;OICK3
M=.2W0.$ENC.HKID\ ^(9)1$+6'S2N[RS<QA\>N-V:Q=2TRYTF[^RW8C$NW<1
M'*KX^I4G!XZ4.$HJ[0.,EJT4Z*]&^%UU+<W\UC/LDMHX]RHT:G!SZXS4'BBP
MOK[Q1>22'[/I5BR-YWE *@PO3CYB6.._6M/8W@IIE^S]U21P%%=3K?C*YOH_
ML=HL<=JHV^88E\R4>K'&/?@"J-EX3UB_M([J*W189#A&FF2/>?;<1FH<+NT=
M27'6T=3$HK330-2;5SI1@$=YG 25PF?H2<&M,^ ?$2W0MFLXUE9=RJUQ&-P]
MN>?PI*G)[(2A)[(YFBKR:-J$FJ_V8EK(UYO"&,#."?7T'O6P/ /B!A*1;VY$
M7^LQ=1?)QGGYN.*%"3V0*$GLCF:*[C0-.@UZ*XT"^AA^VVL3-;7,+AN^=N02
M#U-<9<V[VEU-;2C$D3M&P]"#@T2@TDP<6E<BHHHJ"0HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *](_9\_Y$C4_^PM)_Z+BKS>O2
M/V?/^1(U/_L+2?\ HN*O1P/VOD=>%W9ZS1117HG>8GC'_D1]?_[!MQ_Z+:OF
M;P]_R K7Z-_Z$:^F?&/_ "(^O_\ 8-N/_1;5\S>'O^0%:_1O_0C7'C?X:]3D
MQ7PHTZ***\DX HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH [OX9P-;:TVH3R016IA9 [SHIW;EXVDY['M3O&N
MB7NK>)I[NQ-K+ R@!_MD2_H6!K@J*V]JN3D:-?:+DY;'H TJUTO7/#=G;W%K
M+)!*9[F995V]5SR3[=*V/$,8NOB1H]_#/;/:HD8:07"8&URS=_0BO)Z*I5DE
M:W5/[A^U5K6/9KT)+\2[#4TN+4V<5L4>7[0G!^?C&<]Q1IX2'XD:IJ<EQ:K9
MS1((Y?M"?,0J@\9SU!KQFBK^LZWMUN5[?6]NMSU;0%6W^(VJ7DT]LENR$"0S
MI@Y*D=_2G:/>06'Q+U)[BX@2"ZB<Q2>:I#'<I'(/'&>M>3T5*Q%K66SN)5K6
MTZW/0;"^M?#WQ&N+R\N8C%<R2\QG?L5F!5B1D<CMU'>M#Q#J&JZ?JM]/;ZM;
MKI4J%BT @9V/.$QC<?J?7K7EU%+V[2:7J+VKM8],L[RU\0_#632(;B*.]@(/
MERN$WX.X8)P.>E6=>GT^W^&T&E2ZE;BYVC:%)?)#[L?*#CTYXKRJBCV^FW2P
M_;:;=+!1117.8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5W/P"_P!?XM_Z_(__ &I7#5W/P"_U_BW_ *_(
M_P#VI7?@?BD=6%^)GM%%%%>F>@%%%% !1110 4444 %%%% !1110 4444 %%
M%% '@'QD_P"2K:-_V#/_ &>6N=KHOC)_R5;1O^P9_P"SRUSM>5C?XB]#S<3\
M84445Q'.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 'I_PX\O_A&-8V8\WY=V.O\ %BN.\%_\C=IO_7=?YBI_!GB1?#^I.+C<UE<+
MMF4 'Z'\.?SILDUWX1OO-TNZMIH9P'AN#$CD@=/O#*GGVKJYDXP?8WYDXQ?8
MZ_XE:W?Z9K-M%:O$J- &.^WCD.=S=V4UH>)IY+GX3--*07<1DD*%'^L'8<5Y
MW?>,=9U(HUY);3,C JSVL1(P<@9V]/:IG\>:_+:_9I+BW:W_ .>36D17\MN*
MMUXMRU>I;JQ;EYG4@Q?\*4;[-]_/[W'7/G=_PQ4WB3[/_P *XT7[1_KMT7E9
MZYVG],9K@+#Q#J6FF<6TZB.?_61/&KQGG/W""!^5)?Z_J6I3Q2W4X<PX\M B
MA%QTPH&/TJ?;1Y;>5B?:JWRL>I^*'9=!\/!6(#2P@@'K^[-5/'U]_9OBK0KS
M[.9S&7/EJ,EN5Z>]<3+X\\03I&DMQ ZQD%%:UB(4C@8^7BGQ^+-2UG5K$ZKJ
M,44<,H<7'V=,Q^XPO/TJY5XRNEUM^!;JQ>B\COKJZM+3QG+K4LMUOBMO)-HE
MK*Q+<\;@NT]1@YKRO7[PZAKMY=F!H/-?/EL,%>/2O6;SQ3XBBU&6&VTBSEME
M?:D[72@$>N,YKSKQUJ-CJGB+[18;"GE*LC(N SY.3[]J,19QT?7L%:UM'U-K
MX3_\AZZ_ZX_UKK4\265QXFU+PWJBQB.0@1,RX#94'!/KUKRS2O%6K:+"(["6
M&(?WOL\98_5B,FBX\4ZI=W\5[,UL]S$VY7^RQY)QCGY>?Q]JF%=0@HHF%51B
MDB]XJ\+2^'=; $;M82.&CDZ@#/0GVZ<^E=9X_(_L'0A8Y\G*[/+_ -WCI[5R
M%SX]\0WL#0W-U#-&>JO;1D?^@U4LO%FL6%I':PW"-#&<HLT*2;#[;@<5/M*:
MYE'9BYX*Z6S/0_&GD?\ "<>&]FSS_./F8ZXRN,_K6CJ#L?BAIJ%CM%HQ SP#
MDUY(NOZDNL'53.)+PG/F2(KX^@(P*TF\>^(7N5N6N8#.@PLAM8]P'IG;6BQ$
M;MONG]Q7MHW;\SLHM0;3_BK>*EFT_G *Q0#*#'+?Y]*F74[30X-;EC^TWLMT
MY*0BTE&/E"\EE XP>_2L#PEXAN]2\3M>W]["MT(2L8,2H)C@X!('OUKK+?Q;
MK7VO;J>E6=O8#=YL_P!H#87![ DG/3IWK2$DU>_5]#2,DU>_5G#_  [>23QO
M&ZKM#;RZ@< 8/'YUG>-Q"/%^H>3MV^9SM_O=_P!:Z"RU#3=!O=0U]94WW0<6
M5L@Y(W8W'L.AXK@[FX>ZNIKB4YDE=G8^I)R:Y9M1IJ'6]SGD[0Y?,BHHHKG,
M0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *](_9\
M_P"1(U/_ +"TG_HN*O-Z](_9\_Y$C4_^PM)_Z+BKT<#]KY'7A=V>LT445Z)W
MF)XQ_P"1'U__ +!MQ_Z+:OF;P]_R K7Z-_Z$:^F?&/\ R(^O_P#8-N/_ $6U
M?,WA[_D!6OT;_P!"-<>-_AKU.3%?"C3HHHKR3@"BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\U_PH_X9_P!+_P"ACU?\U_PH^HO^8/JLNYY]17H/_#/^E_\ 0QZO^:_X4?\
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MIGGU%>@_\,_Z7_T,>K_FO^%'_#/^E_\ 0QZO^:_X4OJ+_F*^JR[GGU%>@_\
M#/\ I?\ T,>K_FO^%'_#/^E_]#'J_P":_P"%'U%_S!]5EW//J*]!_P"&?]+_
M .ACU?\ -?\ "C_AG_2_^ACU?\U_PH^HO^8/JLNYY]17H/\ PS_I?_0QZO\
MFO\ A1_PS_I?_0QZO^:_X4?47_,'U67<\^HKT'_AG_2_^ACU?\U_PH_X9_TO
M_H8]7_-?\*/J+_F#ZK+N>?45Z#_PS_I?_0QZO^:_X4?\,_Z7_P!#'J_YK_A1
M]1?\P?59=SSZBO0?^&?]+_Z&/5_S7_"C_AG_ $O_ *&/5_S7_"CZB_Y@^JR[
MGGU%>@_\,_Z7_P!#'J_YK_A1_P ,_P"E_P#0QZO^:_X4?47_ #!]5EW//J*]
M!_X9_P!+_P"ACU?\U_PH_P"&?]+_ .ACU?\ -?\ "CZB_P"8/JLNYY]17H/_
M  S_ *7_ -#'J_YK_A1_PS_I?_0QZO\ FO\ A1]1?\P?59=SSZBO0?\ AG_2
M_P#H8]7_ #7_  H_X9_TO_H8]7_-?\*/J+_F#ZK+N>?45Z#_ ,,_Z7_T,>K_
M )K_ (4?\,_Z7_T,>K_FO^%'U%_S!]5EW//J*]!_X9_TO_H8]7_-?\*/^&?]
M+_Z&/5_S7_"CZB_Y@^JR[GGU%>@_\,_Z7_T,>K_FO^%'_#/^E_\ 0QZO^:_X
M4?47_,'U67<\^HKT'_AG_2_^ACU?\U_PH_X9_P!+_P"ACU?\U_PH^HO^8/JL
MNYY]7I'[/G_(D:G_ -A:3_T7%4'_  S_ *7_ -#'J_YK_A7<^!O!5IX%T:?3
M;.ZGN8YKAK@O,!D$JJXX[?**Z:%#V5];W-J-)P>IT]%%%=)TA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_?-']O>.O\ H<;S_OFDHH^MU>X_;S[B_P!O>.O^AQO/^^:/[>\=?]#C>?\
M?-)11];J]P]O/N+_ &]XZ_Z'&\_[YH_M[QU_T.-Y_P!\TE%'UNKW#V\^XO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#P#XR?\E6T;_L&?^SRUSM=%\9/^2K:-_P!@
MS_V>6N=KRL;_ !%Z'FXGXPHHHKB.<**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** /3?AK;K#HFKWZ_Z["JI]/O5R'@O_D;M-_Z[K_,
M5O?#?5X89;S2+J38EVHV,QP 1GC\<_I6)HLMOX9U[S=8MKM;FV=62.+;C(/.
M<]NG3WKKNN6#['1=6@SL?B4VCC6;;^T8K]Y/(&TV\B*,;FZ[E/-:'B;R3\)F
M^SB018CVB0@MCS!UQ7(>*O$NB>)[N&Y>#4(7C"H0"F"N23^.":OWOC;0KWPO
M_83VNHK#A1Y@*;N&W?2M74BY3U6IHYQO+7<FTVQBT/X92Z[;(G]HSC'FL VT
M>;MP >.@J7Q+ID-QX5TO7T1([\F+S7  #C;CITSTKG=.\56R>'KGP_J,,\FG
M,<PM%@2)\^[G/%+KGBV'4K&PTNVAFBTZT*'YB/,<@8Y[=S6?/#DMY?B3SQY;
M>7XGH&O77V+2-%FB@M_.N'C5W,8SRA)]NHK&\:Z7I*>,M'-TB0V]P2)R/E4@
M%>OIU-4-2\=:)J5G86SVFH(MFZLI!3+;5(YY]ZAUSQ%IOC+6-+2+3KR21)=I
M@+*HD4XR,YX/'J*UG4A)-)WV+G.+32?8[11/%XS\D6T(T1;,.9#$NP-\W.[^
M?->4>+;Q;SQ)=-',LL*'9$R@ ;>O8>I->F:E?^!?M]Q!>W,PN"Q66)7N0,^F
M%X_*O._&VD66B^(/(L"?L\D2RA22=N21CGGMW]:G$7Y='U)K?#IW-WX3_P#(
M>NO^N/\ 6NPFTW1]8N];L[9VAU5PHDDS\XX4C'MT%>>^#O$NE>&9'N98+V6Y
M==K!=NS'MWIUSXHTX^+4UVS.HP.S@S*-G("XP!T[#K[TJ=2,::3"$XQ@DSG]
M1TFYTS5WL+Q2LJR;2?[P)ZUZ)X@"^#M TF+38H@\C*97= WF<<YSZD]JR?$?
MB[PWXC59)M,O8KJ/[DZ,N1[$9P>U59/%^G:MI-C::Y:W,DMH1M> @;P!CG)_
ME4+DAS*+WV9*Y8W2?H=!XBTBVT3QYHUQ8H(Q?2E98\ KP5SP?7=6[>2K%\0+
M'3X[>!8)+8O)B,9?KC/T]O6O/;[QFNJ^*[;4[Z*46EHVZ"&+&X<CKGUP,_2M
MF?Q]HL_B.WUDV>H"6&(QA 4VD?G6RJPN[.VJ-%4A=V?4FL]*T2/XGW<%X$5%
M97MXW;"E_3\\<5T%G-)#%KLNJQQVT,+D02/$J[1L&-N1SR??FN:TC4-,\0>.
MI-66QN&A6(R2^:1^Z(!Y !R>@]36TK> ]:N38)<333S$@(9+G&>O0G'&,U4&
MK7C;=_,J%NEMV<IX"OFF\=LS.91<!T+$ ;EQD<#'H*PO%]DEAXJU"&,_*92X
M]MQSC]:ZGPIIL6B>*-3OI#BPL5<+,QX)S@ >IYQ7%:UJ+ZKK-W>LQ(EE9ER,
M87/ _*N6>E))[W9SRTII/>Y0HHHKF, HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *](_9\_Y$C4_^PM)_P"BXJ\WKTC]GS_D2-3_
M .PM)_Z+BKT<#]KY'7A=V>LT445Z)WA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Z1^SY_P B1J?_ &%I
M/_1<5>;UZ1^SY_R)&I_]A:3_ -%Q5Z.!^U\CKPN[/6:***]$[PHHHH ****
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M?_QRCZG5_IA]7J=BC15[_A OB7_T+UI_X%Q__'*/^$"^)?\ T+UI_P"!<?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
H0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>ea028373001_ex5-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_ex5-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ") =<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#Q#0M"U'Q)
MK$&DZ3;_ &B]GW>7&75,[5+'EB!T![UV/_"D/B%_T E_\#(/_BZ/@A_R5S1?
M]V?_ -$25]>T ?(7_"D/B%_T E_\#(/_ (NC_A2'Q"_Z 2_^!D'_ ,77U[10
M!\A?\*0^(7_0"7_P,@_^+H_X4A\0O^@$O_@9!_\ %U]>T4 ?(7_"D/B%_P!
M)?\ P,@_^+H_X4A\0O\ H!+_ .!D'_Q=?7M% 'R%_P *0^(7_0"7_P #(/\
MXNC_ (4A\0O^@$O_ (&0?_%U]>T4 ?(7_"D/B%_T E_\#(/_ (NC_A2'Q"_Z
M 2_^!D'_ ,77U[10!\A?\*0^(7_0"7_P,@_^+H_X4A\0O^@$O_@9!_\ %U]>
MT4 ?(7_"D/B%_P! )?\ P,@_^+H_X4A\0O\ H!+_ .!D'_Q=?7M% 'R%_P *
M0^(7_0"7_P #(/\ XNC_ (4A\0O^@$O_ (&0?_%U]>T4 ?(7_"D/B%_T E_\
M#(/_ (NC_A2'Q"_Z 2_^!D'_ ,77U[10!\A?\*0^(7_0"7_P,@_^+H_X4A\0
MO^@$O_@9!_\ %U]>T4 ?(7_"D/B%_P! )?\ P,@_^+H_X4A\0O\ H!+_ .!D
M'_Q=?7M% 'R%_P *0^(7_0"7_P #(/\ XNC_ (4A\0O^@$O_ (&0?_%U]>T4
M ?(7_"D/B%_T E_\#(/_ (NC_A2'Q"_Z 2_^!D'_ ,77U[10!\A?\*0^(7_0
M"7_P,@_^+H_X4A\0O^@$O_@9!_\ %U]>T4 ?(7_"D/B%_P! )?\ P,@_^+H_
MX4A\0O\ H!+_ .!D'_Q=?7M% 'R%_P *0^(7_0"7_P #(/\ XNC_ (4A\0O^
M@$O_ (&0?_%U]>T4 ?(7_"D/B%_T E_\#(/_ (NC_A2'Q"_Z 2_^!D'_ ,77
MU[10!\A?\*0^(7_0"7_P,@_^+H_X4A\0O^@$O_@9!_\ %U]>T4 ?(7_"D/B%
M_P! )?\ P,@_^+H_X4A\0O\ H!+_ .!D'_Q=?7M% 'R%_P *0^(7_0"7_P #
M(/\ XNC_ (4A\0O^@$O_ (&0?_%U]>T4 ?(7_"D/B%_T E_\#(/_ (NC_A2'
MQ"_Z 2_^!D'_ ,77U[10!\A?\*0^(7_0"7_P,@_^+H_X4A\0O^@$O_@9!_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOJSXW:1::E\,=1N)T7SK$I/!(1RK;@I'X@D?EZ5\BT ?<_A3Q!#XI\+:=K4
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MG_XFN=^%%]::;\3M%N[ZYAMK:-Y"\TSA$7,;CDG@<D5]5_\ ">>$/^AHT?\
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M?^PI<_\ HQJ* .@^"'_)7-%_W9__ $1)7U[7R%\$/^2N:+_NS_\ HB2OKV@
MHHHH **** /F;]I'_D=M+_[!P_\ 1CUXS7LW[2/_ ".VE_\ 8.'_ *,>O&:
M"BOI?PU\#/!^J^%='U&Y&H>?=V4,\FVX &YD#' QTR:U/^&??!'IJ7_@2/\
MXF@#Y4HKW_XE?![PMX5\ ZEK.FB]^UVYBV>;/N7YI44Y&/1C7@% 'T7^S3_R
M!M?_ .OB+_T%J]TKPO\ 9I_Y VO_ /7Q%_Z"U>Z4 >2?'_Q3_8_@Q-&@DQ=:
MJ^QL'D0K@M^9VCZ$U\MUV_Q8\4_\)9X_OKF*3=9VQ^RVV#P40G)'U;<?H17$
MJ0&!(! /0]Z /K7X'^&?^$?^'EO<RIMNM3;[7)D<A",(/^^>?^!&O,?VB?#7
MV#Q/9^((4Q%J$?ES$#_EJ@QD_5=O_?)JC%^T-XN@A2*+3]$2-%"JJV\@  X
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MK:=(Q:.TNEDCS_")%.0/;*$_B:]KH **** "BBB@#XB\?_\ )1?$O_84N?\
MT8U%'C__ )*+XE_["ES_ .C&HH Z#X(?\E<T7_=G_P#1$E?7M?(7P0_Y*YHO
M^[/_ .B)*^O: "BBB@ HHHH ^9OVD?\ D=M+_P"P</\ T8]>,U] ?'CPCXA\
M0>+=.N=(T>[O88[$1N\$98!O,<X_(BO*O^%9^-O^A8U/_OP: /K;P1_R(/AS
M_L%VW_HI:WJQO"-M-9^"]"M;F)HIX=.MXY(V&"C"-00?<$5LT >??&[_ ))%
MK?UM_P#T?'7R#7V3\7-,OM9^&6K6&FVLMU=RF'9#$N6;$R$X'T!/X5\P_P#"
ML_&W_0L:G_WX- 'L'[-/_(&U_P#Z^(O_ $%J[WXL>*O^$3\ 7US%)MO+D?9;
M;!Y#N#EA]%W'Z@5RWP"\.:SX>TO6H]8TVXL7FGC:-9TVE@%.<5SWQQTKQ;XJ
M\2VUEI>A:A<:981?+)'$2LDKX+$'O@;1]0: / :[3PG\+?$WC32Y-2TF&W^S
M)*8MT\NS<P )QQR.15;_ (5GXV)_Y%C4O^_)KZV\%^'D\*^#],T9 -]O"/-(
M_BD/+G_OHF@#YP_X9_\ ''_//3__  )_^M1_PS_XX_YYZ?\ ^!/_ -:OJVB@
M#X9\4>%]3\(:T^DZM&B7*HL@,;;E96'!![]Q]0:A\.ZU<>'/$5AK%K_K;299
M ,_> /*_0C(_&OHCX\^!;_Q)9Z9JNC6,MW?6[&"6.%<LT3<@_12#_P!]5X?_
M ,*S\;?]"QJ?_?@T ?9>GWUOJFFVU_:OOM[F)98V]589'\Z^7?V@O^2FG_KR
MB_FU>Q?!5=>LO!K:/K^F7=G+8RD6[7"%=\3<@#UP=WX$5P/QG\ ^*?$?CTW^
MD:/-=VOV2-/,1E W#.1R1ZT >0>$8(KGQIH5O/$DL,NH0))&ZY5E,B@@@]01
M7USK_P ,_"7B#3)+.;1;.V8KB.>U@6*2,]B"H'Y'BOGGPK\+?&UAXOT6\NO#
M]Q';P7\$LKETPJK("3][T%?6= 'PSXJ\-7WA'Q%=:/J"$2PM\CX^65#]UQ[$
M?U':K7@WQKJ_@?6!?Z7*"KX6>WDYCF7T(]?0]1^=?4_Q&^'.G^/]*2.1Q;:C
M;@FVN@N=N>JL.ZG].H[Y^:-=^%/C30+AHYM#N;J,'Y9[)#,C#U^7D?B!0![_
M ."?C7HOC+6+/1DTZ^M=1N0V VUXAM0L?FR#T4_PUL_%O_DE?B#_ *]Q_P"A
MK7AWP9\)>(K/XEZ7J-WH>H6UG")O,GGMVC5<Q.HY8#N0*]Z^)FGW>J?#G6[*
MQMY+BZFA"QQ1C+,=RG@4 ?%=?37[-_\ R)&J?]A%O_1:5XA_PK/QM_T+&I_]
M^#7T!\!]!U7P_P"$=0MM7T^>RF>_,BI,FTE?+09^F0: /5",C!Z5\K_&CX;'
MPKJYUK2X<:->N<HHXMY3R5]E/)'XCTKZHJEK&DV6NZ3<Z7J,(FM+E"DB'T]1
MZ$'D'L10!\&UTWPZ_P"2D>&_^PC#_P"ABMGQ'\(/%NCZ]=65CI%WJ-HC9ANH
M(\B1#TSCH?4>M7/ WP^\76'CS0;R[\/:A#;PWT4DDCPD*BA@22: /K2OA#7?
M^1AU/_K[E_\ 0S7W?7QQK'PX\9SZYJ$L7AK4GC>YD96$)P06)!H PO"'B)_"
M?BJQUR.V6Y:T9F$3/M#94KUP<=:]<_X:7O?^A8@_\##_ /$5YG_PK/QM_P!"
MQJ?_ 'X-'_"L_&W_ $+&I_\ ?@T >F?\-+WO_0L0?^!A_P#B*/\ AI>]_P"A
M8@_\##_\17F?_"L_&W_0L:G_ -^#1_PK/QM_T+&I_P#?@T ?5/P[\82>./"J
M:S+9K:,TSQ>4LF\?+CG.!75UYY\%M'U'0_A['9:I9S6ER+F5C%,NUL$C!Q7H
M= !7Q/\ $?\ Y*3XC_["$W_H1K[8KY,\=_#_ ,7:AX]UV\M/#VH36TU]*\<J
M0DJZEC@@T <MX _Y*+X:_P"PG;_^C%K[<KY(\%?#WQ?8^.M N[KP[J$-O!J$
M$DLCPD!%#@DGV KZWH JZG?+IFE7=^\4DJVT+RF.)2S-M!. !U)Q7PUKNL76
MOZ[>ZM>MNN+N5I']!GH![ 8 ]A7W?7G'C7X,>&_%TDEY"ITO4GY:>W4;7/JZ
M=#]1@^] 'S7X9\>>)?"#_P#$GU26*$G+6[_/$W_ 3P/J,&O3=/\ VE-5BB"Z
MCX?M+B0#[\$[1 _@0U<]KGP%\9Z4[&S@M]4A'1K:4*V/=7P<_3-<C/X"\7VS
ME9?#&K@CN+.1A^8&* -_X@_%K5O'UI%826D-CI\<GF^3&Q=G8 @%F.,XR> !
M_*O/JZRP^&7C;4I D'AG45S_ !3Q&%?S? KU?P/^SX;>ZBO_ !=/%*$(9;"W
M)*L?]M_3V'YT ='^S_X=GT?P--J-S&4DU2?S8U(P?*484_B=Q^A%>LTU$2*-
M8XT5$4!551@ #H *=0 4444 %%%% 'Q%X_\ ^2B^)?\ L*7/_HQJ*/'_ /R4
M7Q+_ -A2Y_\ 1C44 =!\$/\ DKFB_P"[/_Z(DKZ]KY"^"'_)7-%_W9__ $1)
M7U[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 ?$7C__ )*+XE_["ES_ .C&HH\?
M_P#)1?$O_84N?_1C44 =!\$/^2N:+_NS_P#HB2OKVOD+X(?\E<T7_=G_ /1$
ME?7M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\1>/_ /DHOB7_ +"ES_Z,:BCQ
M_P#\E%\2_P#84N?_ $8U% %;PKXEO/"/B.UUNPC@DN;8.$6=24.Y2IR 0>C'
MO7H__#1OB[_H':-_WYE_^.5X_10![!_PT;XN_P"@=HW_ 'YE_P#CE'_#1OB[
M_H':-_WYE_\ CE>/T4 >P?\ #1OB[_H':-_WYE_^.4?\-&^+O^@=HW_?F7_X
MY7C]% 'L'_#1OB[_ *!VC?\ ?F7_ ..4?\-&^+O^@=HW_?F7_P".5X_10![!
M_P -&^+O^@=HW_?F7_XY1_PT;XN_Z!VC?]^9?_CE>/T4 >P?\-&^+O\ H':-
M_P!^9?\ XY1_PT;XN_Z!VC?]^9?_ (Y7C]% 'L'_  T;XN_Z!VC?]^9?_CE'
M_#1OB[_H':-_WYE_^.5X_10![!_PT;XN_P"@=HW_ 'YE_P#CE'_#1OB[_H':
M-_WYE_\ CE>/T4 >P?\ #1OB[_H':-_WYE_^.4?\-&^+O^@=HW_?F7_XY7C]
M% 'L'_#1OB[_ *!VC?\ ?F7_ ..4?\-&^+O^@=HW_?F7_P".5X_10![!_P -
M&^+O^@=HW_?F7_XY1_PT;XN_Z!VC?]^9?_CE>/T4 >P?\-&^+O\ H':-_P!^
M9?\ XY1_PT;XN_Z!VC?]^9?_ (Y7C]% 'L'_  T;XN_Z!VC?]^9?_CE'_#1O
MB[_H':-_WYE_^.5X_10![!_PT;XN_P"@=HW_ 'YE_P#CE'_#1OB[_H':-_WY
ME_\ CE>/T4 >P?\ #1OB[_H':-_WYE_^.4?\-&^+O^@=HW_?F7_XY7C]% 'L
M'_#1OB[_ *!VC?\ ?F7_ ..4?\-&^+O^@=HW_?F7_P".5X_10![!_P -&^+O
M^@=HW_?F7_XY1_PT;XN_Z!VC?]^9?_CE>/T4 >P?\-&^+O\ H':-_P!^9?\
MXY1_PT;XN_Z!VC?]^9?_ (Y7C]% 'L'_  T;XN_Z!VC?]^9?_CE'_#1OB[_H
M':-_WYE_^.5X_10![!_PT;XN_P"@=HW_ 'YE_P#CE'_#1OB[_H':-_WYE_\
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*)/&315*B@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ea028373001_ex23-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_ex23-1img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #I UP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF>)F60 $J2,]/:J'_"_M(_Z!%S_W\'^%>0^/O^1]US_K^F_]#:N<H'8^@?\
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MTG^LMG8;Q[@=2.1SBNIH$%%%% !1110!YEK_ ,9M-T#7+K2YM-GDDMV"EUD
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MRLKJ&4@J1D$4M>=?!OQ%_;/@Y+.613<V!$.P \1@ *3^1KT6@D***0D*"2<
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MW%Y,H>."1,K$IYY!ZGIVXYKA?@YX337O$IO[I%:UL,/M8D;F.<8QZ$ U]*@
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M^C4KY5KZJ^+?_)+]:_W8O_1J5\JT#05VOPC_ .2H:+_O2_\ HEZXJNU^$?\
MR5#1?]Z7_P!$O0,^J6574JP!4C!![BOF[XM^ SX>U1M7L(=NFW3\A23Y;D9(
MY]2&-?255-3TVUU?3IK&\C$EO,NUU/I02?%=%=%XR\)7GA#7)+&Y4M$1NAF
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M:+_O2_\ HEZXJNU^$?\ R5#1?]Z7_P!$O0,^JJ***"0H(!&#T-%% 'SC\7/
M$FA:D^MV$1;3KE_G"@?NG(R<X['#'->75]J:GIEIK&GS6-]");>4893_ )XK
MY.\:^$;KP?KSV$Q,D+#?#+MQO7)'\P:!HYRBBB@85]?^!O\ D0]!_P"P?!_Z
M+6OD"OK_ ,#?\B'H/_8/@_\ 1:T"9T%%%% CX\\:?\CWXA_["5Q_Z,:L.MSQ
MI_R/?B'_ +"5Q_Z,:L.@H*]W\-?&/0](\,Z;IT\$IEMK:.)R,XRJ@'^'VKPB
MB@#Z,_X7KX>_Y]YOU_\ B:/^%Z^'O^?>;]?_ (FOG.B@5CZ,_P"%Z^'O^?>;
M]?\ XFC_ (7KX>_Y]YOU_P#B:^<Z* L?1G_"]?#W_/O-^O\ \35W1_C%H>LZ
MO:Z=!!*);F58E)SC+$ =O>OF:ND\ ?\ (^Z'_P!?L/\ Z&M 6/KNBBB@05P7
MQ6US7]$\-"31(&P[A9KA,EHEP>@'(Z#GI7>TR:&*XA:&>-)(G&&1U!!'N#0!
M\2R2/*Y=V+,QR2>]-KU7XD?"F?1)9=4T6-IM.QN>)02T7/XY'3GZUY504%;G
MASQ;K'A6[$^F710$Y>)B=C\?Q $9K#HH ]VT;X^0-'%%J^F%9/\ EI/"_P O
MX+@G]:Z,?&OP@5!-S*#Z>2__ ,37S-10*Q]!ZE\>M'M_EL-/FNR0<-O* 'Z%
M:\I\7_$/6_&!$5Y(L5FK%E@BR%/H6R3DC^IKDJ*!A110 20!U- '6?#72IM6
M\>Z4D0S]GG2X?_=1@37UF!@8KR_X-^##H>BG6+R,?;+Y5:,,G,<?)&#_ +0(
M_*O4*!,****!!1110 5Y_P#&3_DG]S_OBO0*\_\ C)_R3^Y_WQ0!\P4444%'
M;_"7_DHNF_[Q_D:^J*^5_A+_ ,E%TW_>/\C7U10)A1110(**** "HYX([FWE
M@E4-'*A1U/<$8(J2B@#Y-^(?A.;PIXGN(=F+2=VDMV"X&TG.T?3(%<E7UUXV
M\(6?C#0WLYU5;A 6@F(Y1L>OITR/:OE76M&O=!U.6POH6CFC/<$9'J*!HSZE
MM;J>RNH[FVE>*>)@R2(<%2.A%144#/6_#7QSU+3HA!K5H+]%7"R(Q5\YZL3G
M/>N_M/C5X0FC#7%U+;N>J^0[8_$+7S+10*Q]/S?&?P7&A,>H2R-_=^SR#_V6
MN,U[X]N\+0Z'IHCDW<33L64C'91@@UXG10%B_J^M:AKM\UYJ5U)<3D8#.2<#
MT'MS5"BB@85?T72;G7-7MM.M49I)Y ORC.T9Y/T YJI!!+=3I!"C/(YPJJ,D
MFOI;X7_#V/PKIXO[Z-6U2< DE>8AC[HST/)S0!V'AO1(/#OA^STR!0%AC 8@
M8R_\1_$Y-:M%%!(4444 ?)7Q(_Y*%K'_ %U7_P! 6N5KJOB1_P E"UC_ *ZK
M_P"@+7*T%!7U?\+/^29Z)_UR;_T-J^4*^K_A9_R3/1/^N3?^AM0)G84444""
MBBB@ HHHH **** "BBB@ HHHH *0@$$$ @]0:6B@#R_Q[\)K;7"^H:,%M[[.
M7C).R3C\>?R'6O!]4TB_T:[>UU"V>"9#@AO\17V16=K&A:;KUK]FU*TBN(QR
MN]0=I]1GO772Q,H:2U0FCX[HKW'7?@5;R,TNB:@\2A<^5. Y8^Q& *\_U+X7
M^+-+4O+IAD3) ,3JY/X*2:[HUZ<MF*QQU%:;^'-<0X;1]0'_ &[/_A31X?UH
M]-(OS_V[/_A6O,NXC.HK?L/!/B3491'!I%TK'IYL9C'YMBNST;X(:Y=DMJD\
M5@ WW1B0L/JK<5$JL([L#RY5+$!023T KT7P7\)]2\0E+O4=UG8'D'(WN/8<
M_K7KOAOX9>'?#A26.V^TW2D,)IP&*L.Z\<<UV5<=3%WT@58HZ5I%AHEBEEIU
MNL$"#A5R?U/-7J**X6[[C"BBBD 4444 <5\6_P#DE^M?[L7_ *-2OE6OKWQW
MHESXC\%ZCI-GC[1<! FXX'$BL?T!KQ#_ (4=XF]8?^^E_P#BJ!H\QKM?A'_R
M5#1?]Z7_ -$O6S_PH[Q-ZP_]]+_\571^ _A3KOASQIIVK7AB^SVYD+[67/,;
M*._J10![=1110(**** "N7\=^$+7Q?X?FM9(Q]K0;K>7."K Y_49'/K7444
M?%.H6%SI>H3V-W&8YX)&C=3V(.#_ "JM7TK\3?AH?%K0W^F[(]03*R9 'F+Q
MC)XZ8/YUYQ_PH[Q-ZP_]]+_\50.YYC7U_P"!O^1#T'_L'P?^BUKP[_A1WB;U
MA_[Z7_XJO?/#6GS:3X8TO3Y\>=;6L4+X]50 _P J 9JT444"/CSQI_R/?B'_
M +"5Q_Z,:L.O8?$7P<\0ZIXFU74(#%Y-U>33)EE^ZSDC^+WK,_X4=XF]8?\
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MH ^2J*]._P"%'>)O6'_OI?\ XJC_ (4=XF]8?^^E_P#BJ"C(^$O_ "473?\
M>/\ (U]45XEX$^%6N^'?%MGJ=X8O)B)+;67/3ZU[;0)A1110(**** "BBB@
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MP75K0W@D\KR1*-V_.-N/7/%:U !1110 445F:CXBT;2+A;?4=3M;69EWA)9
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M@PR.,@_A1:6EO86D5K:PI#!$H1$08"@#  % B:BBB@ HHHH ^<O!1/\ POF
M9/\ K9__ $0]?1M?./@G_DO4'_76?_T0]?1U V%%%% CY@LR?^%[2\G_ )#[
M_P#I17T_7R_9_P#)=I?^Q@?_ -**^H*!L****!!7SQ\<HS/\0]-A#8\RQB7/
MUED%?0]?/OQJ_P"2G:1_UZ0?^CI*!HN6WP'DN+6&;^U@/,17QD\9&?[M+/\
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M>V:;=F_TNTO"@0SPI*5!SC<H./UI_P!DMO\ GWB_[X%3    # '04""BBB@
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M5=>$HU#?)O$HPV-QQ^F*!'44444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ea028373001_ex23-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_ex23-1img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  L0# 2(  A$! Q$!_\0
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M3Z=J":E9I<1*P5AD9IV8KHNT4@Z\TM PHHHH **** "BBB@ HHHH ***3O0
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M^!72U#V?,9)/F'V/@Q9](ENK[,MW*NY23TI?AY,T,UY:ALC?P#[9KO=H"8
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M<U$FDM#?<44IZ4@I3TK-;#>YY1XWF;_A*(_D,AC(.T=^E7TB\1>(0(XP;6T
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MU<9K93N[LAQ=K(YGP]X.AME2\OOWMRW//1371WUW'IE@]Q("5C&?E'6KB<#
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M^GRN/\*T-,\#6T4GG7\K7,A_A;H*Z^DZ'J/RI^TE:PN5-D<-K%;QK'$@55Z
2"I=O/6E-%9EI)!BBEHH'8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>ea028373001_ex99-2img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_ex99-2img1.jpg
M_]C_X  02D9)1@ ! 0$       #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (V BX# 2(  A$! Q$!_\0
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MLTW^F-E_P6Q^&UY]G#^ =4\._:?^/S[3KFEW_P!@/HV-'.[ Z#CZ$U[+I/\
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M2/[H'-?KAXS_ &*/A+\3[/0=/\<Z(FOR>$;)Y=)47>L:8"-9,2R/NT#Q A8
MZ/&"7SC<"G5Z]C+> ,7B\$WL[:=M]7TL[+S7WZ?S9X@?3&X&RG/,EQN1ZQ4I
M.=KIJU-<JO9J493;W]F[6:=J<U+^*;3OBOX-;Q-J$G@'QG>'_A*.=W_".ZVC
M?\2+13P3KA3H.!CKU;.23]#_  ^U^W\>7.GV&GI?>(]8N^MK]F-@>F.LH?MU
MX.>^2*_K\\*?LD?"7P.FB2Z%H;Z+/I0OQ:!KG6KX#?P^TR^(<-A1N9<-C[N
MQR?HK0_#D6C+%"%%W!;C_1PL418@]2VUR#T]2>.G&:]O"^'[PCM?MMR63>NO
M-HO3:^A^;9[^T+QLL&EDF1PNE9^TJRA-I72Y''A*[NDGK)22;NU)6?\ (]X;
M_9+_ &D]9_M#^P_V;/\ B7W7_,6_X7!X-_+^PSXDQQ@\]N?:NDM_^"1_QN\3
M ZAKWC%_ ,]S=G_B4IH?A'Q1C_N-Q_$5VR/]TG )YQ7];%U96LBSB6!54],
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M/P!]E-G_ ,))DX'.!QD>GW<Y':O[)OB_^RM\+?CG83VOC?1!?VD^/]"^T:W
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M9?<^KZ]V?A>8<1\7<0?[;Q,W-Z^_*S>LFU"Z2]U7TCK96U>Y?AM/(CQG)/\
MGGC SWP>OK5BSZS^Y_\ 9:K_ &L2R8[>^.F.WJ?ICW]*+7R0.)LGZ@>H]/\
M/K7C_5O]M_X'E_6GX'@_65_3_P"";-%%%=!T#7^Z?P_F*Q;J,F;S3*V !BWX
M^;@9Y!SSW[=O7.T_W3^'\Q6+?11>;!,^,J<9ZY!_IQR<^E!AB/@^;_)F7*MB
M!]N/^CW QDD<'@<\=^,]^G%<]+?_ &0MP;B"X;[6<]#P#D8SP01[^V:_.S]I
MO_@H+_PH/XHZ?X&OOAGXP\0Z"5!O=8TGPAJ^I6 8ZWKVAGD?(2&T0EL J<MM
M^4UXS8_\%<OA9KNI:O80^ OB!I\&E6>IYO;SP'K&FZ82 .?[;X5<X[#)QWZC
MR,5:TM===+/SU[:_@?;8;POX]XARG*,9DL/=LFJBG"SU^#D^)>Z[IN\;/>^@
M3_M!_M%:+^WA8?!G7/ ^@S^ +H:9XGM-9/B/_B9CPMKOC/7]!RVB_P#"-C/"
MKDY^ZH'H1^ONGWD-W'#?S3SS_9;@_9(#:[=IYQD $A5&7+=NPZX_FK^#WQE\
M1_'W]O[_ (6+>^.-:T70+7PWI=E9^'B/^)9J'AC_ (33_B1:*0H R3KF3CKU
MXK]C/BI^V=\)?@1K]CX0\7-K=O<W=EIUT!I&CG4L(2IZG )X(X /.=QZ5Z&%
MQ/G^=VM-+?IMY'Z+XD\ 9QE&%R3 JG?//]4$Y<JCRP]YN4G>UVT[:14Y-N\[
M.[^K/%]Y,-*UB"WFN+B_N[,BRL[JS&">N./4]3COZXK\QOV.OVV_$?Q3^)_B
MKX._%_PX/"'B*UNS8Z+:6P?4])UQL>(->4G61X=3</\ A'=#R54J6YP0QS7N
M/B/]N+X/ZYX"U^;2/&7]FZL+,_9-QT@ZKZ@C12Q)(/\ >SQR#QS^6O['OC#P
MAX"\;6VN^//']S\4=9TO6-4O? ?B'Q#>:+_:7@,:]_;ZZZ=$_P"$?8<>*2?^
M$9..6V%/O$ \_P#:7^VVVOIY;]3P.$_#?B_B#AO.9<C?)LK*^B7PK\+*W5>9
M_1U!+-!^XFF%P+O_ (\Q=<#/U ''OCH!SVKJK'R1;1&UP86&5 SG &<\C\,#
ML/7%?SQ_M&?\%:M;^'^IV?AWX*>%O!/Q6\6/<;-'B\4^(M6TWPZH T,ZT=;U
MW0D==!,?AZ37W02*Z!M";Y"&8']__"/B31/%>B6.M:)?VVI:== FTN[6\-\K
M ]O,&[' (..>1D8.:]!8GZV_1^A\%F7"6;\)X6."QU][I]+_ .=MKZ>:9VE%
M%%<QXY3D"C[IRQY[X[_UKD]2L['7OM$&?](M?UP.G\OS[BNK9E8 @Y/].3CT
MZ_\ ZZYE&FDNKCSX/L\'&!G!/'MT^O&*Z*&&^M7<KZ:N^K_#>_X^IOA^9:X:
MRDKW[+^M-CY,^-G['GP;^-MA<:?X\\,:;KT/I?7>LKG/F '_ )#YY!U>3CCC
M=_L5^6OCW_@CA\&)8;^#P=!%X2L/M>I9^QQO]X_>&3KF<*>0<9;T&2*_?6XM
M(Y085EOS@ Y:V(XZ\XC;Z]!P>O-(=.@FB\F]@@N+?N"01G.-OKGOA3SCG!Q7
M/B>%\OQ2NTO2:=WY+E<?E??H?:\!?2"\5/#_ !JP>15:M/3:$XM=-U.G4MIU
MNM.G4_D9\5?LK_M"_LNZQ<?\(KX<N?B-X ./]$N?^);@XZ#^P!S[9!!QR.HK
MY1\5>.]"U[QM;ZW8SZEX:\0:7G_BGO$.C_V8<G)SC7\8)/<8(Z^Y_N-O/#]M
M=VQTC-M!I6"=@&.>N!G P?X02,\?C^=?[2G_  38_9U_:#G?7=?T==/\11MB
MU\0:9IBWNICCD[]K@8!')P",X-?$9UPB\+98'[5K=-]M]ETUTOYZG]8^'/TT
M>(<'Q%.IQK>4<]BU/E3FUW7)&S;VYDDGZ6/Y[O#?Q:T/QA%<6.K3W/\ :%KS
M_9'V+_B6?^#TX].,_EZ_.OAWX+7=MXVU&]\!^(=1\!:\W]F!ET"Q&J+J(_L7
M/(\0@@C/J/?/I]??&'_@FO\ M(_"^^N)_!GB7Q!XR\$!0;4:O(/[24[<L?[$
MT'PVI9<YPQ5?7 S@?#6I_$'XW_#ZZGT/5O#6M>"KG7;S3,>++RSUC3OMPT/@
M_P#(P^HX/X]J_)\3ALYRC&7U75-7Z=4].O5/S/[_ ,MSW@'B5/.>"N,(2NES
M4YM/W9:-5(>])73:Y)PUU33U/VK^ W_!4#Q/\*8)?!_[1G@W^Q-5N;K3+-?%
M.@76L^(]-OBP #G^PO#/_".)(@US15!!1EWL&&X?+^WOP_\ CQX*^(>EC4-
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M??W5MIJG>W,6T,5@YU& R0AE/^CZGDXR"?8@]?XP1V/0U^7/[4?_  4U\/\
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M2.AZ6W]A8+B+79. VMH-Q"*!RSJ%VO[I.8[A!+#]O:S6R%H%.W[!? _Q@8W
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M-/\ !KLUY^6GD?V1G?"'A#XW\.?7<%E49TVF[65XOHX5$[<L5>UVVOYGK?\
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M;QGG$Y2>MISYU'LDGR\B?16:=GN.\V4C/4?A_4UJ64/DICU'^'^/^1BLR&:
M2^0/]?=?YXZ^I/\ 7%;T0R",XY./T_I7H8C#*^O]+:Y\HOJ>+:QN#^:_/3_@
MEJBBBN8W&D+CG@?_ %L"L>_4!X,'.6],=QQBM@E<<\C_ .MD5B7U[;6H)FF@
MM_\ 1V^]C@C'(R?NCHHSUXP>_3AKV7:Z]+VB<V(^J6_VOX+?J_UO\R.&6XF(
M^T0\8YZ8Z#)X&.#_ (#%><?$>XO$\)Z]_9-QHJ7Z^'M3?2[O5Q_Q++'42DFW
M5-:;>=F@J_E/,1E6&5'#*RZ=[\2_ =D9[:;Q+H\&;7[82;Y!A0.7QN&0?89Q
MC(SR/'O&7QG^'DNEZ]I>D>+?#^IF[T'4K![/[8F1J1RNXKNR57N!EOXL9KR,
MP6^U^FJ_S_/R/I,NRCB#%YME2P63U7[T-H55]J.W[O9Z7L]N:]M3^9/X5_$+
MQ%\'?VSOBQJGAS3[OXHJ]UXH\3>);KX4V9\1>&]/U,_$T_VZ-> VE?$>."5P
M0>F.W[O>+_VP/#_PW\$^"-5U[0O&<Z^.[X626ED=&;4]#U,:+_;WS(?$*["!
MC&&;D9S@8;\>/V5="\'6/[;_ ,0CXR_M/P1J'B;Q?XH/AVT\07@TSPUX[_MW
MXF_\2-M#T,X&O_\ "5<L2?[O&>E?TA7?PW^'.LVFCP7WA7PGK4]JHO+,W>CZ
M/J.F6&>O!&1WZGU&!7C87III=>=OAZ][?>C]Z\2,QR?*IY-@L;E%YJ%VU:/.
MM;)Z.T>?56:2;UYE=/\ ";X__MWP>.['6?!-[\$/B1X^T?Q3C1M(N_"OA'1O
M$BZ%A" ==W>)"$QQDJHZ<UU'_!(CPCXC_MGQQXOU4M_8&K#2[+_A'[K.-/70
M6\>*<:*!M5@'RN2"P!V [3M^M_VROA9\+/"WPZ\1>-K'PK<VNHK9*;6Z^&8T
M;PWIM@#_ &&H.N$ *02O!!) !! ."./_ ."96F^'-#^%VLZE!XDMO$>H>(;I
MU^V:1>9TP'0M9U\# Z< GJ?3 Y-=&OUY7^_ROOYVW\TK'H9EQ)@L9X#O^P^$
M>5<W*W:]I+A%*=DWIU3?\UWRN^OZ]_;)S]HQ/;?Z+Q]D_7V]>.>_0UT5BNZ(
M!P".O7'?WX/?CUYX[_#W[0'[57@/]FW7/AW<^,XKJ+X>>,T\4IXX\=3/I*>'
M_!_]B#1(]#;6V/ /BGQ!KJ>&(V^8+)DXRBN?JWP?X_\ !7CG2FU7PGXFT[6K
M"WXN+JTN Z(<9+$CD@]><<X'/&?86ZUMY]C^6[9O]47UW*N77XDON6S777SZ
M['I5%5#=P;X ) 3<?<&>#QQ],GCW-6Z0B =?P;^1KG9(@UQ.PX!YQ_/IU_EC
M@=*Z,YX_W./^^3U_&L6"6*62Z42@>1N\\<<<9P?0<>_'7)Q75AL1]6B_7KII
MU^[?TU.6O_ON6OJJDGYNRO9=V5H %!YX ))_(G\JS]1U.WTZ+[1-<"WM^03R
M>>> ?U[<]^:YK7/B'X)\+:AI%IXA\4:+HT_BCQ%_PC'AX7E[M^W^)I X&B1G
MD%R0>"T8 P2XR"?D?]NSXM7WPT^!'BC7_!\IU/Q1=V6L:1X<TRTQ_:-_JC:2
M2%T8YR9"&RW&."<],[XG$:7ZZ.WE_5M/-:'T.1\.YKQ#Q?E&2X)M/B"HJ:7*
M[-V>SMT:LWHD]Y;7_$/_ (*8_%/4_P!I#XKZ!^S%\,9?^$CNO$.K)8&]TD'4
MGL=30NR*1H !&#H[$#_:.>:_8S]A?]BOP)^RY\/X-/T2Q.L^,[JRTV\O=6U^
MTT>_U@D# =98_#_A$A3DD?*C GE@1BOBK_@GI^S+H_PZDU'XU?%*Y_MWQ_KQ
M;Q)HYU7_ (FFIZ#JVM.^MOH>?$!ZJ^M%6[JP.>:_2GX=_'+P;^T;\/O$\WP=
M\8Z+J7B#3+]]'O+S0+XL=/;1-;.B$!M!).,Z&=B@[47"(%0*H^7PV&MTUV][
MI_PRT\C]T\2>->(<KP,?"3 RMD'#TN=^S:4:C;UNX/6,IZNTO?E9.>A]7P7<
M-Y=FQA@N+G_GYQC^SAG&<DYY/L![Y[JU@ER#>6=Y/=VG3:UV"...%/&>>@Q^
ME?@;K7[0O[<7[(.L>()/B=\/-9^('P[78X\::3I.L?V?IZOYJHQUKQ!XD)VR
M^(M9TE 2"&"2A3E&Q]__ +.__!0KX%_M&1)8>%?'OA5-?P3;:"+U/[44[M<"
MY7Y2P8:*[_*"%"$<;ESZ&&S)X7R>Z6W3H[I?Y].I^48KPRS?$\./'X)+B'(5
M9.=-\S4M%9QIJ<U+S2T6LK*UOO6:'SHOW$%S;=NO3^IX].W7L:O:9:0@>2V
M/3'^\3SG!SUS^9K(O-7GAB$.;>Y//VL$GZ=.Y/?=]1Q2#6+&6T$QOK>WN!D?
M9<@MSTR1C]!SG'O7O+$X3%X1Z1:^=_ZWVZ'P6'S'&:9-@LH>G1:+YI(\>^-7
M[//PX^-/A[5=*\7^%K*]:ZTC4+1[B;1=%D<1L.F=:T61=Q.=KEV4X)PP4,?Y
MNOVC?V$/&G[.-[J_BOP3X#\0>-?AUIUSJOC*^2TTH:_XDT<:(==UEFT")M \
M)^&O#Z'0-)2-0S.RR2(H8NR,_P#5XFH3P6EN+DVYN+E@1N)X]>G)P,=R!TYY
MKD_$GA73->L-6BU&UGE74O#^J:5]FNV&H:9C5_O;M%)P0"<2 XRFY,8R:^:S
M/A3!9JU?2S;O!)/HU9MWLG;S738_<O"GQ\XS\%,7/"Y?FW-DU1*,J%64I4>7
MFM)1@E:,I1<KRU4MI1M*Q_$>/B/I7BG3I])\4V'BNUT;4KM;P:1JB@>.- U0
M#& !]T#L!P!QGI6=XX\(Z=I5QX(\2_"ZX\1Z%XV6[TNSMM7^']Z-+ TKJ3XZ
M.@?\5, !DDMZ'WK]NOVWO^"6]AXKBU#Q]\(5OM"\>VVDZG=3VEL2O@DY77M?
M"OH^AZ QED/B0:,22 S#DY(+-^*?@?Q9X<3QEJOPG^(6F>*M%^*GA@?\*_W6
M=V;#PRZ:)K)T)=<310^,'Q'_ &TP90X9,@#Y@P_'L[X1_P!7L9?!?"WO9V?7
M1M6O9Z[V?E[S_P!4O#_Q4\-O$/)O[8P*2J*/_&94FXMQ5W&,W"-1/V7,M&E&
M\%[JBY1@OUP_8D_X*1W8\3:+\"?V@;"[^'WBBUCTTV?CK5+8^'='\8:=%YFA
MC18]9\0>)&\2:],\A/B5W"Y8@%OF!S_05H>O:-XET6"_T>ZM[O3+H(?[0M;A
M&^UD 8"JH.,'G[Q Y ('%?Q)^)O##>,;E=)\(Z@FL>*/"#_VQ=^(#C4-2L=/
M._1"-#USIN;#OR>3SR2:^^?V)/\ @J/JGP@U*R^%7QIE6VT!KDV-GX@UAF3<
MW\(9]?\ $9=1VR Q49P.,5]'PWQOM@I<UKZ2NT[*T>5.R5U_,M4[)NQ_,OTC
M?HHX'$X27'_ADX2SE*]?#12FE*HW4E4C!RG4C*K%6A3DH4Y)<T%>3O\ U0M;
MVWVB!?/-LN.1C_C]&.P]%)R."1@5H(+>)3@Y!ZG!QT]..H_/'M7FW@3Q7H?C
M/2[#Q!8ZS;:G;:FH^QW=M@HZL.0,'./J1GGIR:](D^PPK^]EP,\ G#>GOZ>O
MY]OUU8C"8I:MO9ZV\]6[WN][?E8_SDQ&7/"8MK&+_A85T]))\RTLDUJDK[:=
MFUJIPT<HXZ]@>3_@?_U\"K:J%&!_G^OZUG+;*.5P/?)/K_C5N#O^/]*Z)6>F
MMNSZ/R.:OA\-;ZWA6F][K1/I_7Y"118N2>G&?K^73^?Y5HUE1-^]S]!GWYQC
MZ'']*T7.0OOS_+_&N=JWWM?<94,3]83;6UU]Q)1112.@**** "BBB@ HHHH
M**** &*I')],8IC*03@$Y.>/\_F*B$\9Q^]&#WR:#=0]IE/U_P#V13NV[WU^
M[8AI4%KS;]4T[_,MTR3[C?2H8IH9OND ^G3CKVXI);J (3YRC/<'GW_^OCFD
M6>;_ &6WM)9YX#]HGO /M=ME<6>>PSSR.F/3T->.?%7XB#X?I/JGB.]M[6"V
MT?4;W^TS:@:>-,&URK$,?G127*@DE5.-P:NI\7?$?0_ 7A?7M;\1:I;:<NA6
M9O3FTS]M&,C&>N3D  \<Y[5_-?\ M%_M+^*_VO=1U:^LM6;PM\"/"W]H:N=
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M3\5/B[%<:IXBN;+31HV@7?.DZ!IR'0=<T/63H@X/B-6#!O$^X$$$';DD5?\
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MA^!OQ \$:YJ-U:F[T7Q-8_;+2]U;3FL=3_L=L*2&Y5,ENI4;SMW$''CY(_\
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M*2UUT[M)JW2[OQ?ZT_\  JD?[Q_#^0JK#-#YO'!.<>WOSSS^'XU98Y)/^>E
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MO\._'[Q!\%A#<Z1K-CX@U/PPNNBP\7:@NHZLGC'^P!HB#_A&U"%W /S/L P
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MR3M&0<\_DK^SCX,^-&J:WX1_:L^+OB. >#M7\=:7XFUJT72M)5M!##0/'?\
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MCD=/Z<9SU[\T2X^WPX_Y]/UR,_K6?%#>Q6%O,;<&_P"/]%)_,=NF!^=:$6H
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MT^[4F\CW_7_ZU2[!ZG]/\*?12**DFT)D9S@ $XQT/?\ E5*;R/LQZ8QQ^?\
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M)8@JH!! 8YX /\B'PET>P^)'[:7B#QC/X5MO%NCVO[0GBBRUCP[_ ,^&E_\
M"S\?VUV''^>]?+\68?!O.,HP<H?%=PNVN57DDKZ\UEH^C<=)(_M/Z&.8\/<+
M<.>.W$V;\,7E2X,A3X3;A"?M*BXOHRE=2:=.;W33]V-79VB?UE?!/PM;Z/\
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M_KWPVQ6"\/.)>$>%N%9^TX[\0:BX/DI.,G255)Q3BN5QBX1;BMW&[O)'P-\
M/VN?$/[..CZQ\*/$>B6UOXW\-:KJ6B>&Q:ZN-3&H+H(T+0M!XQGG^QNA/8
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M*^)7CN#4E'E]Z3<4M]FG'F>FVZ5[6NV7M.^T>3_IOIQG&._IST].]688?)E
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MCT.&ZV,XMQT>&X<O#V>IN,VU:\;RY[<L5+VCE9M3;C;=)N$G]??L&_M<V'Q
MTZ#P!XXN-.M/C!I5YJEEXDTJZW?VF-,8Z_\ V$6&O^(V\3'_ (IW0\DL&QRQ
MP-QK]4X8H-2B^T00BVOB#\V1CZCJ,$=^N1UK^57QC\+/'VF_#/2/VNOA-)J7
MA3XOZ7=7\EUH _M;3]*UQO[;D\# 2:%H$F_7F'AW6-9:,_\ "5[274J['<$_
M:'X$?MT?#'QS\'_"GQ)UF^73K%GU!]3N;F]TH/IXCUC6M#4.P<$XECSA2!MP
M&R2PJN7!JW-IS)2Z.\6[:6ZK5V=MOO[?$3PJQ668=YSPJWQ%3C5E1JN*E&5.
MI23<^>]H2@TU&$HW3;BKJ[Y?T&O7!F%Q.2"H_P!*M03P,\\=#D<<GDYQQP8[
MN&"]T^YT.WA'GVH_Q'!_'/Y5G>#]?T+QM83^(]*OK;4M.U7_ (\_U[CVZ=N.
M.N*ZJUC E>[F$0F09W0CL#SMR,D=\GG&>E=N*N\&_)_@[^??HC^=LPS#%K&9
M3@XI)Z7LK72T\M5HMF[.U]-/YP?^"J/[+5[9QR_'_08'TX)HFIZ)XATK3&_L
M]RNM_*-:+-X=+MM 7<S=R.=Q./RA\.6=[X0^'?P&^(?P[\7W-YIX\8?"[X->
M(]).K K?:9K;+_;NM:X?#^?G5L,OIU^7K7]F'QR^%=C\5? OB?PI?0Z9<G7+
M'4[,K=VH;3@&T8X+<\<@@,3@D$ G!K^.KXS?#;7/V8_BS<_"35+ZVN?#&E_%
M/2_&OAK2K7_H5]"UK^P!\IP3SVR.A%? 9YA\(W]>>[]Z^VK;UT]7M:]V?Z2_
M1E\1L7Q7EZX'6;)9S!*,8-)ITH**C!*5]+1BE>[]Q-W>J^J?AO\ %.__ &(/
MVL-!\>W$VI:C\.OC%_9GA:ZM@473-/\ %?CKXEZ#F1#N\+>&8R/#FBD+NRXY
MX<;=_P#4=\//B!X;^(FCZ!XET<&:#7-!T[4DP?O#6HQJX=B?5&ST!R>>G/\
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MD$DG'0<GDGC\3BMBL_R?)D\_ZCG^N/?H>_04 <[)!I?^HGGMA?\ ;/WOQ_\
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M'_CZL]Q_;_@.TTR\M+RTO?[-QX%T+^W]> XX.1GGV_&OCC6/$OQP_:ZU73_
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M,"Y4DG']WDY]AD_A[U\&_L.?%^?X@_"?3K/Q%8BVUG02W]L:2;PG^PR=8UW
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M70SYYG-X8MHVF$9YZ-M!QGN>H_IT%?(?[6GC@_#GX.>*/$3 ^?!'XCN+7/\
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M8J>>?Z;_ -DW1_!NC?"CP18:)X7MK4?\(WI8N_[)T<+X;L-4_L30C@'MQ@#
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M#_\ 7Q[U._W3^'\Q0/G7GMUQVY_^O^M/2WGT_4PT^M7\_P %N4!<!AD#]/\
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M_P!-L#XDU2]O+6TT?QD-,OQ_8O'/Z<9QGMUKAQ.98'%:63TLM9JUNM]G_P
M_3>&_"/BJ4EC54X0C%-/F?%]#]XG;1)+FIN+76[:DTMDU]"_'[]AGPIHOP[U
MBP^!.MZ?_P )1IF;Q?#]U=:1INF:@=<UG0F(US R  NN$,>&8A5)8X/S5XD\
M-^./#?BC_BH]<T31/ ]U9X\27>DZP1J>@_\ $E_XD?7K_P 5&#_,$CKWOA'X
M??M=?$+PE\1K?3+_ ,5Z'XIU[^R[31=7O#XQTTZ?_8>LG)7/AL<[=PR/X2<5
MZ?X6_8@^-OBGQ;<Z[\7-2T#4M&NF UGPH+W5]2\,W[_V04VZYH?B#PWG)D&B
M>)@O7>"N,@A?&Q*QGUQ63_&SWVT_K7H?K>6Y[DW W-DN85*?$*OU<4U=)M.\
MEUVT6C2U>K^$[/\ :T^.\.C7/CC5?%6I6T%UK'A8^&_#UW><WX&M?V#KO3/'
M?\^>@K[#\?\ [;/[07@W4]8$'PTMI/#%SK&E_P#"#:Q;V/B_=J6FE%7=($15
MW_V^H3@#Y#T((-?;>O\ _!,GX2>/=1\/ZKK>J:IHEMH/]I&S\*^'O[%&E'?G
MU\. \=2 ,X( R<@>\>-OA]\,?"FA8\4Z%IMSX9\, M9_VM9:-_Q(V50/^)*P
M''.,<C=MP.%->QAOKJT^'_/^OZN>?B_%#@S.,:L'@^#D[7CK=Z/LK\K<FDM8
MO3W4[-I_E+<_\%(_VDO"?BNWTFV^#%O<W%IHVIWOBZU^Q>+\Z?J2XPH(0#;Q
MW&<$X-8'B3_@LWX^TW1A]G^$MM<>)_M@O;RQN[+QAML? 8P-<UL_+NW+M 7#
M  #H>,?KSX)\'_!;XLZ /''AO2="U+^W>FJVEIHVHZE?Z8#\O]M\=_ID=L]*
MX'7?^">GP$\5GQ!//H<>G7VO>&]4\,-=VFD:+G3M+US.\:+_ ,4\P4@CL6P/
ME/7-89W]=QF#O@G_ ,+FN]E]^G]:]V>-AN+O!S,DL9G7!LULDH*;^';3GO9>
MCTLGHE;\Q8?^"NGQ-\4>//V</ /@+P%;:G-\4/'GPOL_$IM[/5]2&G^ ?'.M
M_P!A:[K1P!\J\D%LD>N:_7[XY^&Y/C!\%O$_@Z\TD7,NO^&=4L6M#:YP=<T9
MNQ!^;##D8'RX(Z&O!O@)_P $S_@[\!O']IXPTJ]UOQ'?Z)X<30M+N?$-KHNZ
MQ&C:UH&MZ(4<>'4(*/HR$L,_+G:I)4U^BFJ"WT/3HS:Q6JRW&W[3P<X*C<3@
M9/S%AZ# X[CU^&XXW^R%@LYA&4Y:;:VVO=+ITZ?>?'<8<2\&KB7*,;P!PE[.
M--PDY.7+>7O2Y6Y-KE:?O)V>ZT48G\)$W@F^\%0_&#2[ZQ&G3Z#\2/'GABRM
M,Y_XE>A:T/T[]/?->S_#@7WPM^(OPP\;,/LULUWIEY>8X!SHF#R>.YZ\]>,5
M[1^V-X5L-'_:4^)^AWLYT[P]KUCJ?B:[NP?[-/\ :>N^--> YSR .>I/3TY\
M0^-GB32I_!MQ8^%;ZVN=8\+^&]+O;T7=X.=+Z?F/?^5?AV98;_5[./J7GIM?
M3;]/F?Z^X;._];O#;)UCLG3_ -8H^\M;-27!J=F]UJT_*UUJ?V?_  ]U"'6?
M">A7T)_<W6FZ;=@8_ADTW?SSV!'IP._%>C22^2%C49*@ ]/3W_S^M?'W['_Q
M&L/'GP=\(:YHFHZ=J6GGPWI5F;NSN_[0#:GHJ[-<&X* 2"N1A@5)SP"I/U5J
MEU-"(2,98'GU _\ K_YXK]RX=D\7@TGK=WZK[*V[I6/\+N*<+A<AXAS6OC':
MU3EW3>LVEL[7UV=K:]3YY_:=\91^#?@C\5=7M[5K&?1?!OCF[LC>6YL7UW5$
M\%ZZRG1V8DL_ RS#<PYZDY_C;^']]:ZMXV\7ZJ[#QGXG\0?%;4_B6/"9<^(=
M4\)OX@UO:NLZUHH*GP_X?\*D@*!SN(Z\&OZX/VYQ)>?!#Q%8+?:=;6]W_:EN
MK:G_ *H:@=(UI%"GUYRO^P#@$X%?R=^%=&L-'^*&L6Y \.?$BZ\2:I9WMWI/
M_$MTSQ;\+QK>5_L/C_A)O^$B\5^) ".^1QR!7X_X@8CZSC4G>S5UM>UVD^N_
M)?\ 0_OWZ%U".5Y/GV<8AP;SV<L/+XK*5)03C/E47>,:C5DW:Z]YZH^I/AIX
M2A\<_$OPMHEEXU^#^G3W?B72]7/Q!\4^(AI^IWWBA=8=A\ -$UM27V^%2!XF
M_P"%6C)!92512[#^I#X3>'=+\,^$_#%O8BYT^W&GZ;:WUFI&FZ=?:H-&QK6L
MB/J?,P^&) #1E><G'\M/[+O@H>(_B_\ #>QTK[-XCU#PO^TZOC/Q'X4TD_VE
M_8/@,G \:>.-#/?/3Q2<@GCEB=O]:^FGR=-M\16MQML\VEU:V0.FV(*@ \MD
M 'H<#)'89)^WX)PW^Q[?._W>EKVWZQ;L?A?TLL2\)QCE&2X*?,K+W>5+ETU;
M:NVI/5724;:-JY\/?M??L\^(_B[H&E:K\-_$WAS1OCOX*O=5UCX4OX@UO5=/
M\+RZMK?#KXV_X1[P^WBD>'H_#ZM&_P#PC"H=X(/RC)_+[XUO^W%JGBFU\)^,
MOA!8^/K#3K;3UN1\*? GQ(\1_#3Q>_\ 8CRRI\4?^$@9?^$B\/*$9O!2@$CQ
MFK,1A<C^BPV5C--FXAM[F>U!']J'']HV1.,$D@G(P>X!!P0>,9HT[2M2U2RN
M-+U2$6R,3]ETN[5OM_&2=9 R2,9 !&XG(QGBOL%\_E_7>W_#V/P[ASC664X1
M8-)-K1<RVNTWM[VJ5M-+J,GLSXU_81_9MF^!'P\UF^\:WUQJWQ0\:?V=_P +
M(N[F^_M)+\^']:\0CP-N;7O#7A3Q1QX>UO81XI5W5CR@YQ]U2&:5?W,& >O3
M/KQR#G&.GY5?L[2"U VDY<G[6UR QNR1]Y@6QD9/;I\I&,UH,D'0I^I_H*%O
MUWZ;_P##GS#S#"O%O&:-M:73Y;V72Z?ZERK%%%;F 4444 %%%% !1110!7HH
MHH.<*@F_U)^@_E4]+-_J3]!_*@"*)#Y./H<GO@>WOU]J@5,'.1CM^/?\OKU^
ME1>?[?I_]>DFF\JU,^!YY &>N[GD=NGL?K[]";5]?B>NG?\ K<6(PWUE+%+;
M6R[]?ZV)-XZ#)/N.#]2.*IF;$I[^V.?Y8Z]N?8D8K\_?VG_VTIO@'XGUKP:?
M"VIS7-E\%]1^)]AXZNK(?\(5X@\3Q:UKN@_\*PT5GUY&/Q"*Z&^OCPN"[26N
M#YOF.S#YA\'_ /!5KX<WFCZ?/XWUWP[X2\4:I9Z83X>U>]T?3]3);DCYO$C>
MY4 @+C'(XKF68X-;MOY/\]/R/K\D\,.)N(L']=R572T3NK[]M^G5^A^T^[_I
ML>/53_,$TD3JN<^XX'/;''Y\_P"(K\J-!_X*3> ->^W_ &&]M3!:GC-YHW^G
M9ZX_XJ0G. !SZD$U[-X&_;C^&GB6T%[-K.E6_P!JO/L?V.\O](74MP[_ /(P
M.,$DX)R<\A>,CD6=97K^\_\ )4K?I^9]#F?@[XCX+!W>32:ZVCSM[O1+7_+\
M#[Z69<?*,9Z\#.??GK4,,/\ ^O\ K_B?P%?,-I^U+\(TM1/J7C;PKIW/_+UK
MND  =,X9^I]ATZC@&M\?M._!".3%S\5OAXN[/V4?\)5HH[= 5E)&>@Y'ZU']
MLX/=7MZPO]W,CX]\+<0X3"\N-RB=]_X=1KI]I0<;Z[77GU/H3R1_=/Y#_"GX
M Z#%>1V/QR^%NJ _V9XX\.7Y]+36M'/YX;G'U_+K740^,](O?]3JNG6V#_R]
MW@&>W&%'OSP*V^M83NU^/ZV//KY;C,*KO*I)><4G]UK_ 'G72*L:C:IYQ]X$
M'OR3Z=L<&F2S-CYL9Q_G'ZC!]R>U<Y/XFL#%F#4+#!'(#$ 'CG'8\_H1UJ&[
MU:R%J9_M5N9S:%AD@8!QD D=CD@=^*[8XG#;SG=][.[7:]]#R7]<?^QX+*6W
MUT_/4^:/VK_B^/AQX"U 6,UMY^IVFIV8!Z9UK1M?(/7LP'/7.,U^._@KX<V%
MY?ZQXJGG^TW'BG6=4\3<=O[=8:X>G QGVYX[9KZ<_;J\;QZ_9V^AZ->6T^H&
M]'VKGMLUP?@=V[Y?7/%?(G@CQ3KF@VNCZ7/!]H_T/2_Y8./R'Y5\)Q+B;.SU
MMV>GY_AZ^I_H7X,\%8/(.&5GB3CGDDG[R:E;6UT]=GHGLFM$[H]@@T>"SU00
M3_\ 'OC![\C@]/\ /IBM#5].\FTU"" \W5F+*S'?\?\ Z_7ISBN?U[4M5F^S
MS00?9K?Z=.G_ -?KQSZXK?LYK"\M=//V@'[+B[([=>,]2<[C@?3WK\V_YC/Z
M[GZW]9>+MC<;KZ^GY_\ !..TG2;)]2L+*:]N3!:\7:B\ZYP1TZ=N>F,'@5]-
M?LTZ]8^%/&_V*"^/V>Z_Y^[PG./[?XS[\>_TXKQ2UT6RCNIKZ ?OKELG\.G;
MV/N:T_!\,]G\4/#\%A/]FM_^)H+S_P $OO[GCZ8KZG)+6CWO*_\ Y+;]3X[Q
M0RW*<VX=E?X;12VM?5RDNO9?RZ;=3]UX)?M</KCT]_PQ@=.:U[2836XXQV!Z
M^WY#/X=/<<#X5O/.\.>?TN..HYXR1SU[_KWZUT]DTL<< !&1@,,^O;D^F??U
M]:_5\-76,PE[7M^NG]=S_-'.L3]4S?ZE;1?<NG_#,WUEQGC^O^%.K.RXZ$ ?
M4_\ UJ7SIO\ GA^@_P#B:;O?7?S.?#8DL5H5G^=YOX>W^>F?;K^5CS_;]/\
MZ](] L457\_V_3_Z]2[QZ']/\: 'T4S>/0_I_C3Z "BBB@"O-_JL_P"R1G\N
M/T_2L6+[.0?)FSZCU'^>V?\ Z^VQQ&?KQ^7^)K+4YZP\_7'].:;5FUV)=!8K
M"\NS6J=TNZ_3H>/_ !E?Q!#\._&LOAJUGNM7@\)>)'T6WM+74_M[ZJFDZRNB
M[-N"=SD G9GSGP",H#_+?XEE_;-\9^+-"M+GPI\7[-;7Q?IEGJ%OK&C?$E=+
MVC6<DNW'RA1EBQ(  SQQ7];=YY\O^CCG\3C_ #].,\>]<>?AAX5FE\ZX@S.=
M7_MK[7ZZF>3UZY'Z=NU<&)P_URV_G9[IM?)Z+KI=1V/U;PN\3O\ B'SG+^QX
M3D_AYU=1DHS4>[M>;3<;2<&U?8_F8T[]C7XA>//AM\8[SQ_/KEO-8^._'>N7
M#@ZL=0L=+;1<J-#.O^'B?F!)5E!0_P +$X%?0?[/7[ '@;XA>*O#_C3Q(1K7
M@O2_A7X8\& 7?]BZCJCZCH)&&UI3X=/ADA0P5V./G!( !45^Y'CS0-$TWP)X
MXAM=*TQ4NM&\1WEVGV//VV0Z.V[+ ;FSNC7&2H*\#DD_AU_P3K^,>LV?[0?Q
MH^$WB/6M:N8O^%I^/=9L] N]7']FV&E?\)KH.A:$-#T7KC)) R1DGCDFO/Q6
M6QV2>SZIZW=NG;2276S6Y^KXCQBS+BOA#C'&X/*Z60/FIM+EDK4Y1M4C9-N4
MN:#E2<[)*7+.]KO](/!_[!_P=\*VUQ;V'ASPV=/N?^/2T&CZ-QG.,_\ %-\Y
MYQ[C/U]M\#?L\_#3PC?6<NE^%O#=M/IMT0-FCZ1&X)'\+CP^K ^A4QX[,,\>
M]6=JOVRWER!#CIZ CJ?Y_0?E,EF\-VWE0@@'&   ..I)^GZ_GWX;+<'Z-6>J
M^ZW]??U_G+ <;<29MA,V6.S>5I7VTC;EUYMKQ:EI;KMJ8.B:)!HEQ<6=O8VE
MO;W/)%M:;5(//WN<<9X_^O74?V190R>>/M&[C@DX!)YS@9/)!Z>O/-7[>+($
M\Y()'&>O')QG)QG/7_Z].B'EH97;Y2#@#.3D9Z?ISV.,UVO+L)LHMM/N_>;=
MK+O:WXGS&&EC<+_:BQ>:N7,]]-$U=-IO7:VFI@2SBUE_<0W///\ 3'3VZ5X;
M^TAX/_X3;X8^+M#@F^SW.J6)&>^>"!Z]!^?;O7T-J"I%#+<CD 97MGI^'!/;
MN?6N'\4Z/!>:5K>F":<3W0^V>NTL%V@?B,'USZ9KJ6'B]M;I]-?3;II?\3?A
M3$XS"\1IXMMKGCK9;<R]=T]>Q^-?_!*GQ[KEE_PN#X$>)+^YN=8^#?C'2_#%
MG]KO/^86=&&O#\3G_P"OU-?N-9Q"&/\ UYRW<#G(X]OIT_\ K_S<?LR>+9OA
MY_P4N^-G@Q_)MY?%VK^(=<U8J-NGG4-&T?PX<\\#"/N;/ ')Z5_1+9ZPLUK_
M &A!!/<P?:0 /XL9.3_NY[ 8SGIQC@PZP<;WT:<E9[IQLK/MK=?(^^\5^'\5
MPOC<H^HM2AQ#2IU826JDJJE*+3M:SA:2DNDEM>[ZR*:4W7S8//"G//Z=._U'
M'-5KZ'[6Y@';)]^I_'..GOP/4R(WFFUGR1"UJ+K[,0#P3DXZDYSTZ9X]B\M^
M_FEX;.3GMQGCCG.>O/;N>1OB5H]/YM/12O\ Y'P&(Q/U9Y7BU:Z23:Z<T6U\
MTM>VEKW/YB/^"R/PSO?!]A;_ !9TJRN;FYL]7U,WHM+3=]NTL_V_KPSEB>.<
MD]SQU-?F1X<BTKQ?K&C^))M#N=-T?Q1X:\+Z+XCL[NS_ +-SCG'3)K^B7_@K
MGX*L-2_9WUG59P/)T&ZU/6KO/95T;Q#R,]>7Q]?P%?SXS:EX?UCX3ZAJMO?I
MIFK6OAHY/AZ\.FZ<2.F,'&/7(R>W6OPCC?#?\+/UW2UKZ]>K^_H?[+_1<XE?
M%GA5E&!QMY?ZO3<?=6JV46[[6C9M[;-+H?N%_P $8/&%[>?!36O"M_/DZ#XG
M\575D;OMIC>,O$+ C/ILSVY.?45^W][#YL4!]% []@?0^_T_E7\S7_!'#QS#
MX<\3?%+P'JNK#^T(=+\,:C9VEY>=1KVJ^)-:P,\ _/GZ97W/]-EP8Y88"O\
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M[./;]/\ XFH(88.3WST_#^>/;/KC S8KH/COJN$\_P"OD:%%5ZL5T'2%%%%
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M8\LZ)I[+GCYBCYYQSQWKU^ ,R^MX)NW]:]?D?"?3AR!TN*^%,[>^?X>O5_\
M!4&W^??L?R\_\%C/#OAW4_B1I-IKNIW-KJ%WXJAOM( .K8&IMXQ\=G0\%?D.
MSYAD$*2IVD)@UR'[+?QJU"Q\'^)=+6]T*V^)?@7X:ZEI%G=7?AW2-2?7?A#H
M.BZ"KG!&S8^O^6  XPZ$A"26KV__ (+)^"]/TCXI?#3XAWLZKX4N/%>D^"-=
MTEA\JKK?C#QYKFLZT0.2 %&1C.T]N*_.3PUJ&E> KV_TS7/$K?\ "'ZIXN_X
M6S\.-5_L@D-I8.=!^&6T8\2ALE@?%?BL+D'DX5,?$YEA\9_;$]59WT:?>,MK
MZ:[/IK[I_2'AM3RCC?Z,60\+SC/FI?ZW3;4XQ5TN#Z4DY6;FFM9T[*\>27,G
M&S_>G_@D7>3ZGX#^+^N7UC]FM]4^-OQ0UKG/_(T:Z/ /?C!Z?0GD&OUF\5:1
M8:QI<&AZ[IG]M6WB6\-D<@#[#P#N)/ISZ#.0<XY_)3_@DIXK76?AG\1=:@@^
MS:#_ ,+6\>-@];S,7@@!\=]VQD!]\'IFOVEAG_=6_DS_ &C[3:"\_/ 'Z\8_
M#T-?LV2X:V3Q3^U>VCUMKZ+3:]NT=C_,SQ0RY<+<2YU@4_@FD[.^O+>SM:SU
M3:OV3_E/$--^#_PXT86\.A^'=$TS4!>'^R-6-F-3']J$=<G&/KGH>V*D\"?!
M_P"'7PXBB'PUL+?2TO+O4KW5[0%M0?7=P(92VNN2I!QAE*X)/)ZGVD J^//_
M +'U"Y[8&H9 ]AA<XZ8*C![C-<]J5UJ-WJFEP078MKG3BQNM ^PIJ/\ ;(VJ
MJXUO&-#VD%LN 1P#P  ?5GV_#_[4^)P^98S%_P"^M[M^3T>][:/JM%>SNK,]
M$@[_ (_TJQ6=;\C/J/\ "M&O0.?$*W,O/]'_ )!5BJ]6*# **** "BBB@ HH
MHH **** "BBB@ HHHH 8J_+@\9.??H!61?),W^ISG]>V/\CWK69N!CC/I[=O
MS_SS5"\,0$.>H&1CZ=_R^O7-/7;L_N9'UB.%3Q+2:25T]FGM<P+JQL+D"68?
MOAQ].>A''.3R.HQG)P<?#W[3O[.$/Q,\.FST;1E75FQB[.%(;G.6SM.2?Z^M
M?H!+#;_NO-/?KC(SC]?P_#.*J7EG:2#]_"&Z8SGIV/'7.>X[=L"O'S'+?KB=
MWJ][[]V[VWO]Y[7#7%>;\*9NLY@TN5)15VEHK6:6Z6UKK9/I<_E<T;X<?\(C
MXLG\$_%*#[/:V]X"+P7F,J>A_P"*?''![\_CBON#PWH5A96=M-X7G&M:1;?P
MBU.,\_=. 3GY<XVGGCIFOO+XX_LY:7XKT*_;2[+*W0_TL\YQ@8&!KT0]!]T\
MX Z5^)VI6?C'X#W^H:'?3_V;X?NO^//5A_8^I'03TSC_ )F#_D.'-?+XK)/J
M;:\]/^&?XJQ_=W"/B _$3!+ZGG#C*R4J;MHWO=*_:25I6Y7NS[0_X5N?$E]_
M:NJ?\2VW[<\G.>#GU_+\*]0\.>"O#D/VC^R?])U#^7K]>W)Z^G<^*ZW\6H2]
MMIEI)_:&DMC.J[OL &.F''/N2H';K@5U'PF^-5]>VL%EJEP;F"U!Q=_93B^'
M..!X>09QZ8/OGBN#^S5>VGK9[^M[6\QYWEW$KP7,DW=747>+M:ZT:NI/9P=F
MG=/9GT?H<W]DWH&MQ8N" 00>#WQQ_,']*]9MM<MG7S;SIG_0_<GUZ_\ U_:O
M -+\:C4;G4!!/_HX';IP,$^P&/S[#G&!XD\806?$'_'QU_SQ].N3R:5]+=+W
M/S?$9%B\WQJPK2Y^51;UT6[2O>UW>]MU:[/<-7U'2M1N;BW]/_U?SX__ %YK
MR_Q)X)@O(KCR.F,]/0_EP3^>:XCPKK$^I7_GS]?3T//^?\.WL_G"&U\_/U_R
M>N0!Z'K7-B_M_P#;W_MX\*LWX=Q:2V227HM%^"/E76M*U71G,.#V.,'/8_3V
MXY!XP<5Y)K7AF^U>_:8P%0V3C\>!@Y_0\?A7VKJ=G!K/^O@^T_U^N?7W_#WX
M?_A%3%?^?_S#_P#/3N/;U/4XSC!.VJT:=T[['Z?EWB?_ &7@WC,)E"><N/+*
M-K7ON[I[-:67?<XWPCX3FTFUMY_U'KUR ?Z8 (&>M>HZ#-!!+]OG_P"/C\NO
MIR._IZU1U*;[']G@L<?9_P#/\R/Q'ZU3I,T'VB:$@&ZZY]_\^O\ B#5Z:NW0
M\_$YE'BJ[QUE=ZMV7HF_+7\39\7^,-*U&TN( /\ 2/;C^7^>X !%?,^L>&K#
M7K7[=/U[\>V/_K<9JMXCLM5LM4N+VXG_ '&!G![XZ\]\Y^N/KAFAZO$8[V::
M_P#]'!S:VOV0@V( Y& .223SQCBN?%;O7OK_ .!?U\S[#)>$_P"QU]>P.;-Z
M*RBKVNTK):;)W?2R?DCP/QMH-C9_:(+'_CX]1QV_7J>O_P"KQ1M$U2YU/^R]
M.LEFMA:&]O"Q 7^U,Y7!)P"1AOJ:^XKSX<:3K-M!K=]U&/;J>./?KSTZUPX\
M!:9-=:O8Z5I?]FD78^R78N_[14XZD*<\;N@SCG&3BO./VC+N/\GPN"_L7&/7
M57>L;K3WDFI::Z)_,\?O?!-CIN@^#_$ECI7_ !5%KXD\+Z+>?Z9_AG/K^N:^
M:OB)HSZ'\1]/\/ZCX0G-_P")OBCI7B*TNDU=<+_;6M#0QK/'S J&QLS@9'R@
MU]*CQ)JO@OQ%_P (MXBN!J5O;ZN"&%GUU,YP0<9Z'/X_3'C>K>-_#]SIWB[Q
M=!?^1JV@_'+5?!=X18ZP/M^FIHRZXVBM@\;PX(\3JOR[#\W(!PQ.&QF+O]2W
MMMY+>]_1>9V\/8G&93C\TQ^"BG'B%JTDFW>3_=M-/2.K<FTXM-/3<=J&F:!X
M:T#Q'XP\+^$9O%US;7>J^&/%VE#5B,# UW7"X\0/M;GDXV9QC !%?!7BK0?#
MFCQ>,-5L/[2^W_$;1]4T4^'O[8UD_P!@_P!NC^WL9Z>GY<>_OWBG6/'4NL:;
MI7P7877C+XBW8T0Z4O\ 8RC0M-US&=; \0,?#.O G/R[CQA3GFOT<_9*_P""
M:GBK3]6D\5?$&Y.K:AKUJMSJT+KI>D8D>0:PH']B^/I$.)2$& ZGAB0#FGEF
M1YS-]-[-VLE?2^GILE??0]?-/$+AKPXP.;YSQ/F_",YR4G3I7<ZU1P7.XJ^\
MHW46W.VL4YN.K_.WX8_LQ?'[X^^+-'\1^&Q]ET:U\-^&-&O?M2Z+J7V\Z&<M
MT\28R<G)_O$YK]O/V#?V#?$7P/N+?Q-XRU6YN=0-[J-Y]D.0,R2:[&/N^(F(
MP6 Z <\X +#]*OAY\&/!'P\L;#1=+T3[/I]M_IH N]8&-2&,<GYCCKDG!_NU
M[JFCV\C0RB(9MQBUY^ZIR<_R_GU''ZOEF28O"-?77=:7:VZ7/\R/%SQDQWB%
MFTN5<F36DJ::5VU=1=KVUWMT3NUT(O-AS?SPP@S6HTTG(P<DC &/12P/TSWK
M:J:% ,'UR/RZ]N_<YZ8 &,TZO>P^'2W/Y[Q/VK.^_P"3"BBBNDP"BBB@"I(0
ML$WDGI@ G^]@XQ[YS[?C7YC?\%%/ TOB?X'>++^>W6?5_#6B:OXGT6Y V@:G
M'HFN  *. !NX  [*.N:_3>6-9H)8\X6YR![$C&/Q&?SZ8P*\ ^-_@3_A.OAW
MXR\+P0_Z?J'A/5=)%WU4DQ21CMP0LF>^,GCIGFQ]",L+)-M-<_KMH[=?>T?_
M  S/K>!<SP^4<79/CL6D\G4Z?,G9*SJ153LU:FYM;ZQ22NS\Q?V&?VRO ^M_
M##0+?QCJT5MK6E:M_P (;J5I(FL/LL-#&B() /\ A'D) 4E2H,9*[U$@#MM_
M4GX:_$W0_'?AB?7?#3?:["VOM1LB4**1M88SD#*A2<#G"AA\IP:_E#^+?[)7
MQ3^$WQE\3^#]#M\^'_&/AS2\?\@8D:MKNLL.,^)!R0Q&>.#7]'_[$7PAT_X/
M?!;1]!ALUTRZNQ]MNE:]&HL3[ ]_PZ^O?'AS5--75G=:VTN]EKT3]5<_<OI'
M< >%F4Y/E'&G!?&#GG?$3;2OPB]'JUOI9JZ4=--3[BM)?WISG^?7^7!_#Z$F
MM9_NG\/YBL.'_C[_ ,^];C_=/X?S%>MB-GZ?YG\PK_=%ZHAI+RT$Q\T'D <=
M/;TS^/;T-+17-7H*:NN@L-B>OZ?>CQ3XP?"CPG\6O"USX2\<6 U+0;NZ%T;4
M#J V5SWR#GG(ZX]JY[X2_ ?X>?"_3H-+\!Z*NCV-KC:%NOMX)QPOS._/N3[C
MT/T T$2KP0W3';L<CID>O0]P!@FH9H89CT .>^.G(..G ^7.<GMCCC%Y?@^;
MZWJ[+=K2RTM=ZK>UCVXYSQ&L$LGP>;3ADCE*4H1;MS3MS<T(Z2DVEK?SWN%K
M#BYG@AL@L'_/R",$XX /?\#_ "Q6NZE5 /7/^-48\6<7DP]OP]ASG'?KT]/:
M];-D$GU/\@?Y5TZV?:Z^_H>7[#7ZSWU];:^OGN<1XEQ_9;V\V(?M,+C(/5@K
M<<<]1^/'O7\3/[1_P]T,_M+?'#QSI4_V;^P;/[;>9_Y?]4_MG7^H.0/Y]Z_M
M_P!3PT0C./)>%A]002"<^_/3OP.U?Q8?M@>*K[PM^V1\2/!U]/\ \4O:V>E^
M)]8M/^?_ /M[6M?Z9SUZ?YY_*/$##:>K<EIT>GZ?/L?W)]!O-W'C'B[!M22=
M"E%*UEI*4M-W]JVKU7WOS[Q?IOAR'Q;^SAXCTK%MJ%UXE\4'5[0<G_D!_P".
M> 2,=>:_MK^']S!>>'-$NE!^;0].3 /;:Y!Z=L$?_7S7\-/[1>I'3?C/X0\1
MZ7 3]ETNP_T3'%A_Q2#[>O?:1GW'K7]M_P &W2Z\-:;<PMLAGT;3G5#TR%(S
MVYP<?G4^'&BGI=<K3Z:6T['O_3;^M3R/PV<FXIKC.7O6NG[/A6T7TUU_ _GH
M_P""NFO:59_&7X6>')=(GUBTU/QUX5O/$-FO]K[1I/\ PF7CTZV,)N4 '<H"
M\84%1@UXMJO[.-YX=\':!=S:7!JO@+X@^+]*\2^!;=[DZ6WA3Q1KVC%=#(8>
M(4\2-_PBOAU/G_X2CY-RX 7&!ZC_ ,%/_'UYX=_:T\!W6CD76EV^GI::KJ]U
MTT%&^)FO'6\*,C!7!';'/05D7?Q!U;XG6O@CP?X)O9[GP1I6L>&?$WCKQ8+0
MG4_[2W?V%K>BG1"N1N\.:WN("_*3@%PNYGG?U/ZX[[WTUV=VG>]V^O-KOKJ?
M1<$?ZRY5X/\ !6.P$O[ BU>4G#FYX-*2::DH0D^:$H/DDY+W4XWDS].?^"9'
MAOP#HWPY\4V?@VW,%Q:_$?Q19>+D']K@_P#"4K_81UT DXR^[&6.T;<Y +&O
MJWX__M1?"G]G-=(F^)/CO6=&@\3W@T71S!X(UOQ"&U3J<'P]X8F;CH0V ,@*
M2.1\=_\ !*KPM-X9\!?%FRAO[BXT;4OV@OBA?6A/ O0!H0R<D<8!))[#'';]
M#?BY\'?A]\5[7P\/B#H=KXCA\,:O_;GAT776PU0<%NG/0#UP/:ON,LOB\'D^
MB?D[ZV\DX_T_0_B?CK$K%>*.<_VU4>>)S]Z47%2NUHKSC-+77X?+8_-CXK_\
M%*_A!#X1\.W_ (7O=1\9^&?&>L:IX9OM4N?#OC+P]J&@G0^3C1CX81B W .$
MS_=Z"O0O^"<'Q_OOB_X#\4:'/XQU+Q9XH\&7IO";OPY_PC0&E:[K/B Z$2?^
M$<QV;G\A@$UZ]\0OV(OA9X[A@,.E6VBZ]:#-GJ]GEFL?4!5\0\]3PN6/3%>D
M_ W]GSPK\#8M8AT.>YN/$&O6>E66L:L;/!OO["W?V)NZC@$X'KD<8!KZ?ZMY
M+OHM+/Y?GKH89UB>&\5@;9+S7T^+=VLG*7+%+^;9)-W=EN?74'?\?Z4TR@]0
M?\_C_*J,-X)O]1_GV[GMT-6/];_G&,?GZ^_7\BVM^_Z'YEAL2GOJ:%6***YS
MH"BBB@ HHHH **** "BBB@ HHHH **** "JMWY'E'S\;>WK_ )^O>K512PQ2
M@"100.F3B@"I-Y'E?YQ[^^,XI)YX8O(\X8-SQR> < CG\1G!S5GRH?3]#_A3
M)[6"=298E)&<9Z<GV_SW'M-!I)-WMI>V^R]/4#F8[*"X<CS^""/J"/7MG/7^
MN"?DKX]_LY:#\6="NO"]W:?\2_5@HN[D,A "ZSHFNG)_MV-N3HH/(ZC@@ JW
MVH=.M !F(9SU(('?CH,G\,?EFJT]K;K%Y+8&3P.N.WMU'3 Z^HZ\6(PSQ>BL
MV_*[^_S_ !L>WD_$.;9!C(5LGDX\M[>^X+K\2C\5KNW,VNI_-#\0?A!XQ_98
MUZVLA;G6OA]=\X*E?7L1XM8'_A(]<]/?!'3T'PMJ5A>?Z3I6/LP_X\[3(].O
M/0<#)_E7[B_$CX9>$_B'X=N-*US2K:ZR,Y.>GOP.@Y]^3QT/Y _%3X!7OP4U
M4ZIH=]G1]2(%[9^AZC&>,]<'CIG-?+9DOJ?2W]=_^&N?UYX3>+6$XKMDF.:Y
MFM+JUW:[:5WI]JR;TTN6?ACKT\-_J$$^>!^'7'/ZC]<]J]H^QV.K]>+C\L_E
M_G^OS-X.N]4U>Y$]A!]GMP !DY/KG./H?\37TSH,7]F_Z1??Z3_H?^'?MQG'
MY=Q7C_6?/\?_ +8_0>+,-@\)B_\ 8EK;9=^U]$>?WLT_AO5#Y'_'O^G7G^7I
MZCUKT^Q\4#4;"' Z_4D']#TYZ>Y&:\_\5>=KWGS0G[-]FX&>^ 2<?J><>P]5
MT']S;6\'ICG\1^'//?/2L%VO9/[M#E_LQ8S"7QJ3E'TNKJ]CV#1Y_?V__7C^
M7_UJY_QX-5FM<6/'Z_\ ZO7I].!5_1P/)^G2K+:Q!#(1,?W';MZXSCKQQ[>N
M*YCY!8;"83&/ZFODNO\ P^Q9\*Z#Y^@_Z=_Q\8YQTQ^ /KZ'TZG-;FGZ4;73
M)C?'&#V[@]OZ#.2,>O-/_MB ^1/#Q^.<C_Z_/&.OMBC6-8_M&U_<<>WI^."?
MP[^F::;3TW]+GC-9O+%V?PZ/L]&FO35'R]\09H89)PQ!@ &<>O'?OCFOF">:
MQL]4-]!_Q[7>?L?'?IS^''TXKZ7^(5I#+;3B>8G.>_\ 7(ZXYY_6OF :;I6A
M75O]NG M\C^R/K@''H2?R/'6N;$XG^OT_P" _+3<_ICAJV$R;ZY?5))WZZ+J
MTD[[NW<ZC1_B%JLVL_V7/#_Q+[;K^77_  SV&*[;6/&UL='O[*:?[-!IEW_H
M9&.@]<GWXZG)ZY-<U>WEAH^F+/K4^R^N<_9;2QSJ!/IC'OU''7CKQY7X;^%7
MQ2_:%\3OHMC8#0_#V@WF7;.?[0 &.3_N_@">_.?1PV1K%K1MM]+6_7KV.3$8
MO@?"-XW'YK"$8M^\YI]+MI.*LEJFY-6L^F_SEXU\:ZYKOB+7[;2=)_M*>Y\7
MB\L^O0<]O3TX_2O:/V</V&OC)\;_ !:?B#\7M/;1/ GAGQ'_ &UX9\/_ &O2
MM02]U71-8T/7?#^M^;X?USPOXA!_L#6M:&) 5!8,ROE8Y/V4^!O[&O@CP?8Z
M?<7OA?33JMK9XO-5^T$D^OS>A]AC +9K[JT?PMH>FVL$%O8VY"VGV'W_ +,Q
M]T#C'./4$GUYKZG*\D^IN^.7-UMKH^E]-==UUOON?S_XA?2/EAZ<LCX5G[-?
M"YV3]RS4N1J2Y6UI&>\-U!RM;Y-^%G[-'@;P;97]_>Z/;6VH3VA^RZD+S5=A
MTP#<-V?$+."N00%*\X/4<_3VG66G:3;6_DI%M^S+M+Y8E>!G@ *Q/0>F!ALY
M/5#3[8)!$T5OBVP;;+$D < C#')QW(SP/8U/+9V=QQ-#">_RL1R>XR2#Z9'
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M'=VA.--YZD C/ /8YYYQDUZ^Q^%9CDF+PF,2]-K6UVMY>>O3J]>@O,2PK 2
M< <GV'X=?KZ'VKQ>;;QY( X]#^6<^GYU^4O[=/QU^+W[.'COX;^/_#C^(-<^
M#US9IH?CRS U8C3]4UC6R5UG[O'E>'PVP#[C#*[6Z?7W[/7[0/A;XV>#=*\0
M>%M57Q%IMS:XN+NRNQJ']GZAM7Y-9VME3P1V.1D+C%"Q$$K72757[O6VO1NY
MOF/ .-Q7#JXSP:]V5U=7NI+5<U_=2>RM?73K<^I+AU:$>3U'?)X/H?7G!]R?
M<4EH\N_80 IZ\GGCKR/7'X^O?G]-FO9+BXAOIM.,! -I]CNB6/;D#+ _G]"
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MX2\<:K?:'_9MO]BTO^Q[O[&/^@U]?K_AUK^S/]E\S#P-IN<8_L?3>O/.P_\
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MFGUL?(A1110 4444 %%%% !1110 4444 %%%% !1110 4455N_\ 5?G0!9#
M\ TC*#['_/6L^!ICC/'3KCVQ^IY_QI$,P S+N]#C(Z\XS_A^5.SO;K>Q-?\
MV==):]/^'+J?>'X_R-5-1_U1^G]:@\F?S?\ 7C&?QQ^7KQUZ\Y[56U><V=@9
M_./  ^O&..<=N_3I2"O'EBU>_G\F?FY_P4 ^(.J:;\/6TOPY/<6^HW*H ;4
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MVK(+,#J0=(4-CI_"3_\ 7K]B]-_U,'^>YK]!R3$M+U?XKO\ ?^9_&WCKDO\
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M-_T#3BJ^#M#;YB, @9;:N0%!P/?T,+TUMMT?6W-Z>>FI\NWPAQ%QAFZP</\
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MQ \0ZQ;:W\9?BC;ZH1@#2/\ A$-&TL ;AU.@>)"#@?V*<\D8 Q\V1^S'P_\
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M\%^)'[#/PV\8?#Z^^&TMN--\*P@_V!]F;6-RA=7_ +=UE4">(6\3.0Q)?,@
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MZQX&\'V-A_PEW_"S_B3JMD"+W1M-V^&=>#:WHF"/#@VL,LI (*G<,@BOP?\
MB!\(/$GA'XOZ#X<\>>'KSPWXJ:.#PO)9ZBB1WNGS3:SXBL8[:XCC9PKIJEO=
MD9=@RE9$8QLC'[[_ &==8@\-_$;X?P?;O[2U#_A)/[%^QW9_LW_B5Z%SCV[G
MT[U^1Y IX*I@%4ISIU%AJ:G"I%PG&5I7A.$DG%JZ=FD_>NTK\J_U=^D'PID7
M&/A5@\TRVM2Q&:0R_!1I5*,Z=:C6HRP>6U*%>C4I3JTZE*K3G3E3JPJ3A4I^
MRG"3NF?UJVFJHMI87!A^SSW%IDVIQ\O/?'IU[XS[&OQZL_\ @J)\.?#?Q?\
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M5->QKVB?-M.T[6) RN_!!X4U]1G_ (_[?_KS_P *[SXG$87%8-_[8DM_TO\
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MOPSN=$^&GQ+T+7[&RN]:T;Q:;4"S\17/]D:<]YJ90D-HFM!6W#<,$@C&X9!
M)K]W_P#@G%^T(/B;\/;S1+[5H=1U?PNQLVNM3N0VI.?[9UY%\PKK[L,#100=
M\>-O)* @?S5?!"\LKWQ6VA^+_%5KHFD^#M7U76K'5FU@Z8->U;703K>BDZ^2
MVOCPH>"5R1Z'I7WQ^R;\8+'X&_M-:SX'U2?3?">D>.[+2_L-H-NFZ:&T/1-?
MUS(W<;OF.. ,'MG-?E^28G&93C/J5EVT>_9M.ZTONM]=FC_0CZ1/ ^4<0\'S
M7-)YY>-2+:3Y+-WC%KEE*]MGLFE><96C_3'\4OAKH7C;0+G1?$>A:9XUTBZP
M_P#9/BFS_M/[$9#H^/[%&T%"/)9BW1GR-QQS^7]U^V]9CP5H:>$/ 6O6OQ&+
M:E]I\(>-O#QTWQ)8(NKX*MH)\1_\)*,^'R7!7YC\N6Q\E?K[97^J:EI=M?0_
MV>2O_+J2P;UX(Z_AW^M>4ZK^SQ\)KWQ,WBV'X>^&E\1E52ZO5\(^$Q+@ =9D
MT%'SE1\V\,W\3$DY_:<+A_JC>,3M=6E=7ZK9:O6RT7FKH_RGX/S%9!FV:83.
MJ<IY-3;E"G&?*O:\DHKFGS+W?>:NU.*DXRY9:1/C/_@G[X1^)=_XA^._Q:^)
M?AO4?#0^*WB'PMK-CX>U?2=9TO4M/30=#&@X;1O$"DHIVC<P!Y )!((K].(K
MD22F?SR<7)?/;CJ,]0>I]J@L;32M(7R/MNGVW!_T6WN]N1[@$<?@./?I-$^B
M3RP0P7L9-TOVP?9[@'@YR"<YVD]5Z$#I7-EN)3?O:[WUWOY_-_>?.<=YCFO$
M.;K&X%*,;*R7NI)*,$MM$E%+;HNB1TLTW^3^/3^0&?4D]JJO_KH/]W^AJS*8
M'<0SD<C\_P!.#W_/K2_\M;>#KC/'_P"O^?X?3NQ'P_+]&<'^]83S3_%/_@FQ
M1113-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J\_;\/ZU8JO
M/V_#^M !1110 4444 %5ZL57KG NIT/U_H*?3$Z'Z_T%/H **** "BBB@ HH
MHH C<< ^_P#/_P#565/*#U_#_P"M^7'XDUID_NQ[$Y_4UBP10&4$?7IZ_7^F
M:Z,-HD^G^7+<BOAOK.'G'M:WWN_YZ%*,^7'(ZC)"D@=<XQCCO_GK7\Q_[5OP
MJ\=?#+]J?X%>)_"NL^/-2\8?$.U^)MT;N[DU4_8#X(\&Z B _P#"/>'<KO\
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ME6*YR$K,UC>P7MP8 -2/V7[42+\$D+]2K*2,8*Y!X.#6W6V'Q">YX.)Z_/\
M4HL55>2<MSU(Z@C'7)X)_KQ6';6UO)?&83\$GDXP3[G']??OBM*\N3%;PB*
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MZ_\ UJK\2]1G';IC'X^_KWKZC%?[W\O\S\$SC_=E_C1T%%5;659ASQN_TO\
M,X]<8_\ KU?V#U/Z?X5N;G,(9S>2DPY@M@#SCGOQ@D$9S@YR<=L8'#_$/P=!
MXD\-7^ESZ6-2M]34B[LQ:<')Y^7@#/&/3CMDGU9&4_=&,Y[_ .//X8J2C$+Z
MRDEI96^[?^O,WPV8O"8M8S"?$N5VULVNO1[Z^O<_BJ\<?"&Q^#7[4M[X#\?>
M'=-L/#'C/5!?^#_M6DC3\ZJ1K^OZ[\_ 8$\*P !^]P.*^@OBY_PK_P"T>"/'
M _X0RY\;Z VJM^YL]).JZANT7^Q ,O\ /M!;&#D*!LP,8'Z7_P#!4'X"#Q!X
M)T'XP^&O#JZEXX^%NL:CK5I9V=HI;6V8?V'AP,@':58=<@YQC!K\@OV=[+3/
MC.VD>,=3N!/#]KU2QLM*(R!JFA'7]!UTX!SC@XZ<^N"*_&.)/]DSGM=[WV7G
M9:V\M=.NA_J9PAQ_D_BQP%#'YUG7]@9[3@XM12;G)*,9VDY73DX;/?2[AJW_
M $_?";QSH7C3P];:WX<UNWU*P@M.&M+L%2P7."1G' P,\<=Z^@;J;S9+::$\
MCD\C R<X^@/0^@S7\V_[+7Q7^)GP$^,>H>%=<N+?6O"'BCBRMEM"KZ>NA:-K
MVOX#?PAO[;&0,]#WYK^AZUU2'5;:VM)A<[F7<+JU./8AL#/7/\/&?H:_5GG&
M"QF4QG@KW2<?)<UG\[V^7S1_GQXL\%8WAW,'BG:SO.%M-$TI*6F\92O=O52V
MTDS\C_VX_P!M#XE_"[XK_#WX*_"OPI;^+O&VO>&O'&H:M9Z5HQU V']@_P#"
M/,I(/B-6!SK>2&&<@@KCIYC\#OVB/VD;[PVVJ:MXA^&NIZQH=YI?_"2^$[6Q
M\8'Q+H6E_P#,<8[O$?)7"XR".F>G/UW^UEJGACX=^-? GB_Q#\.Q=_9-&\2K
MJ'Q4M;'2"OA],Z$/^)YK+D>)2L@#J&4;6P=Q8J0OP;I?CKP!^U+\8]/TCX.:
M7J=U<:59ZI8ZQ\0O!5\;#P/KPZ?\3S122S?+QEB2W\1YXRR[#-=T][6:WLT^
MGEZZ-=C]'RMY-EG 63O^Q:<HRYXRFI1FI.+<+-).Z=Y:-W@VXR7VC]OOA/\
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M^'G^IZ&-PV+PF)2Q*48M.R5TN^S2NKWLTM;Z7O<W****1@9TF"T9_O(0./\
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M6KVM-[<S/;_#]F-.T^UM\_\ 'U;I=MSS\Q ZCGD,&Z9QS]>E E'3W_O=^HK
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M:G%6M)6TU332W2LG9Z+2%["+07I,WD=<[??@XST/U_6I;/4(;N&":#@7/07
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M-3Q2SMX-)K_7.I3=^CC-*5^]W>Z?GY'XI^)/$^F?%?\ ;O\ #'AFV-SK.D>
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M-G4ARSG2C&+34N9J;2?+%QN_=24+GZ*S7G[1?[:.B^3HES<^"?AOXG_X_6;
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MASQ)K7]N:UKV&?/AQ7'APD\;58G#=\5[#^T9\1OVE?V;O"^@/XT^)^M/+/\
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M5;7?;S_I%Z:>!8)I .,$D]>@.!Z>O3IZ Y%<G/KVE>;;P9N?I_+^GOVKIID
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M=M*SZM]-[:]$TR7SH/+^T8N<^N!G/USG].OOT#J0^U& P$@]2>F,XZ]1Q_\
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M65IPHVEK-V:M><M']I6.G36$$_DBW\BXP?3GKD]CGGU[]>*T-,M!:1&&  0
M 6P.#M!!/7N#U![CL,\Z<$JR C YQ^/]<9Z>_P"A%$%'Z<?Y_$D_05]+A\.E
MKLO7OO\ ?_3T/Y-Q]\5BUC).[M:_X?\ #^>I,BD+M/?CC\N.3_\ KKF==(,)
M*PC[1:V9O.F>02"/?D'.?3GDBNF2?(S@<^@']"/Z]:SKLB1S9YS,;7=G&!SQ
MQUX)QGOQTZ5SXCGM_LEN;K:__#]MO\CH5=1MBETT6GSV^=S^=;]K7]H3XT_\
M+]TR"]\,_$J7X?\ ABZ0B#PI9ZOIIU'^P_&6O -\GB%5;=X=_>$[%&6QM"X
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M=!9CH/Q$T+Q, -C:,_R[L!2VTDA'I_"']G[Q/^T1\:/#^M^)/$>HZW\-]*O
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M3^TSXJ^'/BA\3_ /Q'R=0L](\+G1^='';7QT!&0>!SD'@8.<5^TUE<V:SZA
M"5GMQIR7FTYY\MCD]>P;KQN_V<&NK*\+]5:2NV]-+MJ^FB6^E]/4^ \;,3AL
M9G&48&GFRGDW#ZM3C=KFDT][:JSZ:JWS.C\CW_7_ .M5B#O^/]***[OK-]W^
M-_U/R\K^1[_K_P#6JG<D1R-.(LW MSR .,8)7//<GZCUXK4JM-U/U'\J#GQ/
M7Y_^W'#W=]FYSC&,@?4>_.!^/'N!1>S66FQ#[=CS[J]/V0'KDCMV'OUZCKFN
ME?38Y9!(A'&<#G).">N/3'3\*PM=GL-.C@%]_J1C[)QS_:9SMZ=L@X&>.>.<
M'T,3B+:)-);*VRV6G]:G?F-\UP2P64)*;5GVO:[2;M?JUI\G8S=0U^WCTNXN
M9]MO;VMHUW<VHQDC.3CD\9'L#MSVK\^?VK?$GCCXD:#!\.?@]X<^U>(/%).B
MZOXAM%T8'0-+P!_;1&2<Y&?KVZY^9?V_OVA/$7Q5CF_9T^$BW-G;:LHL_'?B
MJS^4Z=I1&O:%KBGGJ. <8 QQQ7N/_!/?]G7PI\)?#ESJNE^(M2U+QOJ=E]CU
M@ZM>:SJ0)!R.-?\ F)& WOTPW->1BMY+U72^CE^/IYVT/U#)."L7P3P>N*>)
M;O.W9QT:NFERW[733UV;Z;'Q?\/_  '\1?V3?$>@^-9[C4?&O@G2[G5+W6-)
MTJ[_ +/-AJAW?VYD$8/_ !4FML<')(4@\5^S-O\ %#3-9^$%SXTO(/[-L#:N
M['DC:NK.HSV&6.,<=LFL#XR^!=#^('@;Q#X/ M]%&J6KV+7@(U';J/\ :K%F
M(X!^9%&!@\]]I%?EE^W-^U?J7P;^!7BSX4W]O]J\5:U::;::+>6A.G#.B:OH
M&M' /AP+RG?'3\Z\E6P5F]4XR2T6DK2CKMHGKT_#7[>GS^)'^J>)IY/;/H5J
M"F[RC>DITJTK.S][EO'2^UFXMZ5/@;J0_; _:DMOBI8S_9?"_A;_ )%O[3_Q
M,1?C7?!>OZ#KO'8?\2/UXS]2?Z -.TY4MH39BWMU*/D"V'(7J P*X)!))X/'
M?I7Y&_\ !,_X,V_P]^&?@>.Q;F:+Q5]DNL]?.U[QT$_+^VFSSR3TZ"OU_L)%
M:"!(>%$3N?Q.<?\ CH'3'.,8SGW\-A>75W3Y5-/5::N_Y:KON?GGC5# /CS_
M (0W_P (D.%8T%9_:4E=:;.]UW3CJK&G]C@^U>?G_2,>I^N<_3M5CR/?]?\
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M//KO&F4*4.2UKZ*5VW+ELW*ZM&R:\D[Z?D=^S=9?M _MM7>O:3\8)/$7P_\
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MJB=HI0LM[V:3YKW3:FM&E9:'0PWFE:Q^_P!*OK6Y^RDB[P2>!T)X.,\CIC)
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MP6T>(A;A;8X@X*J"2,$X[Y!P>.WI7$>%+6STG1].Q"+=+:/4&Z8Y8N2W7HP
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ML>M::#GUSX;Z<#H.PZU\\_MZ_M3GPK\(+G5?AF?L_CC[']MLKOH1SH.>=?\
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M@<#'  ZX_7Z=?>K;:'%&Y8GC Y]![YQW]/;@UT7RDY+9_#%/(7;C.!QSW/\
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M:0V>@Z'DY->M?LB_LW^/_B#HWB#Q5X5\+:WHG]J69L[3_A-]'UGPW]@U3O\
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00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>ea028373001_ex99-2img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_ex99-2img2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "  3D# 2(  A$! Q$!_\0
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M[PMX7\":Q<WMV+R\FN=/\(:#IPGNYC*T\LLMQ9SN9+DM,S;G9BY8U^],>]5
M9LD\\<#GD=/;&3U]: +5%09/J?S-&3ZG\S0!/14&3ZG\S378A&.X@XX.>C'A
M2?;=C/MVH LT5SDVIQ6"&2]O[9%MU4:I<S2"*WA)^55! VH=RS ';&6( /;$
MRWUO D-S+.! P+(T<K31.ER3/!)YLA5F$D/[P#!"[BJDJ 2 ;M%9\9D\QHY
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MNC$S2 APQRW;^JS_ ()5?'@?M%_L'_LV_%+SS<3ZA\/-,T;4"SQ-(+O09)M
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MVV*REO[.[T^?QY=W 34[F(.+C2(PGES*N0JJ_P!/_LV_\$9OVFOB]K8^)O\
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M+FY^)_PWD%WXNL[>2QCN-7T>V\-:@$>"2[M[=%2%='TJ%MU\[;W4A0 =@!^
M?[-_[4G_  5I_P""DW@'X9?L1_ #4M5^&OP8M=,.C:WXOU32_#]COL[*ZO\
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MB5$=?UGNM\C$Q(TKVES!-Y8*QEQY3_*))2D9SOZ[L \$@C%?R_?\'2&@Z_\
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M?W$$(7:55 5SM( &W=PVW XW  ''7'- 'B'[,WPLN?@E\#?A=\)[S4GU:Z\
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MKVW;?#$Y!'F()-IZKYGS[3D#E=VWH.G0=*854C!4$=,$ C'3&#QTJ=  H &
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MWS+,8E]!G@?@P'^<<57:*,LK3N6$9RDS3;$+>@&2/EY!PQY!R!S0!6L[,+-
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A* )/,]OU_P#K4>9[?K_]:HZ* %)R2?6DHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ea028373001_ex99-2img3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea028373001_ex99-2img3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !9!0$# 2(  A$! Q$!_\0
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MYAB5[7&X[A7.J5;+ZE>O.6)Q&78_),9B'.K5KU:A1117Z.?Q(%%%% !1110
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M)J4*-3$86-:.)CAJ\Z4)U<.L1"%.%=4:DI4O;0IPC4Y'.,5%J_\ F)GV$RG
M9YG.!R'-ZF?Y'@LVS'"9/GM7+*V2U,ZRO#8W$T,OS:>3XG$XS$Y7+,L)1H8[
M^S\1B\37P:Q4</6K3JTZG*4445N>2%%%9^K:I9:)I6IZUJ,C0Z?I&GWNJ7\R
MQO*T5EI]M)=W4BQ1*TDC)!%(PCC5G<C:BEB 4VHIRDU&,4Y2DW9*,4Y2;?1*
M,6V^B3?0NG3J5JE.E2A*I5JU*=*E3A%RG4JU9PI4Z<(K64ZE2I3IPBM93G&*
MUDC0KX__ &KOV\/V8?V)?^$"_P"&C_'U]X'_ .%F?\)3_P (;]C\&^,_%O\
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MF?\ 9@_Z-[^/7_@3\/?_ )J*/^(F?]F#_HWOX]?^!/P]_P#FHKPO^(O>&O\
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M *$W]F?_ ,-[X^_^>Q7)_P 3!^'/_/[/O_#%6_\ F\]__BCY],W_ *%WA/\
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MO13:3JOP7S*?L[M+VG)'Q<J.7)?GY53J<W)R\D^;DG[C_P $<_VV?C#^W3\
M_B?\2_C,WA5];\*?&K5? 6A2>$_#<OA:UE\.6?@SP7K]K-?Z9+KGB';J<MWX
M@O6G,6I30QQ^3;QM)Y)N)OM3]M#X[ZW^S%^RY\:/CYX<T/2_$NM_"_PD?$FG
MZ#K<MW!I>J2IJ>G6;VMY/8O'=PQO#=R,LD#;DD5&*NH9&XK]AO\ 83^$?[ /
MPU\4_"SX.>(OB/XE\/\ BWQS=?$#4KSXF:OX9UG68-9N] T#P[);6-QX6\(>
M#+*/3%LO#ME*D,^G7-T+J6Z=KUH7A@@]?_:8^!&A?M.? CXF? 3Q-K6K>'-
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MPF)PV+HN*K87$8?%47**G%5L+B*&)I.4&TIQ57#TG*#:4HJ46TI-K^+[1?\
M@V7_ &FI],MI?$7[1'P)TK67\[[98:+8_$#7],@VW$JV_P!FU:^\.^&KJ[\V
MU6":;S=%LO(N));9/M,<*7<_PE_P4*_X))_$K_@GI\._ WQ%\;_%GP-\0;'Q
MUXTD\%6>G>%=)U_3[NQNX]#U'73>W,FKHL,EN8=.D@"1'S?-D1L;0U?Z%U?S
M6?\ !S1_R;#^SU_V7FZ_]5[XGK^:O$/P?X%X<X(S_.<KR_'4\QR[!4JN%KUL
MVQN(2J/&8&A*=2E44:51RIUJB:<8QYI*2BFDC_;;Z'O[1SZ5WC+]*'P@\-^.
M^,.%\9P=QIQ7BLOSW*\L\/>%\GJ5,$N'^*<RAA\)F&$J5\?@HT\5EF#<)TZ]
M:M[.E*E.K452I)_SO_\ !.G_ ()UZE_P4&\0?$[0=-^,?ACX0-\-=#\-:U-=
M^)="GUR/6QXCU'6+!+:TC@UK1C;O9?V09979YQ(+A%")M);]4_\ B&K\3_\
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M)99/QP_X.B(HQ)^P],(T$TB?M*122A%$CQPM\ WBC>0#<R1-/,T:$E4::4J
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M&.25_P!EURL2/(PB^,_[/4\A5%+$1PP_%F2:9R 0D44;R2-A(T9B 3_5Q?\
M1E>-?_#WQ7_]#8UXS3;27[3GZ,C;:22\,?H_7;;22_Y/6MVTMUONMSU?P_\
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M .&;^,W_ ,P=?R9_\.5/^"GG_1JVM_\ AQO@S_\ /&H_X<J?\%//^C5M;_\
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MX+AU6_3PC>>(DLK6PLTUZZT1=.FU9+2RL[8:C)<+!:6\6V%/Z8?^(8;XE_\
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M;?POX=BU&[BM&UKQ!<:'I&O:O#HVG&47&I3:;HNIWD%HDL\5E.(W"_O1IO\
MP;<_MM:SIUAJ^D?&7]D'5-*U6RM=2TS4M/\ B'\6[RPU'3[Z".ZLKZRN[?X%
M2075I=VTL5Q;7,$CPSPR)+&[(RL? ?\ @KG_ ,$Q/$'["OQ3E\=^ +*_U?\
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M_$VH^'_"EDFEZ6^HWGC_ ,):)/JK6BN5DO[H)I=O=3J#/<)!').SF(N/._\
MB)?_ &./^B)_M,?^"3X6_P#STJ^JO^"Z=R+W_@EO\<;Q8Y(5N]2^"ER(9E"S
M1"?XP^ 91'*H)"R('VR*"0&!&3BOW;,:WAOF/!''<N"*7#<ZN"X8S18NKDN7
M4L/7H0Q&"JNE&IB)9?AJ_+7^JR7*J\U-4FIQTBS_ "?X1RSZ:W!_THOHHT/I
M1X_QJP^7\3^.W 4^'LO\3.,L?G.59IB,EXHRUXZM@LII<8YUE:KY4L\HU8UJ
MF5X:IAZF-A+#5KSJP7\97[ '[&\_[=?[1.A_ &W^(47PQDUCP[XJ\1/XLF\+
MOXP2UA\+V$%]);)H:>(/#!N);M961)#J\"1,H+*P)Q_1YX1_X-BO@_96T2^/
M/VJOB3XDNQYWGS^$?A[X7\$VT@:4-;^5:ZSKGQ EA\J#,<Q>\G^T2D31BV0&
MW/Y3_P#!OK_RD8\&?]DR^+?_ *CUG7][=?%>#GASP7Q'PJLWSO(Z.8X[Z]5P
M_M*V)Q\:?LH83!5(IX>CC*%!RYZM23FX\[YK-V22_K;]I[],?Z2?@A](+!>'
M7A1XGYAP3PG6\-N$N(JN"RO).%:V,EF^9XWBFCC<2LXS3A[-\TA"M3R_!Q6&
MA7CAH.BI0IQE*;E^"7@3_@W._8"\*O--XFU;X\_$QYO+Q;^*?B!HFCZ?:^6+
MQ3]CB\!>#?"&H#SA<6[W'VW5+[,UA;M;?989;RWN?K[X3?\ !'[_ ()W_!+Q
MEH'Q#^'W[/R:?XX\*ZE::QX<\2ZG\2_BYK]YHNJZ??6NI:?J6G6FL^/+W2;7
M4+&[LX)+6_ATY+V)!+")S!<7$<OZ7T5^YX'P^X&RV5*>"X2X?H5*,XU:-5Y;
M0K5J=2$E.%2%;%2Q=:-2$XQG":J*4)1BXN+C%Q_R3XI^E_\ 2HXUHX[#<3_2
M%\7<SP>9X:M@LPR^/&N9Y9EN-P6)H3PV)P>)RS(J.09?6PF(P]6K0Q&'J825
M+$4:M6G7C7A5JQJE%%%?8'\Y!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-J6@Q20Q6_B?XCM;RQW"K;^#["^0Z5)<026]SXIOM$MI(Y;47WE?K77\/_\
MP7*_8Y_;GM?C5XU_:M^*USI?Q4^!ES>Q:%X-\1> 1?)IOP>\$)<K%X8\)^*_
M"5]OO_#KO=7DXO?$MC/K6@Z_KUS/J5_JNDZCK=GH,'5XM9_G?#W!F8XG(<!C
M<5C,3">#J8["4W4ADF$JTY+%9I7Y)>U@Z=*4J.&JPI3A0Q%98FO.A3P\*A\7
M^SV\(O##QA^DMP9DOBSQ=PQD/#628G#<0X/A;B'&PP=?Q/XAP&-H3R+@3*OK
M5#^SL3'&9A1H9AG6!Q6.PF(S/)L!4R?*\/FF,SC$8./X"66B^(/$5OXGUJSL
MK_5H?#6EIXF\5ZBN^X.EZ7?>(M#\,KK&J3NYD$-SXF\4:#I/VB0NTNH:Q:HQ
M+2EA^I/_  0T_P"4I?[+W_=;/_6=OBW7Z :M^PZW[*?_  0;^.7Q)\;:0]A\
M9OVC=4^ ?C?Q'!>V\L&I>%_ :?%WP1-\/?!UQ!<P07-E>II^H7/B;7[6:&&Y
MM]8U]M(O5=]"MW'Y_P#_  0T_P"4I?[+W_=;/_6=OBW7\BY5PSC.&../#*CF
M'-#&9OBN%\\JX>47&6$AC\]G'#4*E[2=;ZK0H5ZRFDZ=3$JE9.G-'_11X@>.
M/#?CG]%OZ<6/X05&OPUX=9#XZ^%679QAZT:U#B'$\)^%="KGF;X1T_W$<N_U
M@S/-,JRN5"4Z>)P.2?7HSE3QF&/]#*BBBO\ 08_X^ HHHH **** "D) !)(
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M^R#_ /.)H_X>B?MF?]#?\'O_ !$?]D'_ .<37Z,_L#_\%8/V+OV7OV6_A_\
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M,)/ /A#PLU^MU%X1TU&356O5MS"K62VYFNC-_/U_P50_;P_9P_;:_P"%$_\
M#/OP$O?@A_PK/_A9_P#PEWVOP[X$T#_A)_\ A,_^%>?V#Y?_  A,\WVO^Q?^
M$4UK?_:>WR/[67[%GSKO'ZN?\&O*[3^W&,YRO[,C?]]I\?VQ^&<5[WAOFV<4
M_%/*<CH<;YCQ1D%.6,OB*>,S*EE>.E4R'&XI?\)V+E3_ (&*A*$G4HZUL.JJ
M;7)(_+/II^''A]F'T O$;Q:S/Z+?!G@5XK5*?"M*IE6-X<X)Q_'?"E./BSD&
M00C_ *WY!1Q3:S?(G]9I?4<R:I9;FTL#5C!O$4G_ %E5F:WHFC^)-'U/P_XA
MTK3]<T+6K"ZTO6-&U:SM]0TS5--OH7M[RPU"QNHY;:[M+J"1X9[>>-XI8W9'
M4J2*TZ*_LR48RC*,HQE&2<91DE*,HR3C*,HR4HRC*+<91E&491;333:?_,]2
MJU:%6E7H5:E&O1J4ZU&M1J5*-:C6I5(5:5:C6I3I5:56E5ITZM*K2JTZE.I3
MIU*=2G4A"</Q]_X+O@#_ ()A?'L   :U\&@ !@ #XR^ P  .  . !TK^4_\
MX(:?\I2_V7O^ZV?^L[?%NOZL?^"\'_*,/X^?]AOX-_\ JYO =?RG?\$-/^4I
M?[+W_=;/_6=OBW7\H^*7_)\?#_\ Q<)?^M%C#_H"^@;_ ,JLOI>_]>OI"_\
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M'FG*TN6$>;FG+EERQC)\LK<LO]%OXI_\DP^(_P#V(?B__P!1[4:_S(_V4?\
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M@]_\V-'_  WQ^PK_ -'I_LF?^)&_![_YL:/[>R'_ *'N1_\ A[R;_P"? ?\
M$)O%C_HU/BG_ .*P\2__ *71]9T5\F?\-\?L*_\ 1Z?[)G_B1OP>_P#FQH_X
M;X_85_Z/3_9,_P#$C?@]_P#-C1_;V0_]#W(__#WDW_SX#_B$WBQ_T:GQ3_\
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M&I\4_P#Q6'B7_P#2Z/K.BODS_AOC]A7_ */3_9,_\2-^#W_S8T?\-\?L*_\
M1Z?[)G_B1OP>_P#FQH_M[(?^A[D?_A[R;_Y\!_Q";Q8_Z-3XI_\ BL/$O_Z7
M1]9T5\F?\-\?L*_]'I_LF?\ B1OP>_\ FQH_X;X_85_Z/3_9,_\ $C?@]_\
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M/_P]Y-_\^#_)C_B$WBQ_T:GQ3_\ %8>)?_TNCZSHKY,_X;X_85_Z/3_9,_\
M$C?@]_\ -C1_PWQ^PK_T>G^R9_XD;\'O_FQH_M[(?^A[D?\ X>\F_P#GP'_$
M)O%C_HU/BG_XK#Q+_P#I='UG17R9_P -\?L*_P#1Z?[)G_B1OP>_^;&C_AOC
M]A7_ */3_9,_\2-^#W_S8T?V]D/_ $/<C_\ #WDW_P ^ _XA-XL?]&I\4_\
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ML)OM6IZE<8:[U?6=0D7S]2UG4Y[O4]1N"9KRZFD.ZO.?^&^/V%?^CT_V3/\
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MJ<45<55KJ60Y,J&8.>!G]6E#^SX?!_\ Q#&_!3_HZ/XI?^$/X3_^3ZX;7O\
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ML/$O_P"ET?6=%?)G_#?'["O_ $>G^R9_XD;\'O\ YL:/^&^/V%?^CT_V3/\
MQ(WX/?\ S8T?V]D/_0]R/_P]Y-_\^ _XA-XL?]&I\4__ !6'B7_]+H^LZ*^3
M/^&^/V%?^CT_V3/_ !(WX/?_ #8T?\-\?L*_]'I_LF?^)&_![_YL:/[>R'_H
M>Y'_ .'O)O\ Y\!_Q";Q8_Z-3XI_^*P\2_\ Z71]9T5\F?\ #?'["O\ T>G^
MR9_XD;\'O_FQKT/X:?M-_LV_&C7;OPM\'?VA/@?\6/$UAI,^OWWAWX:?%CP%
MX[UVRT*UO+#3KK6KO2/"VOZKJ%MI-MJ&JZ78SZE-;I9PWFI6%K),L]Y;I)I2
MSG)\15A1P^<917K59<E*C0S;*J]:I-IM1IT:.9UJM2349-1ITJDFHR:C:,FN
M/,/#;Q(RG!8K,\V\.?$/*<MP5)U\;F6:^'_'N5Y=@J$94X2KXS,<SX'R[+\'
M0C.K2A*OB\?A:,9U:4764JM.-3W"BBBO2/BPK^>;_B&H_85_Z*O^UG_X77P>
M_P#G$5_0S17S^>\*<-\3_5?]8<EP.;_4O;?5/KL*L_J_UCV7M_9^RQ6&M[7V
M-+GYN>_LXVY;._Z_X4^/_C5X&?V[_P 0?\3.*O#O_6?^S?\ 6#_5K$Y?A_[7
M_L?Z[_9?UWZ]D6=\_P!1_M+'_5_9?5N7ZW6Y_;7C[/\ GF_XAJ/V%?\ HJ_[
M6?\ X77P>_\ G$4?\0U'["O_ $5?]K/_ ,+KX/?_ #B*_H9HKY[_ (A3X;_]
M$9D?_@G%_P#ST/V#_B?_ .FK_P!),>*?_ASR#_Z!#^>;_B&H_85_Z*O^UG_X
M77P>_P#G$4?\0U'["O\ T5?]K/\ \+KX/?\ SB*_H9HH_P"(4^&__1&9'_X)
MQ?\ \] _XG_^FK_TDQXI_P#ASR#_ .@0_GF_XAJ/V%?^BK_M9_\ A=?![_YQ
M%'_$-1^PK_T5?]K/_P +KX/?_.(K^AFBC_B%/AO_ -$9D?\ X)Q?_P ] _XG
M_P#IJ_\ 23'BG_X<\@_^@0_GF_XAJ/V%?^BK_M9_^%U\'O\ YQ%'_$-1^PK_
M -%7_:S_ /"Z^#W_ ,XBOZ&:*/\ B%/AO_T1F1_^"<7_ //0/^)__IJ_]),>
M*?\ X<\@_P#H$/YYO^(:C]A7_HJ_[6?_ (77P>_^<11_Q#4?L*_]%7_:S_\
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M_1&9'_X)Q?\ \] _XG_^FK_TDQXI_P#ASR#_ .@0_GF_XAJ/V%?^BK_M9_\
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MNO@]_P#.(K^AFBC_ (A3X;_]$9D?_@G%_P#ST#_B?_Z:O_23'BG_ .'/(/\
MZ!#^>;_B&H_85_Z*O^UG_P"%U\'O_G$4?\0U'["O_15_VL__  NO@]_\XBOZ
M&:*/^(4^&_\ T1F1_P#@G%__ #T#_B?_ .FK_P!),>*?_ASR#_Z!#^>;_B&H
M_85_Z*O^UG_X77P>_P#G$4?\0U'["O\ T5?]K/\ \+KX/?\ SB*_H9HH_P"(
M4^&__1&9'_X)Q?\ \] _XG_^FK_TDQXI_P#ASR#_ .@0_GF_XAJ/V%?^BK_M
M9_\ A=?![_YQ%'_$-1^PK_T5?]K/_P +KX/?_.(K^AFBC_B%/AO_ -$9D?\
MX)Q?_P ] _XG_P#IJ_\ 23'BG_X<\@_^@0_GF_XAJ/V%?^BK_M9_^%U\'O\
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MQ#4?L*_]%7_:S_\ "Z^#W_SB*_H9HH_XA3X;_P#1&9'_ ."<7_\ /0/^)_\
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M#_Z!#^>;_B&H_85_Z*O^UG_X77P>_P#G$4?\0U'["O\ T5?]K/\ \+KX/?\
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MP>_^<11_Q#4?L*_]%7_:S_\ "Z^#W_SB*_H9HH_XA3X;_P#1&9'_ ."<7_\
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M,>*?_ASR#_Z!#^>;_B&H_85_Z*O^UG_X77P>_P#G$4?\0U'["O\ T5?]K/\
M\+KX/?\ SB*_H9HH_P"(4^&__1&9'_X)Q?\ \] _XG_^FK_TDQXI_P#ASR#_
M .@0_GF_XAJ/V%?^BK_M9_\ A=?![_YQ%'_$-1^PK_T5?]K/_P +KX/?_.(K
M^AFBC_B%/AO_ -$9D?\ X)Q?_P ] _XG_P#IJ_\ 23'BG_X<\@_^@0_GF_XA
MJ/V%?^BK_M9_^%U\'O\ YQ%'_$-1^PK_ -%7_:S_ /"Z^#W_ ,XBOZ&:*/\
MB%/AO_T1F1_^"<7_ //0/^)__IJ_]),>*?\ X<\@_P#H$/YYO^(:C]A7_HJ_
M[6?_ (77P>_^<11_Q#4?L*_]%7_:S_\ "Z^#W_SB*_H9HH_XA3X;_P#1&9'_
M ."<7_\ /0/^)_\ Z:O_ $DQXI_^'/(/_H$/YYO^(:C]A7_HJ_[6?_A=?![_
M .<11_Q#4?L*_P#15_VL_P#PNO@]_P#.(K^AFBC_ (A3X;_]$9D?_@G%_P#S
MT#_B?_Z:O_23'BG_ .'/(/\ Z!#^>;_B&H_85_Z*O^UG_P"%U\'O_G$4?\0U
M'["O_15_VL__  NO@]_\XBOZ&:*/^(4^&_\ T1F1_P#@G%__ #T#_B?_ .FK
M_P!),>*?_ASR#_Z!#^>;_B&H_85_Z*O^UG_X77P>_P#G$4?\0U'["O\ T5?]
MK/\ \+KX/?\ SB*_H9HH_P"(4^&__1&9'_X)Q?\ \] _XG_^FK_TDQXI_P#A
MSR#_ .@0_GF_XAJ/V%?^BK_M9_\ A=?![_YQ%'_$-1^PK_T5?]K/_P +KX/?
M_.(K^AFBC_B%/AO_ -$9D?\ X)Q?_P ] _XG_P#IJ_\ 23'BG_X<\@_^@0_G
MF_XAJ/V%?^BK_M9_^%U\'O\ YQ%'_$-1^PK_ -%7_:S_ /"Z^#W_ ,XBOZ&:
M*/\ B%/AO_T1F1_^"<7_ //0/^)__IJ_]),>*?\ X<\@_P#H$/YYO^(:C]A7
M_HJ_[6?_ (77P>_^<11_Q#4?L*_]%7_:S_\ "Z^#W_SB*_H9HH_XA3X;_P#1
M&9'_ ."<7_\ /0/^)_\ Z:O_ $DQXI_^'/(/_H$/YYO^(:C]A7_HJ_[6?_A=
M?![_ .<11_Q#4?L*_P#15_VL_P#PNO@]_P#.(K^AFBC_ (A3X;_]$9D?_@G%
M_P#ST#_B?_Z:O_23'BG_ .'/(/\ Z!#^>;_B&H_85_Z*O^UG_P"%U\'O_G$4
M?\0U'["O_15_VL__  NO@]_\XBOZ&:*/^(4^&_\ T1F1_P#@G%__ #T#_B?_
M .FK_P!),>*?_ASR#_Z!#^>;_B&H_85_Z*O^UG_X77P>_P#G$4?\0U'["O\
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Submission<br></strong></div></th>
<th class="th"><div>Mar. 27, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissionLineItems', window );"><strong>Submission [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Central Index Key</a></td>
<td class="text">0002007702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Registrant Name</a></td>
<td class="text">CELLYAN BIOTECHNOLOGY CO., LTD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FormTp', window );">Form Type</a></td>
<td class="text">F-1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_SubmissnTp', window );">Submission Type</a></td>
<td class="text">F-1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeExhibitTp', window );">Fee Exhibit Type</a></td>
<td class="text">EX-FILING FEES<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTableNa', window );">Offering Table N/A</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OffsetTableNa', window );">Offset Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_CombinedProspectusTableNa', window );">Combined Prospectus Table N/A</a></td>
<td class="text">N/A<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_CombinedProspectusTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_CombinedProspectusTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeExhibitTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeExhibitTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:feeExhibitTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FormTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FormTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OffsetTableNa">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OffsetTableNa</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:naItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_SubmissnTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_SubmissnTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Offerings - Offering: 1<br></strong></div></th>
<th class="th">
<div>Mar. 27, 2026 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingTable', window );"><strong>Offering:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_PrevslyPdFlg', window );">Fee Previously Paid</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_Rule457aFlg', window );">Rule 457(a)</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTp', window );">Security Type</a></td>
<td class="text">Equity<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingSctyTitl', window );">Security Class Title</a></td>
<td class="text">Class A ordinary shares, par value US$0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_AmtSctiesRegd', window );">Amount Registered | shares</a></td>
<td class="nump">12,499,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxOfferingPricPerScty', window );">Proposed Maximum Offering Price per Unit</a></td>
<td class="nump">0.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_MaxAggtOfferingPric', window );">Maximum Aggregate Offering Price</a></td>
<td class="nump">$ 8,124,990.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeRate', window );">Fee Rate</a></td>
<td class="nump">0.01381%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeeAmt', window );">Amount of Registration Fee</a></td>
<td class="nump">$ 1,123.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_OfferingNote', window );">Offering Note</a></td>
<td class="text">The ordinary shares will be offered for resale by certain Selling Shareholder pursuant to the prospectus contained herein. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), this registration statement also covers any additional number of ordinary shares issuable upon share splits, share dividends, or other distribution, recapitalization or similar events with respect to the ordinary shares being registered pursuant to this registration statement.<br/><br/>Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the closing price per ordinary share as reported on the Nasdaq Capital Market on March 26, 2026.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_AmtSctiesRegd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of securities being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_AmtSctiesRegd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of registration fee (amount due after offsets).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxAggtOfferingPric">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum aggregate offering price for the offering that is being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxAggtOfferingPric</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative100TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_MaxOfferingPricPerScty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum offering price per share/unit being registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_MaxOfferingPricPerScty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegativeDecimal4lItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTitl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The title of the class of securities being registered (for each class being registered).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTitl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingSctyTp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Type of securities: "Asset-backed Securities", "ADRs/ADSs", "Debt", "Debt Convertible into Equity", "Equity", "Face Amount Certificates", "Limited Partnership Interests", "Mortgage Backed Securities", "Non-Convertible Debt", "Unallocated (Universal) Shelf", "Exchange Traded Vehicle Securities", "Other"</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingSctyTp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:securityTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_PrevslyPdFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_PrevslyPdFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_Rule457aFlg">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_Rule457aFlg</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_OfferingAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_OfferingAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fees Summary<br></strong></div></th>
<th class="th">
<div>Mar. 27, 2026 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_FeesSummaryLineItems', window );"><strong>Fees Summary [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOfferingAmt', window );">Total Offering</a></td>
<td class="nump">$ 8,124,990.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlFeeAmt', window );">Total Fee Amount</a></td>
<td class="nump">1,123.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_TtlOffsetAmt', window );">Total Offset Amount</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ffd_NetFeeAmt', window );">Net Fee</a></td>
<td class="nump">$ 1,123.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_FeesSummaryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_FeesSummaryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_NetFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_NetFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlFeeAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlFeeAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOfferingAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOfferingAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ffd_TtlOffsetAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ffd_TtlOffsetAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ffd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>ffd:nonNegative1TMonetary2ItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>2</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>1</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea028373001ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995210 - Document - Submission</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/submissionTable</Role>
      <ShortName>Submission</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea028373001ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995211 - Document - Offerings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesOfferingTable</Role>
      <ShortName>Offerings</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea028373001ex-fee.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995215 - Document - Fees Summary</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ffd/role/document/feesSummaryTable</Role>
      <ShortName>Fees Summary</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="EX-FILING FEES" original="ea028373001ex-fee.htm">ea028373001ex-fee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="2">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="20">http://xbrl.sec.gov/ffd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>24
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea028373001ex-fee.htm": {
   "dts": {
    "inline": {
     "local": [
      "ea028373001ex-fee.htm"
     ]
    },
    "schema": {
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/deprecated-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 1,
   "memberCustom": 0,
   "hidden": {
    "total": 6,
    "http://xbrl.sec.gov/ffd/2025": 5,
    "http://xbrl.sec.gov/dei/2025": 1
   },
   "contextCount": 2,
   "entityCount": 1,
   "segmentCount": 1,
   "elementCount": 107,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/ffd/2025": 20,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "report": {
    "R1": {
     "role": "http://xbrl.sec.gov/ffd/role/document/submissionTable",
     "longName": "995210 - Document - Submission",
     "shortName": "Submission",
     "isDefault": "true",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028373001ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028373001ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
     "longName": "995211 - Document - Offerings",
     "shortName": "Offerings",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028373001ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_offering_1",
      "name": "ffd:PrevslyPdFlg",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028373001ex-fee.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable",
     "longName": "995215 - Document - Fees Summary",
     "shortName": "Fees Summary",
     "isDefault": "false",
     "groupType": "Fee_Exhibit",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028373001ex-fee.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c_report",
      "name": "ffd:TtlOfferingAmt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea028373001ex-fee.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ffd_AggtRedRpPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtRedRpPricPrrFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtRedRpPricPrrFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Redeemed or Repurchased Price, Prior Fiscal Year",
        "terseLabel": "Aggregate Redeemed or Repurchased, Prior FY"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AggtSalesPricFsclYr": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AggtSalesPricFsclYr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Sales Price, Fiscal Year",
        "terseLabel": "Aggregate Sales Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtRedCdts": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtRedCdts",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Redemption Credits",
        "terseLabel": "Redemption Credits"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_AmtSctiesRcvd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Received",
        "terseLabel": "Amount of Securities Received",
        "documentation": "Amount of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_AmtSctiesRegd": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "AmtSctiesRegd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount of Securities Registered",
        "terseLabel": "Amount Registered",
        "documentation": "The amount of securities being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CeasedOprsDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CeasedOprsDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ceased Operations Date",
        "terseLabel": "Ceased Operations Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CfwdFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Form Type",
        "terseLabel": "Carry Forward Form Type",
        "documentation": "The Form Type of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrevslyPdFee": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrevslyPdFee",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Previously Paid Fee",
        "terseLabel": "Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward",
        "documentation": "The fee previously paid in connection with the securities being brought forward from the prior shelf registration statement on which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward Prior Effective Date",
        "terseLabel": "Carry Forward Initial Effective Date",
        "documentation": "The initial effective date of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CfwdPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CfwdPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carry Forward File Number",
        "terseLabel": "Carry Forward File Number",
        "documentation": "The EDGAR File Number of the prior shelf registration statement from which unsold securities are carried forward under 415(a)(6). If the prior registration statement has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_CmbndPrspctsItemAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsItemAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Item [Axis]",
        "terseLabel": "Combined Prospectus",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different references to earlier prospectuses on a single fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Line Items]",
        "terseLabel": "Combined Prospectus:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CmbndPrspctsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CmbndPrspctsTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus [Table]",
        "terseLabel": "Combined Prospectus Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_CombinedProspectusTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CombinedProspectusTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Combined Prospectus Table [N/A]",
        "terseLabel": "Combined Prospectus Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_CshPdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshPdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Paid by Registrant in Transaction",
        "terseLabel": "Cash Consideration Paid",
        "documentation": "Amount of cash consideration paid by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ffd_CshRcvdByRegistrantInTx": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "CshRcvdByRegistrantInTx",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Received by Registrant in Transaction",
        "terseLabel": "Cash Consideration Received",
        "documentation": "Amount of cash consideration received by registrant in connection with the exchange or other transaction being registered (in a 457(f) calculation)."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "ffd_FeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Amount",
        "terseLabel": "Amount of Registration Fee",
        "documentation": "Total amount of registration fee (amount due after offsets)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeExhibitTp": {
     "xbrltype": "feeExhibitTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeExhibitTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Exhibit Type",
        "terseLabel": "Fee Exhibit Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_FeeIntrstAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Interest Amount",
        "terseLabel": "Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note",
        "terseLabel": "Fee Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeNoteMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeNoteMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Note Maximum Aggregate Offering Price",
        "terseLabel": "Fee Note MAOP"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeeRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeeRate",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Rate",
        "terseLabel": "Fee Rate",
        "documentation": "The rate per dollar of fees that public companies and other issuers pay to register their securities with the Commission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesOthrRuleFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesOthrRuleFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees, Other Rule [Flag]",
        "terseLabel": "Other Rule",
        "documentation": "Checkbox indicating whether filer is using a rule other than 457(a), 457(o), or 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FeesSummaryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FeesSummaryLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fees Summary [Line Items]",
        "terseLabel": "Fees Summary:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FnlPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FnlPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Final Prospectus [Flag]",
        "terseLabel": "Final Prospectus"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_FormTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "FormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Form Type",
        "terseLabel": "Form Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_GnlInstrIIhiFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "GnlInstrIIhiFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Instruction II.H,I [Flag]",
        "terseLabel": "General Instruction II.H,I"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrCity": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrCity",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, City",
        "terseLabel": "City"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStatOrCtryCd": {
     "xbrltype": "stateOrCountryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStatOrCtryCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, State or Country Code",
        "terseLabel": "State or Country Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt1": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt1",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 1",
        "terseLabel": "Street 1"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrStrt2": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrStrt2",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Street 2",
        "terseLabel": "Street 2"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrBizAdrZipCd": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrBizAdrZipCd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Business Address, Zip Code",
        "terseLabel": "Zip Code"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_IssrNm": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "IssrNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuer Name",
        "terseLabel": "Issuer Name"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_MaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum Aggregate Offering Price",
        "documentation": "The maximum aggregate offering price for the offering that is being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_MaxOfferingPricPerScty": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "MaxOfferingPricPerScty",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum Offering Price per Security",
        "terseLabel": "Proposed Maximum Offering Price per Unit",
        "documentation": "The maximum offering price per share/unit being registered."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetFeeAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Fee Amount",
        "terseLabel": "Net Fee"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NetSalesAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NetSalesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales Amount",
        "terseLabel": "Net Sales"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvDsclsr": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvDsclsr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure",
        "terseLabel": "Narrative Disclosure"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Amount",
        "terseLabel": "Narrative - Max Aggregate Offering Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_NrrtvMaxAggtOfferingPric": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "NrrtvMaxAggtOfferingPric",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Narrative Disclosure, Maximum Aggregate Offering Price",
        "terseLabel": "Narrative - Max Aggregate Offering Price"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Axis]",
        "terseLabel": "Offering",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different security offerings on a single fee bearing submission."
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Line Items]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Note",
        "terseLabel": "Offering Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Title",
        "terseLabel": "Security Class Title",
        "documentation": "The title of the class of securities being registered (for each class being registered)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Security Type",
        "terseLabel": "Security Type",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OfferingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering [Table]",
        "terseLabel": "Offering:"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OfferingTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OfferingTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering Table [N/A]",
        "terseLabel": "Offering Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_OffsetAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset [Axis]",
        "terseLabel": "Offset",
        "documentation": "A sequence number (1, 2, 3...) used to distinguish different offsets as applied to a fee bearing submission."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetClmInitlFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmInitlFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claim Initial Filing Date",
        "terseLabel": "Initial Filing Date",
        "documentation": "The initial filing date of the earlier registration statement with which the earlier (offsetting) fee was paid for a claimed offset. If the offset fee was paid with an amendment, do not provide the amendment date under this element; instead, provide the date of the initial filing (i.e. the \"parent\" filing) ."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Amount",
        "terseLabel": "Fee Offset Claimed",
        "documentation": "The amount of offsetting fees being claimed."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetClmdInd": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetClmdInd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Claimed Indicator",
        "terseLabel": "Offset Claimed"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetExpltnForClmdAmt": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetExpltnForClmdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Explanation for Claimed Amount",
        "terseLabel": "Explanation for Claimed Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetLineItems",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset:",
        "label": "Offset [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Note",
        "terseLabel": "Offset Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetPrrFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Fee Amount",
        "terseLabel": "Fee Paid with Fee Offset Source",
        "documentation": "The fee previously paid from which an offset is being derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior File Number",
        "terseLabel": "File Number",
        "documentation": "The EDGAR File Number of the earlier registration statement with which the earlier (offsetting) fee was paid. If the offset filing for the offset has a Securities Act File Number and an Investment Company Act File Number, the Securities Act File Number should be used."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFilerNm": {
     "xbrltype": "filerNameItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFilerNm",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Filer Name",
        "terseLabel": "Registrant or Filer Name",
        "documentation": "The name of the registrant that filed the earlier registration statement with which the earlier (offsetting) fee was paid."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Form Type",
        "terseLabel": "Form or Filing Type",
        "documentation": "The Form Type of the offset filing."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrNbOfUnsoldScties": {
     "xbrltype": "nonNegativeIntegerItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrNbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Number of Securities",
        "terseLabel": "Unsold Securities Associated with Fee Offset Claimed",
        "documentation": "The number of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Title",
        "terseLabel": "Security Title Associated with Fee Offset Claimed",
        "documentation": "The title of the class of securities from which offset fees were derived."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrSctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrSctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Security Type",
        "terseLabel": "Security Type Associated with Fee Offset Claimed",
        "documentation": "Type of securities: \"Asset-backed Securities\", \"ADRs/ADSs\", \"Debt\", \"Debt Convertible into Equity\", \"Equity\", \"Face Amount Certificates\", \"Limited Partnership Interests\", \"Mortgage Backed Securities\", \"Non-Convertible Debt\", \"Unallocated (Universal) Shelf\", \"Exchange Traded Vehicle Securities\", \"Other\""
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetPrrUnsoldOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetPrrUnsoldOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Prior Unsold Offering Amount",
        "terseLabel": "Unsold Aggregate Offering Amount Associated with Fee Offset Claimed",
        "documentation": "The aggregate offering amount of unsold securities registered on the prior registration statement that are associated with the claimed offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetSrcFilgDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetSrcFilgDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Source Filing Date",
        "terseLabel": "Filing Date",
        "documentation": "The filing date of the earlier registration statement with which the earlier (offsetting) fee was paid in an offset."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r8"
     ]
    },
    "ffd_OffsetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offset Payment:",
        "label": "Offset [Table]"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_OffsetTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "OffsetTableNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offset Table [N/A]",
        "terseLabel": "Offset Table N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_PrevslyPdFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "PrevslyPdFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable",
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fee Previously Paid [Flag]",
        "terseLabel": "Fee Previously Paid"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RegnFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RegnFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Registration File Number",
        "terseLabel": "Registration File Number"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_RptgFsclYrEndDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "RptgFsclYrEndDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reporting Fiscal Year End Date",
        "terseLabel": "Reporting FY End Date"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 0-11 [Flag]",
        "terseLabel": "Rule 0-11"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule011a2OffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule011a2OffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 0-11(a)(2) Offset",
        "label": "Rule 0-11(a)(2) Offset [Flag]"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_Rule415a6Flg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule415a6Flg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 415(a)(6) [Flag]",
        "terseLabel": "Rule 415(a)(6)",
        "documentation": "Checkbox indicating whether filer is claiming a 415(a)(6) carryforward."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ffd_Rule429AggtOfferingAmt": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429AggtOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Aggregate Offering Amount",
        "terseLabel": "Maximum Aggregate Offering Price of Securities Previously Registered",
        "documentation": "The maximum aggregate offering amount of unsold securities registered on the prior registration statement that are carried forward under Rule 429. Only applicable if 457(o) was used in the fee calculation for the prior registration statement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429CmbndPrspctsFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429CmbndPrspctsFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Combined Prospectus [Flag]",
        "terseLabel": "Rule 429",
        "documentation": "Checkbox indicating whether filer is using a combined prospectus under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFileNb": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFileNb",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier File Number",
        "terseLabel": "File Number",
        "documentation": "The Securities Act File Number of the earlier effective registration statement(s) from which securities may be offered and sold using the combined prospectus pursuant to Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429EarlierFormTp": {
     "xbrltype": "formTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429EarlierFormTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Earlier Form Type",
        "terseLabel": "Form Type",
        "documentation": "The Form Type of the earlier registration statement from which unsold securities are carried forward under Rule 429. This should be an EDGAR submission type (S-3, S-3/A, S-3ASR, etc.), which means there is a fixed set of possible responses. Note that while the XBRL response should be an EDGAR submission type, the human-readable Ex. 107 could include a simpler label (e.g., \"Form S-3\" in the human-readable and \"S-3ASR\" in the XBRL)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429InitlFctvDt": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429InitlFctvDt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Initial Effective Date",
        "terseLabel": "Initial Effective Date",
        "documentation": "The filing date of the earlier registration statement from which unsold securities are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429NbOfUnsoldScties": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429NbOfUnsoldScties",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Number Of Unsold Securities",
        "terseLabel": "Amount of Securities Previously Registered",
        "documentation": "The number of securities registered on the prior registration statement that are carried forward under Rule 429."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ffd_Rule429PrspctsNote": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429PrspctsNote",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Prospectus Note",
        "terseLabel": "Combined Prospectus Note"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTitl": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTitl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Title",
        "terseLabel": "Security Class Title"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule429SctyTp": {
     "xbrltype": "securityTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule429SctyTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesByCmbndPrspctsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 429 Security Type",
        "terseLabel": "Security Type"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Rule457aFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457aFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(a) [Flag]",
        "terseLabel": "Rule 457(a)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(a) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ffd_Rule457bOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457bOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(b) Offset [Flag]",
        "terseLabel": "Rule 457(b) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(b) or 0-11(a)(2)."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ffd_Rule457fFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457fFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(f) [Flag]",
        "terseLabel": "Rule 457(f)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(f) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_Rule457oFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457oFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(o) [Flag]",
        "terseLabel": "Rule 457(o)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(o) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ffd_Rule457pOffsetFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457pOffsetFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(p) Offset [Flag]",
        "terseLabel": "Rule 457(p) Offset",
        "documentation": "Checkbox indicating whether filer is claiming an offset under Rule 457(p)."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "ffd_Rule457rFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457rFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(r) [Flag]",
        "terseLabel": "Rule 457(r)"
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "ffd_Rule457sFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457sFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(s) Flag",
        "terseLabel": "Rule 457(s)"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ffd_Rule457uFlg": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Rule457uFlg",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 457(u) [Flag]",
        "terseLabel": "Rule 457(u)",
        "documentation": "Checkbox indicating whether filer is using Rule 457(u) to calculate the registration fee due."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ffd_Scties424iAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iAxis",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Axis]",
        "terseLabel": "Securities, 424I"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Line Items]",
        "terseLabel": "Securities, 424I:"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Scties424iTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Scties424iTable",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/securities424iTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities, 424I [Table]",
        "terseLabel": "Securities, 424I Table"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_Securities424iTableNa": {
     "xbrltype": "naItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "Securities424iNa",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities 424I [N/A]",
        "terseLabel": "Securities 424I N/A"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissionLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission [Line Items]",
        "terseLabel": "Items"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_SubmissnTp": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "SubmissnTp",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/submissionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Submission Type",
        "terseLabel": "Submission Type"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TermntnCmpltnWdrwl": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TermntnCmpltnWdrwl",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOffsetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination / Completion / Withdrawal Statement",
        "terseLabel": "Termination / Withdrawal Statement"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_TtlFeeAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee Amount",
        "terseLabel": "Total Fee Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlFeeAndIntrstAmt": {
     "xbrltype": "nonNegativeDecimal2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlFeeAndIntrstAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Fee and Interest Amount",
        "terseLabel": "Total Fee and Interest Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOfferingAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOfferingAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offering Amount",
        "terseLabel": "Total Offering"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlOffsetAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlOffsetAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Offset Amount",
        "terseLabel": "Total Offset Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlPrevslyPdAmt": {
     "xbrltype": "nonNegative1TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlPrevslyPdAmt",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Previously Paid Amount",
        "terseLabel": "Previously Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TtlTxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TtlTxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesSummaryTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Transaction Valuation",
        "terseLabel": "Total Transaction Valuation"
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "ffd_TxValtn": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "TxValtn",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transaction Valuation",
        "terseLabel": "Transaction Valuation"
       }
      }
     },
     "auth_ref": []
    },
    "ffd_ValSctiesRcvd": {
     "xbrltype": "nonNegative100TMonetary2ItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvd",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received",
        "terseLabel": "Value of Securities Received",
        "documentation": "Value of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form)"
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ffd_ValSctiesRcvdPerShr": {
     "xbrltype": "nonNegativeDecimal4lItemType",
     "nsuri": "http://xbrl.sec.gov/ffd/2025",
     "localname": "ValSctiesRcvdPerShr",
     "presentation": [
      "http://xbrl.sec.gov/ffd/role/document/feesOfferingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of Securities Received, Per Share",
        "terseLabel": "Value of Securities Received, Per Share",
        "documentation": "Value per share of securities to be received by the registrant (or cancelled upon issuance of securities to be registered on the form). This is included in the explanation of 457(f) fee calculation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "415",
   "Subsection": "a"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "429"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "f"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "o"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "p"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "r"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "s"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "457",
   "Subsection": "u"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Subsection": "f",
   "Section": "457"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>25
<FILENAME>0001213900-26-035450-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-035450-xbrl.zip
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M$&.:_S403R<:!BYW51JSCD:LZ.E$4WRDLJ$K9L-UV8C*<<=C8R+5V.8G6A>
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M$DS"-ZM/S$(*?XA4R"P]%8W2)81<DC A=^+;_9A#\<7_RK\!4$L! A0#%
M  @ 8GI[7-Q0\ ;7"@  _C0  !4              ( !     &5A,#(X,S<S
C,# Q97@M9F5E+FAT;5!+!08      0 ! $,    *"P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>ea028373001ex-fee_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ffd="http://xbrl.sec.gov/ffd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef
      xlink:href="https://xbrl.sec.gov/ffd/2025/ffd-2025.xsd"
      xlink:type="simple"/>
    <context id="c_offering_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007702</identifier>
            <segment>
                <xbrldi:typedMember dimension="ffd:OfferingAxis">
                    <dei:lineNo>1</dei:lineNo>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <context id="c_report">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002007702</identifier>
        </entity>
        <period>
            <startDate>2026-03-27</startDate>
            <endDate>2026-03-27</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <ffd:SubmissnTp contextRef="c_report" id="fee_001">F-1</ffd:SubmissnTp>
    <ffd:FeeExhibitTp contextRef="c_report" id="fee_002">EX-FILING FEES</ffd:FeeExhibitTp>
    <dei:EntityCentralIndexKey contextRef="c_report" id="fee_003">0002007702</dei:EntityCentralIndexKey>
    <ffd:OfferingTableNa contextRef="c_report" id="fee_004" xsi:nil="true"/>
    <ffd:OffsetTableNa contextRef="c_report" id="fee_005">N/A</ffd:OffsetTableNa>
    <ffd:CombinedProspectusTableNa contextRef="c_report" id="fee_006">N/A</ffd:CombinedProspectusTableNa>
    <ffd:FormTp contextRef="c_report" id="fee_007">F-1</ffd:FormTp>
    <dei:EntityRegistrantName contextRef="c_report" id="fee_008">CELLYAN BIOTECHNOLOGY CO., LTD</dei:EntityRegistrantName>
    <ffd:PrevslyPdFlg contextRef="c_offering_1" id="fee_009">false</ffd:PrevslyPdFlg>
    <ffd:OfferingSctyTp contextRef="c_offering_1" id="fee_010">Equity</ffd:OfferingSctyTp>
    <ffd:OfferingSctyTitl contextRef="c_offering_1" id="fee_011">Class A ordinary shares, par value US$0.001 per share</ffd:OfferingSctyTitl>
    <ffd:Rule457aFlg contextRef="c_offering_1" id="fee_012">true</ffd:Rule457aFlg>
    <ffd:AmtSctiesRegd
      contextRef="c_offering_1"
      decimals="0"
      id="fee_013"
      unitRef="shares">12499986</ffd:AmtSctiesRegd>
    <ffd:MaxOfferingPricPerScty
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_014"
      unitRef="USD">0.65</ffd:MaxOfferingPricPerScty>
    <ffd:MaxAggtOfferingPric
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_015"
      unitRef="USD">8124990.90</ffd:MaxAggtOfferingPric>
    <ffd:FeeRate
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_016"
      unitRef="pure">0.0001381</ffd:FeeRate>
    <ffd:FeeAmt
      contextRef="c_offering_1"
      decimals="INF"
      id="fee_017"
      unitRef="USD">1123.00</ffd:FeeAmt>
    <ffd:TtlOfferingAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_018"
      unitRef="USD">8124990.90</ffd:TtlOfferingAmt>
    <ffd:TtlFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_019"
      unitRef="USD">1123.00</ffd:TtlFeeAmt>
    <ffd:TtlOffsetAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_020"
      unitRef="USD">0.00</ffd:TtlOffsetAmt>
    <ffd:NetFeeAmt
      contextRef="c_report"
      decimals="INF"
      id="fee_021"
      unitRef="USD">1123.00</ffd:NetFeeAmt>
    <ffd:OfferingNote contextRef="c_offering_1" id="fee_022">The ordinary shares will be offered for resale by certain Selling Shareholder pursuant to the prospectus contained herein. Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), this registration statement also covers any additional number of ordinary shares issuable upon share splits, share dividends, or other distribution, recapitalization or similar events with respect to the ordinary shares being registered pursuant to this registration statement.&lt;br/&gt;&lt;br/&gt;Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities Act, based on the closing price per ordinary share as reported on the Nasdaq Capital Market on March 26, 2026.</ffd:OfferingNote>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
